Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
01/2009 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions January recently filed with US Patent Office 01/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
01/29/2009 > patent applications in patent subcategories. recently filed with US Patent Office

20090029902 - Peptides for binding calcium carbonates and methods of use: Combinatorially generated peptides are provided that have binding affinity for calcium carbonates. The peptides may be used to deliver benefit agents to various calcium carbonate surfaces.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090029901 - Process for crystallizing lactose particles for use in pharmaceutical formulations: A process for producing a plurality of lactose particles comprises subjecting a plurality of lactose particles, to conditions such that at least a portion of smaller lactose particles detach from the plurality of the lactose particles and disperse in the liquid medium; subjecting the liquid medium to conditions sufficient to... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090029903 - 1,1'-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors: The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090029904 - Compositions and methods for treatment of insulin-resistance diseases: Compositions and methods are provided for modulation of Target of Rapamycin (TOR) activity. Reduction of TOR blocks insulin resistance and metabolic syndrome phenotypes caused by expression of a constitutively activated version of the insulin responsive transcription factor, FOXO. These TOR-mediated responses are also linked with protection against age-dependent functional organ... Agent: Biotechnology Law Group C/o Portfolioip

20090029905 - Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes: m

20090029906 - Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators: The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or... Agent: Patent Docket Administrator Lowenstein Sandler Pc

20090029909 - Modulation of synaptogenesis: Soluble proteins, e.g. Hevin, can trigger synapse formation; and other soluble proteins, e.g. SPARC antagonize this activity. Such proteins are synthesized in vitro and in vivo by astrocytes. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090029907 - Recombinant method for production of an erythropoiesis stimulating protein: The present invention relates to the recombinant method used for the production of a highly glycosylated form (in total five N linked glycosylations as opposed to three N linked glyosylations in the natural EPO) of erythropoietin. The added sites for glycosylation will result in greater number of carbohydrate chains, and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090029908 - Uteroglobin in the treatment of iga mediated autoimmune disorders: Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or... Agent: Klarquist Sparkman, LLP

20090029910 - Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes: The present invention relates to a combination of two or more Somatostatin (SRIF) peptidomimetics (also referred to as Somatostatin- or SRIF-analogs) which have different selectivity for the five human somatostatin receptor subtypes, the use of such combination in the treatment of a disease mediated by activation of somatostatin receptors, and... Agent: Novartis Corporate Intellectual Property

20090029914 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090029916 - Fibroblast growth factor-14: Disclosed is a human Fibroblast growth factor-14 polypeptide and DNA(RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for promoting wound healing for example as a result of burns and ulcers, to prevent neuronal damage... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090029919 - Leptin peptide antagonists: Disclosed herein are peptides comprising a leptin sequence and methods for their use in preventing ObR signaling in a leptin-responsive cell. A leptin peptide of the present invention binds to but does not activate ObR signaling in a leptin-responsive cell, thereby inhibiting the up-regulatory effects of leptin on ObR signaling... Agent: Kevin M. Farrell

20090029911 - Liquid human growth hormone formulation containing polyethylene glycol: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, polyethylene glycol, a tonicifier such as a sugar alcohol, and optionally, an antimicrobial agent and optionally, a chelating agent. Also disclosed are associated means and methods for preparing, storing and using such formulations.... Agent: Ade & Company Inc Po Box 28006

20090029918 - Method for producing mature vwf from vwf pro-peptide: s

20090029921 - Method for removing endotoxin from proteins: Disclosed is a method for removing endotoxin from proteins. Also disclosed are products made by using the method. The method may be used, for example, to produce endotoxin-free lactoferrin. Bovine milk-derived lactoferrin may be produced in commercial quantities by the method, and endotoxin-free bovine lactoferrin may be used for a... Agent: Donna J. Russell

20090029912 - Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc): The present invention relates to methods of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) and/or progeny derived therefrom in vitro or in vivo comprising exposing the MPC or progeny to SDF-1 or analog thereof. The invention also relates to compositions comprising isolated MPCs or progeny derived therefrom and... Agent: Cooper & Dunham, LLP

20090029917 - Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production: The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and/or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20090029920 - Methods and compositions for treating ocular disorders: The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in... Agent: David S. Resnick

20090029913 - Novel exendin agonist compounds: Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090029915 - Regulation of mineral and skeletal metabolism: A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting... Agent: Bozicevic, Field & Francis LLP

20090029922 - Use of s1p receptor agonists in heart diseases: The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090029923 - Use of thrombin-derived peptides for the therapy of chronic dermal ulcers: Disclosed is a method of promoting healing of a chronic dermal skin ulcer, such as a diabetic ulcer, on a subject. The method comprises the step of contacting the chronic dermal skin ulcer with an effective amount of an agonist of the non-proteolytically activated thrombin receptor.... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20090029924 - Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens: Disclosed are compositions and methods for preventing or reducing harm resulting from pathogen infection. For example, disclosed are peptides that inhibit the processing of toxins normally cleaved by proprotein convertase enzymes.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090029925 - Interaction of bim with trim2, an e3 ubiquitin ligase: Methods, compositions, and cells for drug screening based on interaction between (1) a Bim polypeptide and/or an E2 polypeptide and (2) a TRIM2 polypeptide, which is identical to or corresponds to a Bim-selective E3 ubiquitin ligase. Methods and compositions for treating cancer based on levels of Bim protein, TRIM2 protein,... Agent: Stanley M. Hollenberg Kolisch Hartwell, P.c.

20090029926 - Lys-thr dipeptides and their use: Dipeptides and derivatives and analogs, such as Pal-KT have been developed. These dipeptides, derivatives and analogs may be used alone or in an additive, to produce cosmetics, topical pharmaceuticals and personal care products, particularly for skin care. Methods of making the dipeptides, derivatives, analogs and additives containing same are also... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090029927 - Compounds having inhibitory activity against sodium-dependent glucose transporter: The invention is directed to compounds of the formula (I) described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof, and pharmaceutical compositions and methods of treatment.... Agent: Philip S. Johnson Johnson & Johnson

20090029928 - Peeling process and composition: Process for the treatment of visible and/or tactile irregularities of human skin, by applying topically, to the skin, a composition containing at least one hydroxy acid chosen from α-hydroxy acids, β-hydroxy acids, α-keto acids, β-keto acids, and mixtures thereof, and at least one cationic polymer, leaving the composition in contact... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090029937 - Biodegradable cationic polymer gene transfer compositions and methods of use: The invention provides biodegradable, cationic compositions based on cationic α-amino acid-containing PEA, PEUR and PEU polymers for use in preparation of non-viral gene transfer compositions. In the invention gene transfer compositions a poly nucleic acid is condensed with the polymer to form a soluble unit wherein the electrical charge of... Agent: Dla Piper LLP (us)

20090029935 - Centrosomal proteins and secretion: Described are methods for modulating cellular secretion, and methods for identifying novel modulators of cellular secretion, that target centrosomal proteins.... Agent: Fish & Richardson Pc

20090029929 - Decoy nucleic acid to synoviolin gene promoter: The present invention provides a decoy nucleic acid for the Synoviolin gene promoter. Also provided is the decoy nucleic acid can inhibit the promoter activity by binding to the transcription factor of the Synoviolin gene promoter. It also provides a decoy nucleic acid as expressed in (a) a decoy nucleic... Agent: Dickstein Shapiro LLP

20090029932 - Identification and use of mirnas for differentiating myeloid leukemia cells: The invention relates to the use of nucleic acid miRNA derived molecules for producing a drug for treating a myelogenous leukemia and to a method for identifying therapeutic agents or the efficient combination thereof for inducing the differentiation of myelogenous leukemia cells.... Agent: Harness, Dickey & Pierce, P.L.C

20090029933 - Inhibitor of peroxisome proliferator-activated receptor alpha coactivator 1: The present invention refers to the use of an antisense DNA oligonucleotide for the messenger RNA of the PGC-1α protein, useful as drug for the treatment of diabetes mellitus, insulin resistance and metabolic syndrome. More specifically, the present invention deals with a compound used as drug, through enteral or parenteral... Agent: Ladas & Parry LLP

20090029936 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20090029930 - Methods of gene therapy using nucleic acid sequences for atp-binding cassette transporter: The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP... Agent: Woodcock Washburn LLP

20090029938 - Oligonucleotide compositions and methods for treating disease including inflammatory conditions: The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory... Agent: David S. Resnick

20090029934 - Rna interference in respiratory epithelial cells: The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules.... Agent: Viksnins Harris & Padys Pllp

20090029931 - Topical administrations of antisense compounds to vla-4 for the treatment of respiratory conditions: A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin α4 comprising administering to the animal a composition comprising from. 0.001 to 1000 μg per kg body... Agent: Quine Intellectual Property Law Group, P.c.

20090029939 - Pre-organized tricyclic integrase inhibitor compounds: A1 and A2 are moieties forming a five, six, or seven membered ring. L is a bond or a linker connecting a ring atom of Ar to N. X is O, S, or substituted nitrogen. Ar is aryl or heteroaryl, Q is N, +NR, or CR4. The aryl carbons may... Agent: Gilead Sciences Inc

20090029941 - Methods for cell mobilization using in vivo treatment with hyaluronan (ha): The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090029940 - Plymorphic form of inulin and uses thereof: The present invention relates to a new polymorphic form of inulin, designated delta inulin (dIN), to methods for the preparation of dIN, compositions comprising dIN and uses thereof. The present invention also relates to the use of dIN and compositions comprising dIN in the preparation of gamma inulin (gIN), compositions... Agent: Woodcock Washburn LLP

20090029942 - Administration of copper to an animal: The present invention is directed to the administration of copper to an animal using a composition containing copper dextran. A method is described for increasing the copper levels in an animal by the administration of a composition containing copper dextran. A preferred method of administration is intra muscularly. The use... Agent: Fish & Richardson Pc

20090029943 - Glucosamine and derivatives thereof useful as tg inhibitors: Disclosed herein is a transglutaminase inhibitor comprising glucosamine or a derivative thereof. Exhibiting potent inhibitory activity against transglutaminase, the overexpression of which is responsible for the etiology of various diseases, glucosamine or derivatives thereof can be useful in the prevention and treatment of such diseases. Also, a pharmaceutical composition comprising... Agent: Arenson, Tanya A. Casimir Jones

20090029944 - Methods for adding fatty acids to agents in aqueous solution to improve bioavailability: Adding fatty acids to agents enhances deliverability of the antioxidant, making the agent less likely to be degraded prior to intercellular delivery. Additionally, adding fatty acids to agents provides a time lapse-type mechanism to the agents. Fatty acid modified agents are made with a novel process in aqueous solution, reducing... Agent: Greenberg Traurig LLP (la)

20090029945 - Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators: to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with... Agent: Pepper Hamilton LLP

20090029946 - Aqueous oral solution of bisphosphonic acid: The present invention relates to stable aqueous oral formulation of bisphosphonic acid or its pharmaceutically acceptable salts. More particularly, the present invention relates to stable aqueous oral formulation of alendronate sodium. The present invention also relates to a process for the preparation of stable aqueous oral formulation of alendronate sodium.... Agent: Jay R Akhave

20090029948 - Organic derivatives, their salts and use for the control of phytopathogens: Organic compounds are described, which are capable of forming quaternary salts, quaternary salts thereof with a structure having general formula (I) and their use for the control of phytopathogen fungi.... Agent: Hedman & Costigan P.c.

20090029947 - Sphingosine-1-phosphate receptor agonist and antagonist compounds: The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the... Agent: Abbott Bioresearch

20090029950 - Composition for reducing the exudation of serum proteins: Disclosed is a composition for reducing the exudation of the serum proteins. More specifically the composition of the present invention relates to a composition capable of improving conditions such as atopic dermatitis, atopic eczema, skin pruritus, atopic nasitis, atopic erythema or erythroderma, contact dermatitis, asthma, chronic obstructive pulmonary disease, etc.... Agent: Foley & Lardner LLP

20090029949 - Gpcr ligands identified by computational modeling: Disclosed are pharmacophores for developing and screening compounds having G-protein-coupled receptor antagonist activity, including LPA1, LPA2, LPA3 and S1P antagonists. These compositions have therapeutic benefit in the fields of cancer chemotherapy, cardiovascular disease prevention, and fertility protective agents during radiation and chemotherapy.... Agent: Donna J. Russell

20090029951 - Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin: The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or... Agent: King & Spalding LLP

20090029952 - Unique combination of acetylsalicylic acid, ethylenediamine dihydroiodide (eddi), and buffer for use in animal drinking water: A unique combinations include acetylsalicylic acid (aspirin), ethylenediamine dihydriodide (EDDI), potassium iodide, sodium acetate, and sodium diacetate, useful in helping poultry, swine, and cattle overcome certain symptoms after vaccination. The inventive combinations readily dissolve in water at room temperature to form an effective concentration for inclusion in the animal's drinking... Agent: E. J. Asbury Iii, Esq. E. J. Asbury Iii, Llc

20090029953 - 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter: The invention relates to novel 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones of general formula (I), where Z=O, H2, ═NOR or ═NNHSO2R, where R=H, a straight- or branched-chain 1-4 or 3-4 C alkyl group, R4=H, halogen, methyl or trifluoromethyl, R6 and/or R7 can be α- or β-positioned and independently=branched- or straight-chain 1-4 or 3-4 alkyl, or... Agent: Millen, White, Zelano & Branigan, P.c.

20090029954 - Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen: The present invention relates to the single use of the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof for the prophylaxis and treatment of BRCA1- or BRCA2-mediated breast cancer, as well as to a combination comprising the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue... Agent: Millen, White, Zelano & Branigan, P.c.

20090029957 - 8-beta-substituted estratrienes as selectively active estrogens: their use as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action in the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing... Agent: Millen, White, Zelano & Branigan, P.c.

20090029958 - Phenethanolamine derivatives as beta2 adrenoreceptor agonists: The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The... Agent: Morgan Lewis & Bockius LLP

20090029955 - Pyridothienopyrimidine derivatives: e

20090029956 - Substance mixture: A substance mixture comprising at least one glucocorticoid and at least one N-chloro compound and/or at least one O-chloro compound as well as a medicament containing such a substance mixture as well as the use and manufacture of such a medicament for the topical treatment of inflammations.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20090029959 - Antiglucocorticoid therapy for the prevention of neurological damage in premature infants: This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods.... Agent: Townsend And Townsend And Crew, LLP

20090029960 - Macrocyclic compounds useful as base inhibitors: i

20090029961 - Bio-film resistant surfaces: The present invention relates to methods and compositions for rendering a surface resistant to bio-film formation by a combination of an alkanediol and an antimicrobial agent (and, optionally, an organic hydroxy acid). The invention provides for compositions which may be used to render surfaces bio-film resistant, articles having bio-film resistant... Agent: Baker Botts L.l.p.

20090029962 - 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands: R1, R2, R3, Ar, n and o are as defined herein and to their pharmaceutically acceptable active salts. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090029964 - Novel carbapenem compound: wherein m and n independently represent 0 or 1; A and B independently represent methylene, carbonyl or the like; Y represents methylene, ethylene, oxygen atom, —OCH2—, —NRaCH2— (wherein Ra represents hydrogen atom, optionally substituted C1-C4 alkyl group or the like) or the like.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20090029965 - Vasopressin v1a antagonists: The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.... Agent: Foley And Lardner LLP Suite 500

20090029963 - Pyrazol derivatives: e

20090029966 - Combination therapy with parp inhibitors: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with temozolomide (TMZ).... Agent: Paul D. Yasger Abbott Laboratories

20090029967 - Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders: There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090029968 - Quinazoline derivatives used as inhibitors of erbb tyrosine kinase: e

20090029969 - Thiophene compounds:

20090029970 - Pain remedy containing rock inhibitor: Since a ROCK inhibitor exerts a potent analgesic effect by a single dose after the onset of a cartilage-related disease such as osteoarthritis, and can regenerate or suppress destruction of cartilage tissue and alleviate pain associated with cartilage diseases by multiple doses, administration of an therapeutically effective amount of the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090029971 - Sulfonyl-substituted bicyclic compounds as modulators of ppar: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20090029972 - Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals: The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, and their use in the preparation of medicaments for the treatment of neoplastic conditions... Agent: Merchant & Gould Pc

20090029973 - Fused heterocyclic compound: wherein W is C(R1) or N, each A is an optionally substituted aryl group or a heteroaryl group, X1 is —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to A to form an... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20090029974 - Tumor treatment with gliotoxin derivatives: The present invention describes the use of Notch2 inhibitors for producing a medicament for the treatment of tumours, which tumours are characterised by ligand-independent Notch2 fragments.... Agent: Fulbright & Jaworski L.l.p.

20090029975 - 1,3-benzothiazinone derivative and use thereof: A compound represented by the formula (I) or a salt thereof: (I) wherein R1 independently represents a halogen atom, a hydroxy, a nitro, an alkyl, alkenyl or alkynyl which may be halogenated, an alkoxy which may have a substituent, an acyl or an amino which may have a substituent; R2... Agent: Edwards Angell Palmer & Dodge LLP

20090029976 - Benzofuran and benzothiophene-2-carboxylic acid amide derivatives: c

20090029977 - Dual modulators of 5ht2a and d3 receptors: wherein R1, R2, X and n are as defined in the specification as dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use for the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090029978 - Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity: The use of a compound comprising formula (I), or a salt, ester, amide or prodrug thereof in the treatment of obesity and related disorders. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I): A is an... Agent: Choate, Hall & Stewart LLP

20090029979 - 5-htx modulators: This invention relates to compounds which bind to serotonin receptors inside or outside the central nervous system, in particular compounds which bind to the 5-HT2 or 5-HT7 receptors, their preparation and use, compositions containing them, and methods of treatment using them.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090029980 - C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents: The present invention relates to C-7 isoxazolyl quinoline/naphthyridine derivatives useful as antimicrobial compounds, pharmaceutical compositions comprising said derivatives and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.... Agent: Philip S. Johnson Johnson & Johnson

20090029981 - Substituted 4-phenylpiperidines: The application relates to substituted 4-phenylpiperidines of the general formula and their salts, preferably their pharmaceutically acceptable salts, in which R2, R3, W and X have the meanings explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20090029983 - Novel heterocyclic compounds having anti-hbv activity: e

20090029982 - Protein kinase inhibitors: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the structure (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Z, L2 and w are as defined herein. Also... Agent: Seed Intellectual Property Law Group Pllc

20090029985 - Pyridazine compounds and methods: The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular... Agent: Millen, White, Zelano & Branigan, P.c.

20090029984 - Synergistic combination for the treatment of pain (cannabinoid receptor agonist and opioid receptor agonist): The invention relates to a pharmaceutical dosage form comprising an analgesic combination for simultaneous or sequential use which comprises a peripherally restricted cannabinoid CB1 receptor agonist having a brain Cmax to plasma Cmax ratio of less than 0.1 and an opioid receptor agonist, as well as to a method for... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090029986 - N-aroyl cyclic amines: e

20090029987 - Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices: The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090029991 - Benzamide derivatives useful as histone deacetylase inhibitors: e

20090029990 - Dihydropteridinones in the treatment of respiratory diseases:

20090029988 - Hydroxyalkyl substituted imidazoquinolines: Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-α biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: Wolf Greenfield & Sacks, P.c.

20090029989 - Substituted pyrazolopyrimidines: Pyrazolo-pyrimidine derivatives are described herein. The described invention also includes methods of making such derivatives as well as methods of using the same in the treatment of diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090029993 - Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein: Methods and compounds are disclosed for affecting gastrointestinal motility and gastric emptying, which comprise inhibiting tryptophan hydroxylase (TPH) in patients in need thereof.... Agent: Lexicon Pharmaceuticals, Inc.

20090029992 - Substituted pyrazole compounds: Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.... Agent: King & Spalding LLP

20090029994 - Trisubstituted amine compound: wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted phenyl group, and the like; R1 is an optionally substituted alkyl group, and the like; and R2 is an optionally substituted amino group, and the like;... Agent: Birch Stewart Kolasch & Birch

20090029995 - Hetero biaryl derivatives as matrix metalloproteinase inhibitors: e

20090029996 - Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors: The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives, to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodiesterase 4 (PDE4) and are thus useful in the treatment, prevention and suppression of related pathological conditions, diseases and disorders, in particular... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090029997 - Thiazole derivatives and use thereof: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090029998 - Thiazole derivatives and use thereof: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090029999 - Synephrine derivatives useful as anti-inflammatory agents: e

20090030000 - Antiviral agents:

20090030001 - Therapeutic agent for corneal disease: A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090030003 - Amino-heterocyclic compounds: t

20090030005 - Combinations for the treatment of cancer: This invention is in the field of pharmaceutical agents and specifically relates to combinations, compositions, uses and methods for treating cancer.... Agent: Amgen Inc.

20090030002 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20090030004 - Specific salt, anhydrous and crystalline form of a dihydropteridione derivative: The present invention relates to a specific salt of a dihydropteridione derivative, namely the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to its crystallisation in the form of an hydrate with water, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090030006 - Spiroketal derivatives and use thereof as diabetic medicine: wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C7-C14 aralkyl group and —C(═O)Rx; Rx represents an optionally substituted C1-C6 alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted C1-C6... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090030007 - Novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives: The present invention relates to novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives and, more particularly, to novel solvate and crystalline forms of trans-1{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride. Processes for the preparation of these forms, compositions containing these forms, and methods of use thereof are also described.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20090030008 - Piperazine derivatives and their use as therapeutic agents: e

20090030009 - Heterobicyclic carboxamides as inhibitors for kinases: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in... Agent: Novartis Institutes For Biomedical Research, Inc.

20090030010 - 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents: e

20090030012 - Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators: The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.... Agent: Merck And Co., Inc

20090030011 - Triazolopyridine derivatives as inhibitors of lipases and phospholipases: The invention relates to triazolopyridine derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090030013 - Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments: e

20090030014 - Indole derivative having pgd2 receptor antagonist activity:

20090030015 - Novel multi-cyclic compounds:

20090030016 - Benzimidazole poly(adp ribose)polymerase inhibitors: Compounds which inhibit the activity of poly(ADP-ribose)polymerase (PARP), compositions containing the compounds and methods of treating diseases using them are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090030018 - Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex: m

20090030017 - Therapeutic agent for dyskinesia: The present invention relates to a therapeutic agent for dyskinesia excluding tremor, comprising 1,2-dihydropyridine compound, a salt thereof, or a solvate thereof, which shows AMPA receptor antagonism and is highly useful as a pharmaceutical drug.... Agent: Venable LLP

20090030019 - Purine derivatives having, in particular, anti-proliferative properties, and their biological uses: This invention provides 2-, 6, and 9-substituted purine derivatives, particularly 2(1-R hydroxymethylpropylamino)-6-benzylamino-9-isopropyl purine, having, in particular, antiproliferative properties, and suitable for use as pharmaceutical compositions and herbicidal compositions. Also provided are pharmaceutical compositions and herbicidal compositions comprising the 2-, 6, and 9-substituted purine derivatives, and methods of treatment using the... Agent: Foley And Lardner LLP Suite 500

20090030020 - 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors: i

20090030021 - Quinazoline derivatives and therapeutic use thereof:

20090030022 - Fungicidal composition comprising cyprodinil: A fungicidal composition in the form of a liquid concentrate, which, in addition to at least one formulation adjuvant, comprises cyprodinil and an unsaturated C18-fatty acid selected from oleic acid, linoleic acid and linolenic acid.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090030023 - Pyrimidine compounds and medicinal composition thereof: wherein, R1 and R2 are the same as or different from each other and each represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a non-aromatic heterocyclic group, an aromatic hydrocarbon cyclic group, an aromatic heterocyclic group, an acyl group... Agent: Birch Stewart Kolasch & Birch

20090030024 - Thiazoles as fungicides: e

20090030025 - Trans-fused chromenoisoquinolines synthesis and methods for use: Optionally substituted chromenoisoquinolines and analogs and derivatives thereof are described herein. In addition, syntheses of these compounds are described herein. In addition, uses of these compounds as dopamine receptor binding compounds are described herein.... Agent: Bose Mckinney & Evans LLP

20090030026 - Sustained release formulations of nalbuphine: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.... Agent: Davidson, Davidson & Kappel, Llc

20090030027 - Androgen receptor modulator compounds and methods: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors, and to methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.... Agent: Bell, Boyd & Lloyd LLP

20090030028 - Tetrahydroquinolines: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.... Agent: Millen, White, Zelano & Branigan, P.c.

20090030029 - Novel benzonaphthyridines: s

20090030030 - Arylalkenyl and arylalkynyl substituted imidazoquinolines: Arylalkenyl and aryalkynyl substituted imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.... Agent: 3m Innovative Properties Company

20090030031 - Method of preferentially inducing the biosynthesis of interferon: A method of preferentially inducing IFN-α biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and... Agent: Wolf Greenfield & Sacks, P.c.

20090030032 - Bicyclic compound, production and use thereof: wherein, R1 is a 5- to 6-membered ring group which may be substituted; X1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X2 is a bivalent... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090030033 - Novel compounds 894: The invention relates to 2-aza-bicyclo[2.2.2]octane compounds and uses thereof. Particularly the invention relates to such compounds and their uses as pharmaceuticals in treating pyshoses such as schizophrenia and other diseases, disorders, or conditions.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090030034 - Use of fgf inhibiting substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis: The present invention thus relates to the use of 1,2,3-substituted indolizine derivatives in the preparation of medicaments of use in the treatment of diseases related to pathological choroidal angiogenesis, which derivatives correspond to the following general formula (I):... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090030035 - 3-aryloxy-8-aza-bicyclo[3.2.1]]oct-6-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: e

20090030036 - Nuclear receptor binding agents: The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBAs are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, oxidative... Agent: Pearl Cohen Zedek Latzer, LLP

20090030037 - Sustained release formulation and dosing schedules of leukotriene synthesis inhibitor for human therapy: The invention relates to materials and methods for therapy to inhibit the production of leukotrienes, and therapeutic and prophylactic applications thereof.... Agent: Marshall, Gerstein & Borun LLP

20090030038 - Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor: The present invention relates to new compounds of formula I. (I) wherein R1 to R12, X, Q and n are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090030039 - Piperidine derivatives as cxcr3 receptor antagonists: e

20090030040 - Substituted heterocyclic ethers and their use in cns disorders: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090030041 - N-substituted n-(4-piperidinyl) amide derivative: An N-substituted N-(4-piperininyl)amide derivative represented by the following formula (I): (wherein R1 represents C1-6 alkyl, furyl, etc.; R2 represents amino, acetylamino, ureido, etc.; R3 represents hydrogen, C2-8 alkoxycarbonyl, etc.; R4 represents optionally substituted phenyl, etc.; R5 represents hydroxyl, benzyloxy, etc.; R6 represents hydrogen or methyl; and m is 1 or... Agent: Nixon Peabody, LLP

20090030042 - Amide addition reaction:

20090030043 - Potassium channel inhibitors: The present invention relates to tetraaryl methyl amine compounds and derivatives thereof having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20090030044 - Crystal of salt of benzimidazole compound: A crystal of a salt of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole which is useful as a medicine, and use of the crystal.... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20090030045 - Factor xa inhibitors: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number... Agent: Foley & Lardner LLP

20090030046 - Novel glucokinase activators and methods of using same: e

20090030047 - Peritoneum protecting agent: It is an objective of the present invention to provide a novel peritoneal membrane protecting agent which can effectively suppress deterioration of peritoneal functions in long-term peritoneal dialysis (PD) patients and the like. The present invention provides a peritoneal membrane protecting agent comprising a pyridoxine or a salt thereof, as... Agent: Greenblum & Bernstein, P.L.C

20090030048 - Novel pharmaceutical compounds:

20090030049 - Medicament for genital herpes: [MEANS FOR SOLVING PROBLEMS] An N-[2-[(4-substituted phenyl)amino]-2-oxoethyl]tetrahydro-2H-thiopyran-4-carboxamide derivative in which the phenyl group is substituted at position 4 by a specific 5- or 6-membered heteroaryl group has an excellent anti-herpesvirus effect and can exert excellent therapeutic effect on genital herpes after the development of lesions. Therefore, the compound is useful... Agent: Sughrue-265550

20090030050 - Heterocyclic compounds, compositions comprising them and methods of their use: Heterocyclic compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of inflammatory and autoimmune diseases and disorders are disclosed. Particular compounds are of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20090030051 - Inhibitors of impdh enzyme: The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention... Agent: Honigman Miller Schwartz & Cohn LLP

20090030052 - Pharmaceutical tablet compositions containing irbesartan: A pharmaceutical tablet composition comprising irbesartan and lactose, said composition being essentially free of surfactant.... Agent: Volpe And Koenig, P.c.

20090030054 - Cytoplasmic antigens for detection of candida: The present invention relates to a method and a means of diagnosing Candida infection. In particular the present invention relates to a method of diagnosing Candida infection by measuring the levels of antibody to Candida cytoplasmic antigen present in a biological sample taken from a subject at risk of, or... Agent: Foley And Lardner LLP Suite 500

20090030053 - Fungicidal compositions: The invention relates to a composition capable of controlling phytopathogenic fungi on a plant or propagation material thereof said composition comprising as active ingredients a mixture of: (A) Difenoconazole or a salt or metal complex thereof; and (B) Chlorothalonil, wherein said Difenoconazole or the salt or metal complex thereof and... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090030055 - Pkc activation as a means for enhancing sappalpha secretion and improving cognition using bryostatin type compounds: The present invention relates to compositions and methods to modulate α-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20090030056 - Novel sodium channel blockers: The present invention is directed to novel phenyloin derivative compounds and the use of such compounds as sodium channel blockers. Such compositions have utility as anti-cancer agents and can be used to limit or prevent PCa growth and/or metastasis.... Agent: Clark G. Sullivan Arnall Golden Gregory LLP

20090030057 - Pharmaceutical composition of telmisartan: The present invention provides a pharmaceutical composition of telmisartan comprising a) a telmisartan compound, b) a surfactant, c) a basic agent, and d) at least one diluent wherein the composition comprises less than 25% of water soluble diluents. The telmisartan compound is preferably present from about 12.5% to about 15.5%.... Agent: Kenyon & Kenyon LLP

20090030058 - Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer: The present invention relates to a tosylate salt of Compound 1 and polymorphs thereof, in particular crystalline and amorphous forms of Compound 1 tosylate salt, and methods of preparation thereof. Pharmaceutical compositions containing these salts as active ingredient, their use in the manufacture of medicaments for use in the treatment... Agent: Morgan Lewis & Bockius LLP

20090030059 - Pharmaceutical composition for external use: Provided is a pharmaceutical composition for external use, including: (i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and (ii) α-hydroxycarboxylic acid and/or a salt thereof.... Agent: Knobbe Martens Olson & Bear LLP

20090030060 - Intravaginal treatment of vaginal infections with metronidazole compositions: The present invention provides a buffered non-flowing composition suitable for the treatment of bacterial vaginosis. The composition includes metronidazole in a concentration of about 0.50% (w/w) to about 1.50% (w/w). The metronidazole is present together with a buffer system in a physiologically tolerable medium. The buffer system provides an acidic... Agent: Schwegman, Lundberg & Woessner, P.a.

20090030061 - Benzoisoindole derivatives and their use as ep4 receptor ligands: e

20090030062 - Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine d3 receptors:

20090030063 - Combined pharmaceutical preparation for treatment of type 2 diabetes: For controlling the condition of type 2 diabetes, a pharmaceutical including a combination of mitiglinide, a pharmacologically acceptable salt thereof or a hydrate thereof and an α-glucosidase inhibitor such as voglibose or acarbose, and a therapeutic method using the pharmaceutical are provided. The pharmaceutical according to the present invention has... Agent: Wenderoth, Lind & Ponack, L.l.p.

20090030064 - Sugar-coated preparation: A preparation wherein an active ingredient unstable to oxygen is stabilized by coating a portion containing the active ingredient unstable to oxygen with a sugar-coated layer containing (1) sugar alcohol as a sugar-coating base material and (2) a binder is provided.... Agent: Edwards Angell Palmer & Dodge LLP

20090030065 - Use of pde1c and inhibitors thereof: The present invention relates to the use of PDE1C as a novel target for the identification of compounds, which can be used for the treatment of pulmonary hypertension, fibrotic lung diseases or other fibrotic diseases outside the lung. The present invention further relates to the use of PDE1C inhibitors in... Agent: Nath & Associates Pllc

20090030066 - Small molecules for the protection of pancreatic cells: Embodiments of the present invention include the in vivo and in vitro use of a family of anticancer heterocyclic compounds containing a quaternary ammonium group as exemplified by the thioxanthone and thioxanthene compounds [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride, or CCompound1, N,N,-diethyl-N-methyl-2-[9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide, or CCompound3, and N,N,N-trimethyl-3-(9H-thioxanthen-9-ylidene)-propane-1-aminium iodide, or CCompound19 to maintain and increase... Agent: Faegre & Benson LLP Patent Docketing

20090030067 - Anti-proliferative combination therapy comprising satraplatin or jm118 and a taxane: The present invention describes a method of prevention and/or treatment of a cancer or a tumor, and in particular a combination therapy, methods, compositions and pharmaceutical packages comprising a taxane and certain platinum-based chemotherapeutic agents.... Agent: Leon R. Yankwich

20090030068 - Antitumour compounds: as well as their corresponding pharmaceutically acceptable salts, derivatives, prodrugs and stereoisomers. These compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. These compounds have cytotoxic activity and can be used for the treatment of the... Agent: King & Spalding

20090030070 - External preparation for skin containing flavanone derivative: To increase a tissue regeneration ability of a living body such as a collagens production ability of fibroblast in the dermis in a skin defect area typified by a large wrinkle or wound, a flavanone derivative such as farrerol is used as an active ingredient of an external preparation for... Agent: Knobbe Martens Olson & Bear LLP

20090030069 - Insect repellent with sun protection factor: An insect repellent composition that includes a blend of either all natural oils or synthetic ingredients, a sunscreen vitamin F, volatile silicones to extend the effective repellent life of the spray and a film forming polymer to resist water wash off. The natural oils and extracts can include citronella and... Agent: Malin Haley And Dimaggio, Pa

20090030071 - Treatment of cardiovascular disease in mexican americans using nebivolol: Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such as, but not limited to, hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention relates to methods for treating and/or preventing cardiovascular disorders in persons of Hispanic descent, particularly Mexican Americans, using compositions... Agent: Frost Brown Todd, Llc

20090030072 - Pharmaceutical combination of opioid and prostaglandin compound: b

20090030073 - Plant-derived therapeutic agent for malignant:

20090030074 - Synthesis, polymorphs, and pharmaceutical formulation of faah inhibitors: Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. The alkylcarbamic acid aryl ester of Formula (I), KDS-4103, is a FAAH inhibitor. Described herein is a process for the preparation of the compound of Formula (I), characterization of polymorphs of the FAAH... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090030075 - Remedy for and method of treating ischemic cerebral stroke: a

20090030076 - Prostaglandin derivatives: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.... Agent: Pfizer Inc

20090030077 - Novel fenofibrate formulations and related methods of treatment: The invention provides novel omega-3 oil liquid formulations of fenofibrate. These formulations can be substantially free of any food effect, effective in small volumes, and readily bioavailable. Notably, because the formulations of the invention contain an omega-3 oil as the major ingredient, they not only provide anithypercholesterolemic and antihypertriglyceridemic effects... Agent: Ratnerprestia-j&j

20090030078 - Therapeutic agent for pain: The present invention relates to an agent for prevention, treatment or inhibition of symptom progression of a pain and/or for control of an analgesic comprising (2R)-2-propyloctanoic acid, a salt thereof or a prodrug thereof, in which an amount per dose is from 1 mg to 5000 mg (preferably from 10... Agent: Sughrue-265550

20090030079 - Uses of trientine and penicillamine as countermeasures to metal contamination: Methods are provided for the alleviation, prevention and treatment of negative effects of overexposure to metal contaminants. Subjects exposed to a metal contaminant can be treated using trientine and/or penicillamine or salts, esters, solvates thereof. In addition, communities can protect its members by securing sufficient quantities of such countermeasures.... Agent: Foley And Lardner LLP Suite 500

20090030080 - Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states: This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20090030081 - Use of lr-90 and lr-102 to overcome insulin resistance: The present invention provides methods for ameliorating, overcoming, or inhibiting insulin resistance in a subject, comprising administering to the subject an effective amount of a compound selected from the group consisting of LR-90 and LR-102, or a pharmaceutically acceptable salt or derivative thereof. Methods of treating type 2 diabetes and... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20090030082 - Synthetic ligands selective for lxrbeta over lxralpha, identification and methods of use thereof: LXR nuclear receptor agonists have been previously shown to increase cholesterol efflux, raise plasma HDL cholesterol, stimulate cholesterol excretion, and reduce atherosclerotic lesions. However, these agonists have also been associated with the unwanted side effect of hypertriglyeridemia. This hypertriglyeridemia appears to be mediated by the LXRα subtype rather than LXRβ,... Agent: Perkins Coie LLP

20090030083 - Use of n-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury: R

20090030084 - Compositions and methods of use of electron transport system inhibitors: The invention provides compounds of the formula: or a pharmaceutically acceptable salt thereof, where m, n, R1, R2, R3 R4, R5, R6, R7 are those defined herein. The invention also provides pharmaceutical compositions comprising a compound of the invention, methods for using compounds and/or pharmaceutical compositions of the invention, and... Agent: Don D. Cha

20090030085 - Use of bis-amines to enhance the antimicrobial activity of aqueous compositions: The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.... Agent: Alcon

20090030086 - Antimicrobial agents: A benzoquinone or hydroquinone for use in the topical treatment of a condition which is caused, exacerbated or transmitted by bacterial, in particular staphylococcal or propionibacterial, activity. The condition may be a skin or skin structure condition such as acne. The invention also provides the use of a benzo- or... Agent: Weaver Austin Villeneuve & Sampson LLP

20090030087 - Extracts derived from chenopodium plants and uses thereof: The present invention relates to pesticides. More particularly, the present invention relates to botanical pesticides. In particular, the present invention relates to compositions and methods for controlling plant-infesting pests with plant extracts and notably with compositions comprising oil extracts derived from Chenopodium sp. plant material. The invention further relates to... Agent: Agraquest, Inc.

20090030088 - Therapeutic benefits of gossypol, 6-methoxy gossypol, and 6,6'-dimothxy gossypol: 6-methoxy gossypol and 6,6′-dimethoxy gossypol were isolated from cottonseeds. Bioactivities of these two gossypol derivatives and gossypol were investigated regarding their antioxidant activities, DNA damage prevention ability, anti-cancer, and anti-trypanosomal activities. Both methoxy compounds had nearly equivalent bioactivities, but gossypol showed greater bioactivities than either methoxy derivative on free radical... Agent: J. Bennett Mullinax, Llc

20090030089 - Silicon substituted oxyapatite: The invention is a silicon substituted oxyapatite compound (Si—OAp) for use as a synthetic bone biomaterial either used alone or in biomaterial compositions. The silicon substituted oxyapatite compound has the formula Ca5(PO4)3-x(SiO4)xO(1-x)/2, where 0<x<1.0.... Agent: Medtronic Attn: Noreen Johnson - Ip Legal Department

20090030090 - Carbon nanotube reinforced polymer nanocomposites: The present invention is directed to carbon nanotube (CNT)/polymer composites, i.e., nanocomposites, wherein the CNTs in such nanocomposites are highly dispersed in a polymer matrix, and wherein the nanocomposites comprise a compatibilizing surfactant that interacts with both the CNTs and the polymer matrix. The present invention is also directed to... Agent: Winstead Pc

20090030091 - Brown film composition and method for preparing the same: The present invention provides a film composition containing caramel (Caramel I, II, III or IV) as a brown colorant, particularly a film composition containing a water-soluble cellulose derivative as a base component and suitably used for a capsule base, the film composition ensuring high degree of transparency because of the... Agent: Fitch, Even, Tabin & Flannery

20090030092 - Thickening agent: Thickening agents which containing a specific N-acylamino acid (component A) and a specific amideamine (component B) are capable of generating, when used in combination with a wide variety of oily bases including a hydrocarbon oil and silicone, a creamy thickening composition having a practical dissolution temperature and a smooth feeling... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090030093 - Method for emulsion polymerisation of olefins: Process for the emulsion polymerization of one or more olefins by reacting a quinoid compound with a metal compound and a phosphine compound which is substituted by at least one polar radical and subsequently using the reaction product for the polymerization or copolymerization of olefins in water or in a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

  
01/22/2009 > patent applications in patent subcategories. recently filed with US Patent Office

20090023627 - Compositions and methods for alzheimer's disease: The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (Aβ) protein or peptide. Anti-Aβ antibodies are selected and sequenced. In certain embodiments, synthetic Aβ binding peptides are... Agent: Faegre & Benson LLP Patent Docketing

20090023629 - Compositions comprising polycation-complexed protein crystals and methods of treatment using them: The present invention relates to compositions comprising polycation-complexed protein crystals and hyaluronic acid. Advantageously, the compositions of this invention are stable, long-acting and avoid local reactions at the injection site. Compositions according to this invention include sustained-release human growth hormone compositions. Such compositions are useful for treating a subject having... Agent: Lowrie, Lando & Anastasi, LLP

20090023628 - Cosmetic composition and a process for preparing this cosmetic composition and a cosmetic product: The present invention relates to a cosmetic composition comprising: a wetting system that comprises at least glycerin in an amount ranging from 8.0% to 10% by weight, based on the total weight of the composition; an emollient system that comprises at least cetyl lactate and Shea butter; an emulsifying system... Agent: Alston & Bird LLP

20090023631 - Composition and method of use for soft tissue augmentation/drug delivery: A composition for augmenting soft tissue and drug delivery is provided. The composition includes an active ingredient, a carrier, and a cross-linking agent, wherein the carrier is cross-linked with the cross-linking agent and the active ingredient is combined with the cross-linked carrier into a combination having a therapeutic effect. Techniques... Agent: Ryan, Mason & Lewis, LLP

20090023630 - Methods and means for use in diagnostics and treatment of diabetes: The present invention identified novel epitopes from the insulin B chain which is embodied in methods and means for diagnostics and treatment of type 1 diabetes. The epitopes were found in a peptide comprising a fragment of the human insulin B chain. Using HLA-A2 tetramers having the peptide of the... Agent: Morgan Lewis & Bockius LLP

20090023632 - Hemoglobin-haptoglobin complexes: Construct-complexes of a hemoglobin, a hepatocyte modifying substance bound to the hemoglobin, and a haptoglobin bound to the hemoglobin, are provided, for administration to mammalian patients. The construct-complex may be formed ex vivo, or a hemoglobin-hepatocyte modifying substance combination may be administered to the patient so that haptoglobin in the... Agent: Nixon & Vanderhye, Pc

20090023633 - Regulation of mineral and skeletal metabolism: A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting... Agent: Bozicevic, Field & Francis LLP

20090023634 - Regulation of mineral and skeletal metabolism: A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting... Agent: Bozicevic, Field & Francis LLP

20090023635 - Factor vii or viia - like molecules: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.... Agent: Bayer Healthcare Llc

20090023636 - Methods and compositions for the prevention and treatment of anemia: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a... Agent: Amgen Inc.

20090023637 - Methods for detecting and treating interstitial cystitis: The invention provides a method for diagnosing and inhibiting conditions associated with reduced amounts of THP and/or reduced amounts of total carbohydrate content in the THP, such as Interstitial Cystitis and its symptoms, and damaged mucin layers in a subject by administering an effective amount of a Tamm-Horsfall protein to... Agent: Mandel & Adriano

20090023639 - Methods of treatment: A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the method comprising administering to... Agent: Patrea L. Pabst Pabst Patent Group LLP

20090023638 - Spill resistant antibiotic formulations: The disclosure is directed to a pharmaceutical kit with a first set, a second set and a third set of components. The first set of components can be a carbomer in an aqueous vehicle, the second set of components can be an antibiotic, and the third set of components can... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20090023641 - Cyclic antimicrobial peptides: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.... Agent: Morgan, Lewis & Bockius LLP (sf)

20090023642 - Isolation, purification, and structure elucidation of the antiproliferative compound coibamide a: Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman

20090023640 - Use of a cyclic undecapeptide for the preparation of a medicament for administration during myocardial ischaemic events: The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event.... Agent: Nixon & Vanderhye, Pc

20090023645 - Aib1, a novel steroid receptor co-activator: The invention features a substantially pure DNA which includes a sequence encoding a novel steroid receptor co-activator which is overexpressed in breast cancer cells, diagnostic assays for steroid hormone-responsive cancers, and screening assays to identify compounds which inhibit an interaction of the co-activator with the steroid hormone.... Agent: Klarquist Sparkman, LLP

20090023654 - Axmi-008, a delta-endotoxin gene and methods for its use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin and delta-endotoxin-associated polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria.... Agent: Alston & Bird LLP

20090023655 - Biased ligands for receptors such as the pth receptor: Disclosed are compositions and methods for modulating the β-arrestin pathway selectively over the G protein pathway of a G protein couple receptor, such as parathyroid hormone receptor.... Agent: Clark G. Sullivan Arnall Golden Gregory LLP

20090023657 - Catecholamine regulated protein: A novel family of mammalian catecholamine proteins is identified. These proteins are useful in methods of diagnosing neurological diseases, including schizophrenia and bipolar disease, as well as cardiovascular disease. This family of CRP40 proteins are also useful to treat neurological diseases.... Agent: Borden Ladner Gervais LLP Anne Kinsman

20090023656 - Combination comprising combretastatin and anticancer agents: This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090023646 - Ghrh analogues: The present invention relates to growth hormone-releasing hormone (GHRH) analogues. More particularly, the invention relates to synthetic GHRH analogues of amino acids or more, exhibiting concomitantly an increased resistance to proteolysis and high binding affinity to human GHRH receptor in in vitro studies, in comparison with human native GHRH (1-29)NH2.... Agent: K&l Gates LLP

20090023651 - Inhibitors of human plasmin derived from the kunitz domains: This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins.... Agent: Lowrie, Lando & Anastasi, LLP

20090023647 - Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis: The present invention relates to the treatment of coronary heart disease by revascularization therapy, and more particularly to the intramyocardial injection of a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 protein or a fragment of a recombinant fibroblast growth factor-1 protein, optionally, with a physiologic glue for inducing local... Agent: Knobbe Martens Olson & Bear LLP

20090023653 - Method of using broad-spectrum delta-endotoxins: Disclosed are novel synthetically-modified B. thuringiensis chimeric crystal proteins having improved insecticidal activity and broader insect host range against coleopteran, dipteran and lepidopteran insects. Also disclosed are the nucleic acid segments encoding these novel peptides. Methods of making and using these genes and proteins are disclosed as well as methods... Agent: Howrey LLP

20090023659 - Methods and materials relating to cd84-like polypeptides and polynucelotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of... Agent: Nuvelo, Inc

20090023643 - Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same: This invention relates to methods of treating acute myocardial infarction by administering calcitonin gene related peptide (CGRP). This invention also relates to preventing an acute myocardial infarction by administering calcitonin gene related peptide (CGRP). This invention further relates to compositions of CGRP for use in such methods. This invention also... Agent: Morrison & Foerster LLP

20090023648 - Methods for treating body tissue: Methods of treating body tissue including repairing defects in body tissue as well as augmenting body tissue. Body tissue defects are repaired by injecting a polymeric adhesive composition through an injector into the region of the defect and allowing the adhesive composition to cure to repair the defect or to... Agent: Morgan, Lewis & Bockius, LLP

20090023644 - Methods of using cgrp for cardiovascular and renal indications: The present invention provides methods of treating and preventing mortality associated with heart failure and renal insufficiency in a Stage B, C, or D heart failure patient, and for improving quality of life by providing improved methods of administering a therapeutically effective amount CGRP. One method comprise administering between about... Agent: Morrison & Foerster LLP

20090023658 - Neovascularization inhibitors derived from hgf and methods involving the same: Novel neovascularization inhibitory factors and neovascularization inhibitors useful in preventing and treating various diseases in association with neovascularization. These neovascularization inhibitors contain as the active ingredient polypeptides with the following definition (a) or (b): (a) a polypeptide having an amino acid sequence of PyrGlu32-Val478 in HGF (hepatocyte growth factor); or... Agent: Sughrue Mion, Pllc

20090023660 - Novel hemopoietin receptor protein, nr12: A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was... Agent: Fish & Richardson Pc

20090023652 - Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders: The present invention provides methods and kits for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders. In particular, methods for lowering serum PTH and serum calcium using polycationic calcium modulator peptides are provided. The calcium modulator peptides can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism;... Agent: Morrison & Foerster LLP

20090023649 - Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments: The present invention is directed to an isolated polypeptide including: (1) the A subunit of Shiga-like bacterial toxin, wherein said subunit has the nucleic acid sequence of SEQ ID NO:9; and (2) human vascular endothelial growth factor wherein the growth factor has the nucleic acid sequence of SEQ ID NO:10;... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090023650 - Treatment of egfr-dependent tumors by abin (a20 -binding inhibitor of nf kappab): The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors.... Agent: Trask Britt

20090023661 - Use of antagonists of the bradykinin b2 receptor for the treatment of osteoarthrosis: e

20090023662 - Identification of agonistic autoantibodies associated with humoral kidney rejection: The invention relates to a method for detecting autoantibodies associated with humoral kidney rejection, which recognize extracellular structures of G protein-coupled receptors, and to the use of peptides, which comprise these loops or fragments thereof, for treating humoral kidney rejection.... Agent: Norris, Mclaughlin & Marcus, P.a.

20090023663 - Thymosin beta 4 compositions and methods: A method of treatment for skin, dermal or epidermal tissue utilizes a composition including an actin-binding polypeptide which may include amino acid sequence LKKTET [SEQ ID NO: 1] or a conservative variant thereof.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20090023664 - Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors: α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.... Agent: Banner & Witcoff, Ltd.

20090023665 - Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus... Agent: Pharmacia & Upjohn

20090023666 - Modulators of hypoxia inducible factor-1 and related uses: The invention features compounds of formulas I or II: and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.... Agent: Clark & Elbing LLP

20090023667 - Composition for preventing harmful organisms: wherein, in the formula, R1 represents a hydrocarbon having 1 to 6 carbon atoms which is substituted with halogen or the like; R2 and R7 each independently represent a hydrogen atom, a hydrocarbon having 1 to 6 carbon atoms or the like; R3 and R4 each independently represent a hydrogen... Agent: Buchanan, Ingersoll & Rooney Pc

20090023668 - Method for treating blepharitis: The present invention is related to a method for treating blepharitis, the method comprising administering to an ocular area of a subject in need thereof a composition comprising about 0.001% to about 0.01% (w/v) dexamethasone and an antibiotic, wherein the composition is substantially free of lipids, and wherein the composition... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090023669 - Antibacterial agents: The present invention, in one aspect, provides a method of inhibiting bacterial growth by contacting bacteria with an effective amount of at least one monosaccharide compound of formula (1) as described herein:... Agent: Morrison & Foerster LLP

20090023672 - Age-2 aptamer: An AGE-2 aptamer which binds to a glyceraldehyde-derived advanced glycation end product (AGE-2) but not to human serum albumin and comprises at least 35 bases and in which the cytosine content in the bases is at least 35%, or the guanine content in the bases is at least 32%. Since... Agent: The Webb Law Firm, P.c.

20090023673 - Lipid containing formulations: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.... Agent: Lowrie, Lando & Anastasi, LLP A2038

20090023670 - Regulation of transgene expression by rna interference: Expression of transgenes delivered into a host organism cells can be regulated by RNA effector molecules delivered to or present in the host organism cells. Regulation can be mediated by delivery of RNA interference inducing molecules that target the transgene mRNA or by incorporating engineered RNA effector binding sites into... Agent: Mirus Corporation

20090023675 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent: Sima Therapeutics, Inc.

20090023676 - Rna interference mediated inhibition of map kinase gene expression or expression of genes involved in map kinase pathway using short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating MAP kinase gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA),... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20090023671 - Rnai agents for maintenance of stem cells: The present invention provides compositions and methods suitable for delivering RNAi agents against genetic targets in stem cells so as to direct cell growth and differentiation.... Agent: Patton Boggs LLP

20090023674 - Snrna gene-like transcriptional units and uses thereof: By a computer search for upstream promoter elements (DSE, PSE) typical of small nuclear RNA (snRNA) genes, we have identified a number of previously unrecognized, putative transcription units whose predicted products are novel noncoding RNAs with homology to protein-coding genes. By elucidating the function of one of them, we provide... Agent: Juneau Partners

20090023677 - Modulation of telomere length in telomerase positive cells and cancer therapy: Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention of tumorigenic telomerase positive cells from having a chance to grow into a tumor and methods for promoting tumor regression (decrease in size... Agent: Reed Smith LLP

20090023678 - Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds: The invention relates to pharmaceutical compositions that provide sustained-release of a pharmaceutically active compound and to methods of treating or preventing a condition in an animal by administering the pharmaceutical compositions to the animal. When the pharmaceutical compositions are administered to an animal by injection, they form a drug depot... Agent: Townsend And Townsend And Crew, LLP

20090023679 - Compounds and methods for treatment of sickle cell disease or complications associated therewith: Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described.... Agent: Seed Intellectual Property Law Group Pllc

20090023680 - Fixed ratio drug combination treatments for solid tumors: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.... Agent: Morrison & Foerster LLP

20090023681 - Method of using beta-glucan from schizophyllum commune: Disclosed herein is a method for high-yield production of Schizophyllum commune-derived beta-glucan having a homogeneous composition, comprising subjecting mycelia of Schizophyllum commune to liquid culture with an addition of a synthetic adsorbent, and a composition for external application comprising the beta-glucan produced therefrom, which is capable of relieving dry skin... Agent: Birch Stewart Kolasch & Birch

20090023683 - Complexes comprising zoledronic acid and cyclodextrins: The present invention relates to stable compositions comprising zoledronic acid, wherein zoledronic acid is complexed with a cyclodextrin, such as hydroxypropyl-β-cyclodextrin. The invention further relates to processes for making the compositions.... Agent: Dr. Reddy''s Laboratories, Inc.

20090023682 - Composition comprising dietary fat complexer and methods of using same: A composition includes α-cyclodextrin and at least one lipase inhibitor. A method for promoting weight loss, inhibiting weight gain, or maintaining weight in a subject in need thereof includes administering α-cyclodextrin and at least one lipase inhibitor to the subject, thereby reducing the bioavailability of ingested fat and reducing the... Agent: Cahn & Samuels LLP

20090023684 - Fluid for peritoneal dialysis: The present invention has an object to provide a fluid for peritoneal dialysis with satisfactory body fluid removability, high biocompatibility, and improved storage stability, and the object is attained by a fluid for peritoneal dialysis containing one or more saccharides selected from cyclonigerosylnigerose, cyclomaltosylmaltose, and L-ascorbic acid 2-glucoside.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090023685 - Nebulized or sprayed cidofovir for recurrent respiratory papillomatosis: A solution of 2.5-20% cidofovir is administered as droplets having a mean size of about 1 micron to about 20 microns either nebulized or as a spray to an individual having recurrent respiratory papillomatosis.... Agent: Ade & Company Inc.

20090023686 - Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions: A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts,... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20090023687 - Method for controlling phytopathogenic organisms: The present invention is directed to methods of protecting crops of useful plants against attack by phytopathogenic organisms as well as the treatment of crops of useful plants infested by phytopathogenic organisms comprising administering a combination of glyphosate and at least one fungicide to the plant or locus thereof.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090023688 - Microbicidal composition: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.... Agent: Rohm And Haas Company Patent Department

20090023689 - Oral drug delivery system: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.... Agent: Thomas P. Mccracken Durect Corporation

20090023690 - Oral drug delivery system: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.... Agent: Thomas P. Mccracken Durect Corporation

20090023691 - Delaying the ageing process and disorders caused by ageing: The present invention relates to the field of ageing, particularly to the prevention and/or treatment of ageing process and disorders caused by ageing and particularly to the prevention and/or treatment of atherosclerosis, neurodegenerative disorders and malignant diseases. A composition is provided, which comprises four or more active ingredients to reduce... Agent: Bell, Boyd & Lloyd, LLP

20090023692 - Compositions for inhibiting and preventing vascular occlusion containing nutritional supplements: Compositions for inhibiting vascular occlusion in humans comprising aspirin for inhibiting vascular occlusion which further contain nutritional supplements are disclosed. The compositions are provide in a dosage form that provides stability of the active ingredient allowing for improved shelf life. A further composition included a cholesterol-lowering agent in combination with... Agent: Seyfarth Shaw LLP

20090023694 - Contraceptive: The present invention relates to an administration form for hormonal contraception consisting of a particular number of hormone-containing daily units, comprising a hormone combination consisting of at least one oestrogen selected from the group comprising ethinyl oestradiol (I) and oestradiol (II) as the oestrogen component, and at least one metabolite... Agent: Norris, Mclaughlin & Marcus, Pa

20090023695 - Method of making and using 7alpha,11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate: e

20090023693 - New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen:

20090023696 - Use of c3-c10 17alfa-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents: The present invention relates to the use of C3-C10 17α-esters of 9,11-dehydrocortexolone as agents for inhibiting gonadotrophin secretion. The present invention therefore relates to the use of C3-C10 17 α-esters of 9,11-dehydrocortexolone for the preparation of a medicine for the treatment of disorders associated with the secretion of gonadotrophin and... Agent: Darby & Darby P.c.

20090023697 - Analgesia method: Opioid tolerance is reduced by treating the patient with a neurosteroid of formula (I) wherein R1 is H or methyl; R2 is OH and R3 is H, or R2 and R3 taken together are O; R4 is H or methyl; R5 and R6 are each H, or R5 and R5... Agent: Knobbe Martens Olson & Bear LLP

20090023699 - Method for obtaining a natural mixture of conjugated equine estrogens depleted in non-conjugated lipophilic compounds: A method for obtaining an extract containing the natural mixture of conjugated equine estrogens by liquid-liquid extraction of the mixture of conjugated equine estrogens, wherein the mixture obtained is depleted in non-conjugated lipophilic compounds selected from the group consisting of non-conjugated flavonoids, non-conjugated isoflavonoids, non-conjugated norisoprenoids, non-conjugated steroids, in particular... Agent: Crowell & Moring LLP Intellectual Property Group

20090023698 - Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid: The present invention provides a method for preparing a compound of formula (I), the method comprising contacting a compound of formula (II) with an effective amount of a compound of formula (III) or (IV). The present invention also provides a method for preparing a compound of formula (VI), the method... Agent: Schwegman, Lundberg & Woessner, P.a.

20090023700 - Neuroprotective treatments: The present invention provides a therapeutic method for treating traumatic neural injury or a degenerative disorder in a mammal by administering a neuroprotective compound, wherein the neuroprotective compound is a peroxovanadium compound, a peroxovandium derivative, or a compound with inhibitory activity of protein tyrosine phosphatases.... Agent: Viksnins Harris & Padys Pllp

20090023701 - Cytokine inhibitors: e

20090023702 - Pyridone gpr119 g protein-coupled receptor agonists: Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR 119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090023703 - Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase: v

20090023704 - Novel compounds 737: having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of... Agent: Pepper Hamilton LLP

20090023705 - Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders: The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a... Agent: Alston & Bird LLP

20090023706 - Method of treating organophosphorous poisoning: The present invention is directed to various methods for treating organophosphorus poisoning in an animal that is at risk of exposure to an organophosphorus compound or preventing organophosphorus poisoning in an animal that has been exposed to an organophosphorus compound, by administering a therapeutically effective amount of galantamine or a... Agent: Evans & Molinelli, Pllc

20090023708 - Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses: The present invention relates to compounds of formula (I) comprising a lactam or a lactam derivative moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090023709 - Inhibitors of 11b-hyrdoxysteroid dehydrogenase: e

20090023707 - Aminoalkylazole derivatives as histamine-3 antagonists:

20090023710 - Compound: There is provided a compound having Formula (I) wherein each of R1, R2, R3, R4, R5, R6 and R7 are independently selected from (a) H, (b) R17, —OC(R17)3, —OCH(R17)2, —OCH2R17, —C(R17)3, —CH(R17)2, or —CH2R17 wherein R17 is a halogen; (c) —CN; (d) optionally substituted alkyl, (e) optionally substituted heteroalkyl; (f)... Agent: Frommer Lawrence & Haug

20090023711 - Piperazines and piperidines as mglur5 potentiators: e

20090023712 - Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin: The invention relates to new pharmaceutical compositions for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090023713 - Heterocyclic compounds: e

20090023714 - Combined preparation of a thiazide diuretic and a loop diuretic: The invention relates to pharmaceutical preparations which contain a combination of a thiazide diuretic and a low-dose loop diuretic and which are particularly useful for treating hypertension and heart failure. It is not only the overall natriuretic/diuretic effects which are increased due to said combination of thiazide diuretic and loop... Agent: Catalyst Law Group, Apc

20090023715 - Wound healing: A phenothiazinium compound, compositions and medicaments for use in promoting wound healing and a method for promoting wound healing or cosmetic use by applying or administering a phenothiazinium compound to a wound site or the skin, and optionally exposing the wound site or skin to light.... Agent: Morgan Lewis & Bockius LLP

20090023716 - Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents: wherein Ring A is a benzene ring optionally having a substituent(s) other than R1 etc, R1 is a group of the formula: RaSO2NH— etc, Ra is an alkyl group etc, R2 and R3 are each a hydrogen atom, a phenyl group, an optionally substituted alkyl group etc, X is an... Agent: Birch Stewart Kolasch & Birch

20090023717 - Morphine-bridged indazole derivatives: The present invention relates to novel morpholine-bridged indazole derivatives which stimulate soluble guanylate cyclase, to process for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of disorders of the central nervous system.... Agent: Edwards Angell Palmer & Dodge LLP

20090023718 - Diamine and iminodiacetic acid hydroxamic acid derivatives: The present invention relates to a novel class of hydroxamic acid derivatives having a diamine or iminodiacetic acid backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively including terminal differentiation, arresting cell... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo Attn: Patent Intake Customer No. 35437

20090023719 - Pyrimidine derivatives 934: e

20090023720 - 2-amino 1h-imidazo ring systems and methods: 1H-Imidazo ring systems (e.g., imidazopyridines, imidazoquinolines, imidazonaphthyridines, 6,7,8,9-tetrahydro imidazoquinolines and imidazonaphthyridines) with an amino substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases... Agent: 3m Innovative Properties Company

20090023722 - Amide substituted imidazoquinolines: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.... Agent: Wolf Greenfield & Sacks, P.c.

20090023721 - Novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives and their use as a medicament: i

20090023724 - Heteroaryl compounds, compositions thereof, and methods of treatment therewith: wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering... Agent: Jones Day

20090023723 - Purinone derivatives for treating neurodegenerative diseases: e

20090023725 - Fused heteroaryl derivatives for use as p38 kinase inhibitors:

20090023726 - Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase:

20090023727 - Phthalazinone derivatives: wherein: R represents one or more optional substituents on the fused cyclohexene ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; if X=NRX, then RX is selected from the group consisting of H, optionally substituted C1-20 alkyl,... Agent: Morgan Lewis & Bockius LLP

20090023728 - 1,2,3,4-tetrahydroisoquinoline derivatives, preparations thereof and uses thereof: Compounds of general formula (I) wherein D, E, R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090023729 - Trisubstituted amine compound: wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted heterocyclic group, and the like; R1 is an optionally substituted alkyl group, wherein the alkyl group further may optionally be substituted by an optionally substituted homocyclic... Agent: Birch Stewart Kolasch & Birch

20090023732 - Citrate salt of an indole derivative and its pharmaceutical use: The salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing it and the use of it in therapy, and particularly in the therapy of GSK3 related conditions and disorders.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090023733 - Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them: The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as... Agent: Fish & Richardson P.c.

20090023731 - Soluble epoxide hydrolase inhibitors: Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory,... Agent: Foley & Lardner LLP

20090023730 - Substituted aryl acylthioureas and related compounds; inhibitors of viral replication: s

20090023734 - Inhibitors of histone deacetylase: The invention provides compounds and methods for treating cell proliferative diseases. The invention provides new inhibitors of histone deacetylase enzymatic activity, compositions of the compounds comprising the inhibitors and a pharmaceutically acceptable carrier, excipient, or diluent, and methods of using the compounds to inhibit cellular proliferation in vitro and therapeutically.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090023736 - Compounds for treating proliferative disorders: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20090023735 - Sulphonamide derivatives: The invention relates to sulphonamide derivatives of formula (I), where RC is selected from a group consisting of dialkylamino, NO2, CN, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkanoyl, oxazol-2-yl, oxazolylaminocarbonyl, aryl, aroyl, aryl-CH(OH)—, arylaminocarbonyl, furanyl, where the aryl, aroyl and furanyl moieties may be substituted, guanidinyl-(CH2)z—N(R′)—, Het-(CH2)z—N(R′)—, Het-CO—N(R′)—, Het-CH(OH)— and Het-CO—, where Het... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090023739 - Capase inhibitors and uses thereof: wherein R1 is hydrogen, CHN2, R, or —CH2Y; R is an aliphatic group, an aryl group, an aralkyl group, a heterocyclyl group, or a heterocyclylalkyl group; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; X2—X1 is N(R3)—C(R3), C(R3)2—C(R3), C(R3)2—N, N═C, C(R3)═C, C(═O)—N,... Agent: Vertex Pharmaceuticals Inc.

20090023738 - Diaminopyrimidines as modulators of the ep2 receptor: The present invention relates to diaminopyrimidines of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.c.

20090023737 - Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands: are provided, as are methods for their preparation. The variables Z1, Z2, R3, Z4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the... Agent: Cantor Colburn, LLP

20090023740 - Sodium channel inhibitors: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of... Agent: Townsend And Townsend And Crew, LLP

20090023741 - Aryl/hetarylamides as modulators of the ep2 receptor: The present invention relates to aryl/hetarylamide derivatives of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.c.

20090023742 - Thiazolones for use as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090023743 - Inhibitors of protein kinases: Compounds that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090023744 - Combination therapy for depression: A combination therapy for treating depressive disorders is provided herein. The combination therapy comprises administering an effective amount of bupropion or its metabolites together with at least one serotonin 5-HT1A partial agonist or its metabolites to a patient in need of treatment of the depressive disorder. Pharmaceutical formulations, including packaged... Agent: Wolf Greenfield & Sacks, P.c.

20090023745 - Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors: Substituted pyrazolo[4,3-c]pyridine derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like... Agent: Scully Scott Murphy & Presser, Pc

20090023746 - Compounds and their uses 707: b

20090023747 - Cysteine protease inhibitors: A compound of the formula (II) wherein one of R1 and R2 is halo and the other is H or halo; R3 is —C1-C5 straight or branched chain, optionally fluorinated, alkyl or —CH2CR5C3-C4-Cycloalkyl; R4 is H; R5 is H, C1-C2 alkyl, C1-C2 haloalkyl, hydroxyl, OC1-C2alkyl, fluoro; R6 is a stable,... Agent: Birch Stewart Kolasch & Birch

20090023748 - Cysteine protease inhibitors: c

20090023749 - Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2- -carbamoylbenzofuran-5-yl) piperazine hydrochloride: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders,... Agent: Millen, White, Zelano & Branigan, P.c.

20090023750 - Novel salts of piperazine compounds as d3/d2 antagonists: The present invention relates to novel monohydrochloride, dihydrochloride, monohydrobromide, maleate and methanesulphonate salts of trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or their hydrates and/or solvates. Moreover, the invention relates to the process for preparing the salts and their hydrates and/or solvates, to their use in the treatment and/or prevention of conditions which require modulation... Agent: Fish & Richardson Pc

20090023751 - Compounds that protect against sensory hair cell death: The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects.... Agent: Karen S. Canady Canady & Lortz LLP

20090023753 - 1,3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents: This invention relates to novel 1,3-thiazole-5-carboxamide compounds, pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.... Agent: Bayer Health Care Llc

20090023752 - N-heterocyclylphthaldiamides as insecticides: i

20090023755 - Use of istradefylline for treating behavioral disorders: The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like.... Agent: Fitzpatrick Cella Harper & Scinto

20090023754 - Modified release famciclovir pharmaceutical compositions: A modified release pharmaceutical composition of famciclovir contains at least 60% by weight famciclovir with at least 5% by weight of a release retardant. Particularly useful as a release retardant include polymers, especially a mixture of polyvinyl acetate and polyvinylpyrrolidone. A method of making such pharmaceutical compositions using a extruder... Agent: Novartis Corporate Intellectual Property

20090023756 - Substituted quinazolines as pde10 inhibitors: The invention pertains to substituted quinazoline compounds of structures (I) and (II) that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds which are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use... Agent: Pfizer Inc Steve T. Zelson

20090023757 - Process for preparing bicyclic compounds: The present invention relates to a novel process for preparing compounds of formula (IA), which are potent and specific antagonists of corticotropin-releasing factor (CRF) receptors, from intermediate compounds of formula (I), by a coupling reaction catalysed by copper.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090023758 - Macrocyclic inhibitors of hepatitis c virus: Compounds of the formula (I): and N-oxides, salts and stereoisomers thereof wherein A is OR1, NHS(═O)pR2, NHR3, NRaRb, C(═O)NHR3 or C(═O)NRaRb wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl or NRaRb; R3 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl, —OC1-C6alkyl, —OC0-C3alkylenecarbocyclyl, —OC0-C3alkyleneheterocyclyl; wherein any alkyl, carbocyclyl or heterocycylyl in... Agent: Birch Stewart Kolasch & Birch

20090023759 - Quinazoline derivatives as inhibitors of egf and/or erbb2 receptor tyrosine kinase: m

20090023760 - Anti-cancer cyclopenta[g]quinazoline compounds: Cyclopenta[g]quinazolines of the formula (I): wherein: A is a group OR or NR0R1 wherein R0 and R1 are each independently hydrogen C1-4 alkyl, C1-4 alkenyl, C1-4 alkynyl, C1-4 hydroxyalkyl, C1-4 halogenoalkyl or C1-4 cyanoalkyl, or R0 and R1 together with the intermediate N form a five- or six-membered heterocyclic ring,... Agent: Nixon & Vanderhye, Pc

20090023761 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20090023762 - Substituted 2-aminopyrimidine-4-ones, their pharmaceutical compositions and their use in the treatment and/or prevention of ab-related pathologies: This invention relates to novel compounds having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel en compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Pepper Hamilton LLP

20090023763 - Condensed pyridine derivatives useful as a2b adenosine receptor antagonists: New antagonists of the A2B adenosine receptor represented by formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of the A2B adenosine receptor.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090023764 - Use of pyrimidinedione derivative for preventing or treating hepatitis c: A pyrimidinedione derivative of formula (I) or a pharmaceutically acceptable salt thereof exhibits excellent inhibitory activity against hepatitis C virus.... Agent: Sughrue Mion, Pllc

20090023765 - Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic... Agent: Global Patent Group - Apx Ms. Lavern Hall

20090023766 - Pharmaceutical formulation of apomorphine for buccal administration: The present invention provides a kit comprising, in separate compartments of a container, the following components (a) and (b): (a) a combination of apomorphine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient or carrier; and (b) a solution which comprises a diluent and a pH... Agent: Buchanan, Ingersoll & Rooney Pc

20090023767 - Inhibitors of checkpoint kinases: The instant invention provides for compounds which comprise fused pyrazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.... Agent: Merck And Co., Inc

20090023768 - Rapamycin derivatives for treating neuroblastoma: A rapamycin derivative for use in the treatment of neuroblastome, optionally in combination with a second drug substance.... Agent: Novartis Corporate Intellectual Property

20090023770 - Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for preparing them and pharmaceutical compositions containing them: The present invention relates to novel 1,2,3-substituted indolizine derivative which are inhibitors of fibroblast growth factors, to methods or preparing such derivatives, to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising such derivatives.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090023769 - Organic compounds: e

20090023771 - Pharmaceutical composition comprising a proton pump inhibitor and protein component: The present disclosure relates to, inter alia, pharmaceutical compositions comprising a H+,K+-ATPase proton pump inhibitor and a protein component; to methods for manufacture of such compositions, and to use of such compositions in treating and preventing diseases and/or disorders.... Agent: Mayer Brown LLP

20090023772 - Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors: e

20090023773 - Compositions and methods for modulating gated ion channels: Disclosed are compounds that modulate the activity of the gated ion channels. Compounds that modulate these gated ion channels are useful in the treatment of diseases and disorders related to pain, inflammation, the neurological system, the gastrointestinal system and genitourinary system. Preferred compounds include compounds of the Formulae 1, 2,... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090023774 - Pyridine analogs as c5a antagonists: The present invention provides novel compounds of Formula I which are antagonists of the C5a receptor. Compounds of the present invention are useful for the treatment of various C5a-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of C5a-mediated diseases using the novel compounds described... Agent: Merck And Co., Inc

20090023775 - 1-[2-(4-benzyl-4-hydroxy-piperidin-1 -yl )-ethyl]-3-(2-methyl-quinolin- 4-yl)- urea as crystalline sulfate salt: The invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt and a process for its preparation. Further, the present invention relates to the use of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt alone or in combination with other compounds. Further, the present... Agent: Dickstein Shapiro LLP

20090023776 - Farnesyl protein transferase inhibitor combinations with antiestrogen agents: The present invention is concerned with combinations of a farnesyl transferase inhibitor and an antiestrogen agent for inhibiting the growth of tumor cells, useful in the treatment of cancer.... Agent: Philip S. Johnson Johnson & Johnson

20090023777 - Substituted 4-amino-benzylpiperidine compounds: This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder,... Agent: Theravance, Inc.

20090023778 - Composition containing anti-dementia drug: An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention... Agent: Venable LLP

20090023779 - Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents:

20090023780 - Therapeutic use of a derivative of thienylcyclohexylamine: The invention concerns the use of a thienylcyclohexylamine, on its own or associated with other substances with pharmaceutical activity, for preparing a medicine designed to prevent and/or treat pain and/or nociception.... Agent: Charles A. Muserlian C/o Hedman And Costigan

20090023781 - Haloalkyl containing compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Millen, White, Zelano & Branigan, P.c.

20090023782 - Increasing plant vigor: Compositions and processes for improving plant vigor are disclosed.... Agent: Dow Agrosciences Llc

20090023783 - Benzofuran derivatives useful for treating hyper-proliferative disorders: The invention relates to novel benzofuran derivatives, processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders... Agent: Edwards Angell Palmer & Dodge LLP

20090023784 - Use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron: A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain... Agent: Apotex, Inc.

20090023785 - 6-substituted nicotinamide derivatives as opioid receptor antagonists: A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein.... Agent: Eli Lilly & Company

20090023786 - Histone deacetylase inhibitor prodrugs: The present invention is directed to prodrugs of hydroxamic acid based histone deacetylase (HDAC) inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The prodrugs are acylated derivatives having increased aqueous solubility and cellular permeability as compared with the free hydroxamic acid, and are useful for inhibiting HDACs, and for selectively inducing terminal... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo Attn: Patent Intake Customer No. 35437

20090023787 - Technetium-dipyridine complexes, and methods of use thereof: One aspect of the invention relates to novel complexes of technetium (Tc) with various heteroaromatic ligands, e.g., pyridyl and imidazolyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to novel pyridyl ligands that form a portion of... Agent: Foley & Lardner LLP

20090023788 - Treatment of crth2-mediated diseases and conditions: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090023789 - Novel compounds as cannabinoid receptor ligands: e

20090023790 - Microbicidal composition: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.... Agent: Rohm And Haas Company Patent Department

20090023791 - Ph-dependent nmda receptor antagonists: NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neurprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor... Agent: King & Spalding LLP

20090023792 - Inhibitors of melanocyte tyrosinase as topical skin lighteners: Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for... Agent: Connolly Bove Lodge & Hutz LLP

20090023793 - Inhibitors of melanocyte tyrosinase as topical skin lighteners: Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for... Agent: Connolly Bove Lodge & Hutz LLP

20090023794 - Use of sumoylation inhibitors for the treatment of neurodegenerative disease: The invention generally provides screening methods for the identification of therapeutic compounds useful for the treatment of a neurodegenerative disease, and related prophylactic and therapeutic compositions and methods.... Agent: Edwards Angell Palmer & Dodge LLP

20090023795 - Kinase inhibitors and methods of use thereof: The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.... Agent: Viksnins Harris & Padys Pllp

20090023796 - Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents: e

20090023797 - Indol-alanine derivatives as selective s1p4-agonists:

20090023798 - Thiohydroxamates as inhibitors of histone deacetylase: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase. Also described herein are methods of using such HDAC inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC activity.... Agent: Wilson Sonsini Goodrich & Rosati

20090023800 - Cannabinoid receptor modulator: s

20090023799 - Crystals of (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(4-chlorophenyl)methanone:

20090023801 - Inhibitors of beta amyloid production: Novel sulfonamide compounds useful in the treatment of conditions related to the production of beta-amyloid are described, as are routes to their preparation. The sulfonamide compounds are of the following structure, wherein R1-R3 are defined herein. Also provided are pharmaceutical compositions containing these compounds and/or prodrugs of these compounds and... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20090023802 - Benzochromene derivatives: v

20090023804 - Electrochemical methods for redox control to preserve, stabilize and activate compounds: To maximize and maintain the antioxidant or pro-oxidant state for foods, beverages, personal care products, cosmetics, nutritional supplements, reagents, analytical standards, medical device formulations, pharmaceutical preparations or drags, the present invention discloses methods and devices to control redox equilibrium of such preparations throughout the processing steps and storage prior to,... Agent: Catalyst Law Group, Apc

20090023803 - Use of cacao polyphenols for treating a prostate hyperplasia, a specific cacao extract and applications: The invention relates to the use of cacao polyphenols for preventing or curing a prostate hyperplasia, to a cacao polyphenol extract which also comprises, in particular lipids and/or xanthines, and to the applications of said extract in food and pharmaceutical products for treating a prostate cancer, cognitive disorders, oxidative stress... Agent: Hoxie & Associates Llc

20090023805 - Method of administration: The present invention relates to the use of mycophenolic acid, a salt or prodrug thereof in immunosuppression, particularly for prevention or treatment of transplant rejection and immune-mediated and/or inflammatory diseases, wherein mycophenolic acid, the salt or the prodrug thereof is administered with an initial intensified dosage regimen.... Agent: Novartis Corporate Intellectual Property

20090023806 - Aluminum-storage disease improving agent: A safe and easy-handling method to eliminate aluminum, which can easily accumulate in a dialysis patient body, in the course of a dialysis treatment and a dialysate used in the above method to eliminate aluminum ions from blood and tissues in the body are provided. A method to eliminate aluminum... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090023808 - Production and purification of esters of polyunsaturated fatty acids: The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can... Agent: Sheridan Ross Pc

20090023807 - Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-diho-molinolenoyl or arachidonoyl patty acid glycerol monoesters: A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a monoglyceride or metabolic precursor thereof of general formula (I), wherein R1 is the fatty acyl group of an essential polyunsaturated fatty acid selected from γ-linolenoyl,... Agent: Nixon & Vanderhye, Pc

20090023809 - Hydrogen cyanamide pesticide formulations: Agricultural crops are protected from the growth of undesirable vegetation as well as nematode and insect infestations, by the application of hydrogen cyanamide in combination with a short-chain, water-soluble monocarboxylic acid, with improved pesticidal effect.... Agent: Townsend And Townsend And Crew, LLP

20090023810 - Methods of translation and/or inflammation blockade: The present invention relates to a method of translation or inflammatory response blockade by using a compound that binds to eIF4A, which is the 264th amino acid residue, a method of developing an anti-inflammation, anti-cancer or anti-viral agent by screening a compound that binds to eIF4A.... Agent: Jhk Law

20090023811 - Biphenyl compound selective agonists of gamma rar receptors: e

20090023812 - N,n-dihalogenated amino acids and derivatives: The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds.... Agent: Foley & Lardner LLP

20090023813 - Diphenyl urea derivatives: The invention relates to novel specifically trifluoromethyl and halogen substituted 1,3-diphenyl ureas and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects like the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as... Agent: Dickstein Shapiro LLP

20090023814 - Compositions and methods having mt1 receptor activity: The present invention is directed to compositions and to methods comprising a composition comprising a therapeutically effective amount of a pharmaceutically active agent such as (R)-verapamil, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats and/or manages at least one condition having MT1 receptor activity and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090023815 - Process for the recovery of tyrosol and hydroxytyrosol from oil mill wastewaters and catalytic oxidation method in order to convert tyrosol in hydroxytyrosol: e

20090023816 - Process for making a solid compound by precipitation, suspensions of solid in liquids and solids obtained by the process and their use as additives: Process for making a solid compound by precipitation, using a high intensity mixing reactor and comprising the steps of (A) introducing a first fluid material containing a first reactant and a second fluid material containing a second reactant into said reactor, in order to obtain a mixed fluid, in order... Agent: Solvay North America, Llc C/o Kim Manson, Esq.

20090023817 - Aqueous compositions comprising alkyl polyethylene glycol ether sulfates: wherein the mixing ratio of compounds of formulae (1) and (2) is chosen such that the compounds of formula (1) comprise at least 10% by weight and at most 99% by weight of the total amount of compounds of formulae (1) and (2).... Agent: Clariant Corporation Intellectual Property Department

20090023818 - Wetting agent based on a mixture of monoesters and diesters of butylene glycol: Pigment wetting agent contains a mixture of monoesters and diesters of butylene glycol and fatty acids.... Agent: Heslin Rothenberg Farley & Mesiti Pc

20090023819 - Use of an artificial sweetener to enhance absorption of nicotine: The present invention relates to increased absorption of nicotine over the prior art. In particular the absorption of nicotine is enhanced after administration of a composition containing nicotine and a sweetener such as an artificial sweetener like saccharin to the oral mucosa in the form of a spray.... Agent: Fulbright & Jaworski, LLP

  
01/15/2009 > patent applications in patent subcategories. recently filed with US Patent Office

20090018054 - Cholesteryl ester transfer protein inhibitors: Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A1 is a cyclic group, and B is a cyclic group which is attached to the... Agent: Merck And Co., Inc

20090018053 - Formulations for amylin agonist peptides: The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090018056 - Heteroarylcarbamoylbenzene derivatives: e

20090018052 - Treatment of diabetes and related pathologies: Methods for treating diabetes mellitus and related conditions and symptoms are described. The methods are directed to administering a therapeutically effective amount of a compound. Compounds suitable for the invention include pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.... Agent: Merchant & Gould PC

20090018055 - [6,5]-bicyclic gpr119 g protein-coupled receptor agonists: t

20090018057 - Oil in water emulsion comprising nsaids and quaternary ammonium halides: Oil-in-water emulsion comprising a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof.... Agent: Young & Thompson

20090018081 - Activatable clostridial toxins: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.... Agent: Allergan, Inc.

20090018078 - Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same: Protein containing nanoparticles and methods of use thereof for the treatment of proliferative disorders are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman

20090018063 - Compositions and methods for the treatment of disorders involving epithelial cell apoptosis: The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient.... Agent: Fulbright & Jaworski L.L.P.

20090018061 - Compositions and methods for treating cardiac conditions: Pharmaceutical polypeptide compositions promote the survival of cardiac cells, recruit cardiac cells to the cardiac area, stimulate the differentiation of cardiac cells, stimulate the proliferation of cardiac cells, and promote the activity of cardiac cells, thereby treating cardiac conditions. Methods of providing these compositions to the cardiac area include catheterization... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090018071 - Epididymis-specific receptor protein: The present invention relates to a novel transmembrane receptor protein which is specific to the mammalian epididymis, DNA sequences which code for the protein and specific ligands and to the use thereof for the preparation of agents for diagnosis of male infertility and for controlling maturation of spermatozoa.... Agent: Millen, White, Zelano & Branigan, P.C.

20090018076 - Fibroblast growth factor-like polypeptides: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090018077 - Fibroblast growth factor-like polypeptides: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090018070 - Fsh mutants: FSH mutants with increased glycosylation and longer half-lives are described. The use of FSH mutants for inducing folliculogenesis in human patients is also described.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090018068 - G-protein coupled receptors: The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host, cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.... Agent: Foley And Lardner LLP Suite 500

20090018072 - High protein supplement: The present disclosure relates to high protein dietary supplements for treating various symptoms and diseases associated with protein deficiency including weight gain, obesity, catabolic diseases, fibromyalgia, anxiety reactions, posttraumatic stress and chronic fatigue syndrome. Embodiments of dietary supplements comprise combinations of proteins, essential and semi-essential amino acids including L-Lysine, L-Arginine,... Agent: Knobbe Martens Olson & Bear LLP

20090018062 - Malignant tumor-inhibiting preparation comprising des a fibrin: A malignant tumor-inhibiting preparation is provided which comprises Des A fibrin and therefore can inhibit the spreading and migration of malignant tumor cells and thereby can inhibit the malignant tumors.... Agent: Husch Blackwell Sanders, LLP Welsh & Katz

20090018059 - Method for maintaining pluripotency of stem/progenitor cells: The present invention relates to a method for maintaining pluripotency and/or self-renewing characteristics of stem/progenitor cells. The invention also relates to a method for modulating gene expression in a cell. The methods include contacting at least two transcription factors, or a functional fragment thereof, with the promoter region of the... Agent: Foley & Lardner LLP

20090018069 - Methods and compositions related to mutant kunitz domain i of tfpi-2: Disclosed are methods and compositions relating to plasmin inhibition.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090018073 - Methods for treating muscle diseases and disorders: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.... Agent: Klauber & Jackson

20090018080 - Methods for treating viral infection using il-28 and il-29 cysteine mutants: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20090018079 - Optimized dna and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins: Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of... Agent: Smith Patent Consulting Consulting, LLC

20090018074 - Peptides for inhibiting insects: The subject invention pertains to the use of peptide fragments of cadherins (including cadherin-like proteins). The subject invention includes a cell (and use thereof) comprising a polynucleotide that expresses the peptide fragment. The subject invention includes methods of feeding the peptides to insects. In preferred embodiments, the peptides are fed... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090018075 - Peptides in inhibiting insects: The subject invention pertains to the use of peptide fragments of cadherins (including cadherin-like proteins). The subject invention includes a cell (and use thereof) comprising a polynucleotide that expresses the peptide fragment. The subject invention includes methods of feeding the peptides to insects. In preferred embodiments, the peptides are fed... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090018066 - Pharmaceutical compositions for modulating the activity of a novel triglyceride hydrolase: Use of an inhibitor or activator of the triglyceride hydrolyse activity of a protein comprising a polypeptide strand encoded by the DNA sequence according to SEQ No. 1 for the preparation of a pharmaceutical composition for the treatment of medical disorders where it is desirable to modulate the activity of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090018065 - Plant pr-5 proteins as mammalian therapeutic agents: The Proteins of the PR-5 family having a lectin-like P barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like P barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional... Agent: Bose Mckinney & Evans, LLP

20090018064 - Regulation of mineral and skeletal metabolism: A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting... Agent: Bozicevic, Field & Francis LLP

20090018067 - Regulatory t cell epitopes, compositions and uses thereof: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.... Agent: Foley & Lardner LLP

20090018060 - Thymus-specific protein: The invention provides the novel thymus-specific human protein T101, an 84-amino acid polypeptide isolated from the human thymus. The full T101 peptide contains a 33-amino acid signal peptide and a 51-amino acid T101 peptide sequence with both immune stimulatory and inhibitory activities. Also provided are modified peptides and partial T101... Agent: The Nath Law Group

20090018082 - Use of factor viia or factor viia equivalents for treating trauma: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for treatment of trauma.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090018058 - Vitamin d receptor modulators: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating and psoriasis.... Agent: Eli Lilly & Company

20090018083 - Methods and compositions for inhibition of bcl6 repression: Provided are peptides or mimetics that block corepressor binding to a BCL6 lateral groove. Also provided are methods of blocking corepressor binding to the BCL6 lateral groove. Additionally, methods of inhibiting BCL6 repression in a mammalian, cell, and methods of treating a mammal with cancer are provided.... Agent: Craig J Arnold Amster Rothstein & Ebenstein

20090018084 - Methods of restoring cognitive ability using non-peptidic compounds: Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from Aβ1-42 monomers.... Agent: Foley & Lardner LLP

20090018085 - Use of a gnrh antagonist peptide in the treatment of sex hormone-dependent diseases: A method for treatment of benign prostate hyperplasia, prostate cancer, estrogen-dependent breast cancer, endometrial cancer, ovarian cancer, endometriosis and precocious puberty, or for use for contraceptive purposes or in an in vitro fertilization programme, or for treatment of sex offenders is provided. The method comprises the administration by subcutaneous or... Agent: Foley And Lardner LLP Suite 500

20090018086 - Monomethylvaline compounds having phenylalanine side-chain replacements at the c-terminus: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.... Agent: Townsend And Townsend And Crew LLP

20090018087 - Novel inhibitors of glutaminyl cyclase: The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation,... Agent: Sonnenschein Nath & Rosenthal LLP

20090018088 - Treating cancer with cardiac glycosides: The invention provides methods to treat cancer with cardiac glycosides.... Agent: Viksnins Harris & Padys Pllp

20090018089 - Crystalline forms of macrolide compounds endowed with antiinflammatory activity: the present invention relates to macrolide compounds endowed with antiinflammatory activity and more particularly relates to new stable crystalline forms of a macrolide derivative with antiinflammatory activity, processes for the preparation of such forms, pharmaceutical compositions containing them as active ingredient and the use of said crystalline forms for the... Agent: Lucas & Mercanti, LLP

20090018090 - Process for preparation of anhydrous azithromycin: The present invention provides a stable form of azithromycin derivatives that act as antibiotics. These compounds are in anhydrous form and have increased stability over the hydrated forms.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090018091 - Nitric oxide enhancing antimicrobial compounds, compositions and methods of use: The invention describes compositions and kits comprising at least one nitric oxide enhancing group antimicrobial compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention... Agent: Wilmerhale/nitromed

20090018095 - Fusion proteins of mycobacterium tuberculosis: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and... Agent: Townsend And Townsend And Crew, LLP

20090018094 - Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration: A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the... Agent: Knobbe Martens Olson & Bear LLP

20090018100 - Materials and methods for treating ocular-related disorders: The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and... Agent: Leydig Voit & Mayer, Ltd

20090018096 - Methods for regulating the growth and/or survival of tumor cells and stem cells by modulating the expression or function of the transcription factor atf5: The present invention provides methods for regulating the growth and/or survival of tumor cells and stem cells by modulating the expression or function of ATF5. The present invention also provides methods for promoting or suppressing differentiation of stem/progenitor cells, for producing differentiated cells and for isolating/purifying differentiated cells, including neural... Agent: Baker Botts L.L.P.

20090018097 - Modification of double-stranded ribonucleic acid molecules: A double-stranded RNA (dsRNA) molecule comprising between about 15 base pairs and about 40 base pairs, wherein at least one ribonucleotide of the dsRNA is a 5′-methyl-pyrimidine and/or at least one 2′-O-methyl ribonucleotide, and a method of improving ribonuclease stability, reducing off-target effects of a double stranded siRNA molecule, or... Agent: Nastech Pharmaceutical Company Inc Mdrna, Inc.

20090018093 - Nucleic acid ligands specific to immunoglobuline e and their use as atopic disease therapeutics: The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and/or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE.... Agent: Mintz, Levin, Cohn, Ferris, Glovskyand Popeo, P.C.

20090018099 - Protein production: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090018092 - Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”).... Agent: Townsend And Townsend And Crew, LLP

20090018098 - Targeting the absence: homozygous dna deletions as signposts for cancer therapy: The present application relates to methods and compositions for targeting a homozygous DNA deletion (HD) in cells. Methods, structures, vectors and compositions for activating a payload in cells having an HD are provided. In some embodiments, the method comprises administering, to a population of cells comprising at least one cell... Agent: Knobbe Martens Olson & Bear LLP

20090018101 - S-adenosyl-l-methionine analogs with extended activated groups for transfer by methyltransferases: R1, R2 and R3 are independently selected from H, D and C1-C12 alkyl. Also disclosed are complexes of the compound with a methyltransferase, pharmaceutical compositions comprising the same, methods for modifying biomolecule using the compound, and methods for detecting sequences specific methylation of biomolecules using the compound.... Agent: Kening Li Pinsent Masons

20090018102 - Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith: Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions... Agent: Buchanan, Ingersoll & Rooney PC

20090018103 - Diaminoalkane aspartic protease inhibitors: Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090018104 - Triarylcarboxylic acid derivative: wherein A is an optionally substituted aryl or heteroaryl, and B is an optionally substituted monocyclic heteroaryl; and a pharmaceutical composition comprising the same and a pharmaceutically acceptable carrier. The triarylcarboxylic acid derivative (I) exhibits potent xanthine oxidase inhibiting action and is therefore useful as a therapeutic agent for preventing... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090018105 - Means and methods for the treatment and prevention of allergic diseases: The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization. Preferred in this context are edelfosine and miltefosine. In a... Agent: Foley And Lardner LLP Suite 500

20090018106 - Intravenous formulations of pyridoxal 5'- phosphate and method of preparation: The present invention provides a lyophilized formulation of pyridoxal 5′-phosphate and a method of making the same. The present invention also provides an injectable formulation of pyridoxal 5′-phosphate reconstituted from the lyophilized formulation. The present invention further provides uses of the lyophilized and injectable formulations.... Agent: Merchant & Gould PC

20090018107 - Novel composition to increase muscle strength: The present invention relates to a composition for increasing testosterone physiological levels comprising a sufficient amount of at least two ketosteroid derivatives of testosterone metabolism in association with a liposomal carrier bound to a saliva-absorbing carrier for increasing testosterone physiological levels.... Agent: Bereskin And Parr

20090018109 - Combinations of steroids and methylxanthine compounds: There is provided a medicament comprising a combination of a methylxanthine compound of formula I and a steroid of formula II and their use as pharmaceuticals, in particular for the treatment of inflammatory or obstructive airways diseases.... Agent: Novartis Corporate Intellectual Property

20090018108 - Treating skin hyperpigmentation with dermatological compositions comprising hydroquinone, fluocinolone acetonide and tretinoin: Hyperpigmentary skin disorders, notably those associated with psoriasis or eczema, are prevented/treated by administering to individuals in need of such treatment, thus effective amounts of medicaments containing a combination of fluocinolone acetonide, hydroquinone and tretinoin, formulated into a physiologically acceptable medium therefor.... Agent: Buchanan, Ingersoll & Rooney PC

20090018110 - Haptoglobin genotyping for prognosis and treatment of chronic vasospasm following subarachnoid hemorrhage (sah): This invention relates to methods and systems for providing a prognosis to a subject on developing vasospasm as a results of hemorrhagic event, and compounds and compositions for treatment thereof. Specifically, the invention relates to the use of haptoglobin genotyping in the prognosis of the development of vasospasm following SAH,... Agent: Pearl Cohen Zedek Latzer, LLP

20090018111 - Novel antimicrobial medicament: wherein R1 is lower alkyl or the like, R2 is H or lower alkyl group, X is O, S or NH; m and n are 0 to 4, provided that the sum of m and n is 0 to 4; Y1 is halogen or the like; and Y2 is hydrogen,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090018112 - Compounds and uses thereof: e

20090018114 - Novel compounds as cannabinoid receptor ligands:

20090018113 - Novel cylopenta[b]benzofuran derivatives and the utilization thereof: The present application relates to a novel cyclopenta[b]benzofuran derivatives, processes for their preparation and their use for the manufacture of medicaments, in particular for the prophylaxis and/or therapy of acute or chronic disorders characterized by elevated cellular stress, by local or systemic inflammatory processes or by hyperproliferation.... Agent: Norris, Mclaughlin & Marcus, Pa

20090018115 - Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite... Agent: Knobbe Martens Olson & Bear LLP

20090018116 - Therapeutic compounds: s

20090018117 - 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof:

20090018118 - Heterocyclic compounds: The invention is related to novel substituted diazaheterocycles useful as effective antihypercholesterolemic agents, methods of their preparation, and pharmaceutical compositions containing them.... Agent: Manelli Denison & Selter

20090018119 - Use of n-desmethylclozapine to treat human neuropsychiatric disease: Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease.... Agent: Knobbe Martens Olson & Bear LLP

20090018120 - Amidine derivatives and their applications as a medicament: The invention concerns amidine derivatives of general formula (I) exhibiting an inhibitory activity of calpains and/or a trapping activity of reactive forms of oxygen.... Agent: Hunton & Williams LLP Intellectual Property Department

20090018121 - Preventive and/or therapeutic agent for rheumatoid arthritis: The present invention relates to a preventive and/or therapeutic agent for rheumatoid arthritis. The present invention provides a preventive and/or therapeutic agent for rheumatoid arthritis containing 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and a COX2 inhibitor.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090018122 - Aryloxy and arylalkyleneoxy substituted imidazoquinolines: Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are... Agent: 3m Innovative Properties Company

20090018123 - Oxazolidinones bearing antimicrobial activity composition and methods of preparation: The present invention concerns recombinant DNA's comprising cDNA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNA's are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines.... Agent: Bio Intellectual Property Services (bio Ips) LLC

20090018124 - Novel benzoimidazole derivatives and pharmaceutical composition comprising the same: Disclosed herein are novel benzoimidazole derivatives functioning as antagonists to vanilloid receptor-1, and a pharmaceutical composition comprising the same. They are useful in preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraines, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neurological illness, neurodermatitis, strokes, bladder hypersensitivity, irritable bowel... Agent: Jhk Law

20090018125 - Pharmaceutical composition and its use: Polyunsaturated fatty acid (“PUFA”) or a pharmacologically acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent, said agent(s) having at least one amino acid residue, or a pharmacologically acceptable salt or derivative thereof... Agent: Bacon & Thomas, PLLC

20090018126 - 4-aminophenylmorpholinone derivatives and their preparation: l

20090018128 - Compounds: The present invention relates to novel pyrrolopyrazine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090018127 - Ergoline derivatives: Disclosed are ergoline derivatives, Formula (I), wherein either each of R1 and R2, independently, is H; optionally R10 and/or R11-substituted-phenyl or -phenyl-C1-4alkyl; optionally R10 and/or R11-substituted-heteroaryl or -heteroaryl-C1-4alkyl; optionally R10 and/or R11-substituted heteroaryl N-oxide; optionally R10-substituted C1-C8 alkyl; optionally R10-substituted C2-C8 alkenyl, optionally R10-substituted C2-C8 alkynyl; optionally R10-substituted C3-C8 cycloalkyl,... Agent: Novartis Corporate Intellectual Property

20090018129 - Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same: in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted aminopyrazolopyridines, to methods of preparing said substituted aminopyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the... Agent: Millen, White, Zelano & Branigan, P.C.

20090018130 - Derivatives of 5-aryl-1h-pyrrolo [2, 3b] pyridine-3-carboxamide or 5-aryl-1h-pyrrolo [2, 3b] pyridine-3-carboxylic acid: The present invention relates to new compounds of formula I as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090018131 - Quinazoline derivatives as p13 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090018132 - Substituted heterocyclic ethers and their use in cns disorders: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090018133 - Novel adamantane derivatives: The invention provides compounds of formula (I), in which m, A, R1 and Ar have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.... Agent: Fish & Richardson P.C.

20090018134 - Compounds - 945: e

20090018135 - Methods of treating bowel disorders: The present invention relates to methods for treating or preventing bowel disorders using calcimimetics.... Agent: Amgen Inc.

20090018136 - Methods and compositions for the treatment of vascular disease: The present invention is directed to a novel methods and compositions for the therapeutic intervention of vascular complications associated with diabetes, hyperlipidemias, and various cardiovascular disorders including but not limited to recalcitrant hypertension, coronary artery disease, pulmonary arterial hypertension, congestive heart failure, and hemolytic anemias. More specifically, the specification describes... Agent: Marshall, Gerstein & Borun LLP

20090018137 - Modulation of cell fates and activities by phthalazinediones: Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth,... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090018138 - Treatment of crth2-mediated diseases and conditions: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090018139 - Treatment of crth2-mediated diseases and conditions: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090018140 - Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20090018141 - Kinase inhibitors, compositions thereof, and methods of use therewith: wherein A, L, X and ring B are as defined herein, compositions comprising an effective amount of a Compound and methods for treating or preventing cancer, hypoxia, diabetes, stroke, autoimmune disease or a condition treatable or preventable by inhibition of Chk2, the ATM-Chk2 pathway or RSK2 comprising administering an effective... Agent: Jones Day

20090018143 - Thio-substituted arylmethanesulfinyl derivatives: wherein Ar, X, Y, R1, R2, R3, and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity... Agent: Cephalon, Inc.

20090018142 - Use of phosphatases to treat tumors overexpressing n-cor: This invention provides a method of treating a patient suffering from a tumor overexpressing N—CoR comprising administering to the patient a phosphatase ligand, alone or in combination with a retinoid receptor ligand, a histone deacetylase ligand, or both, in amounts effective to treat the patient. This invention also provides a... Agent: Cooper & Dunham, LLP

20090018144 - Capped pyrazinoylguanidine sodium channel blockers: i

20090018146 - Combination therapy with triterpenoid compounds and proteasome inhibitors: The present invention provides therapeutic compositions comprising a natural triterpenoid and a proteasome inhibitor. These compositions will be particularly useful in the treatment of malignancies and inflammation. The present invention also provides methods of treating a subject having a malignancy or an inflammatory disorder comprising administering to the subject a... Agent: Fulbright & Jaworski L.L.P.

20090018145 - Compositions and their use as anti-tumor agents: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090018147 - Compounds for modulating trpv3 function: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.... Agent: Ropes & Gray LLP

20090018148 - Xanthine derivatives, processes for preparing them and their uses: The present invention concerns xanthine derivatives, having formula (I), processes for preparing them, pharmaccutical compositions containing them and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090018149 - 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections: Described are 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of mycobacteria-induced infections and opportunistic infections, as well as compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene derivative and/or pharmaceutically acceptable salts thereof. Furthermore, the present application refers to the use of mycobacterial... Agent: Amin & Turocy

20090018150 - 5-ht2b receptor antagonists: Compounds of formulae: (I), (II), (IIIa), (IIIb), (IVa) and (IVb): or a pharmaceutically acceptable salt thereof, for use as pharmaceuticals, in particular for the treatment of a condition alleviated by antagonism of a 5-HT2B receptor.... Agent: Nixon & Vanderhye, PC

20090018152 - Aminophenyl derivatives as novel inhibitors of histone deacetylase: m

20090018153 - Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase: This invention comprises the novel compounds of formula (I) wherein R1, R2, R3, R4, R5, X and Y have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.... Agent: Philip S. Johnson Johnson & Johnson

20090018151 - Topical treatment of peripheral diabetic complications: This invention relates to agents for treating, ameliorating, or preventing diabetic complications specifically diabetic neuropathy and skin ulceration by topical application of materials containing one or more arterial or venous dilation components and one or more fast sodium channel inhibitors. Particularly, the invention relates to treating or ameliorating agents that... Agent: Mark J. Pandiscio Pandiscio & Pandiscio, P.C.

20090018154 - Opioid and methods of making and using the same: An opioid derivative of oxymorphol, called 8-hydroxy-6-α-oxymorphol, has been discovered. This opioid is believed to bind at least to mu-opioid receptors and produce an analgesic or anti-tussive effect. Pharmaceutically acceptable salts of 8-hydroxy-6-α-oxymorphol, and pharmaceutical compositions comprising 8-hydroxy-6-α-oxymorphol or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carrier, are also provided.... Agent: Ip Group Of Dla Piper US LLP

20090018155 - Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy: Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon... Agent: Edwards Angell Palmer & Dodge LLP

20090018156 - Pyrrolo [2,3,b] pyridine derivatives useful as raf kinase inhibitors: The present invention provides pyrrolo pyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090018157 - Chemical compounds: Compounds of Formula (I) wherein: R1—X— is selected from: methyl, methoxymethyl and Formula (X); R2 is selected from hydrogen, methyl, chloro and fluoro; n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their... Agent: Morgan Lewis & Bockius LLP

20090018158 - Crystal forms of an imidazole derivative: The invention relates to the essentially pure Λ/-[({2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1 -yl)phenyl]ethyl}amino)carbonyl]-4-methylbenzenesulfonamide Polymorph Forms A and B and to processes for the preparation of, compositions containing and to the uses of, such crystal forms.... Agent: Pfizer Inc.

20090018159 - Treatment of diabetes: The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of diabetic patients.... Agent: Birch Stewart Kolasch & Birch

20090018160 - Heterocyclic compounds with affinity to muscarinic receptors: the symbols Wa, Ya and Za and the substituent R1a have the same meanings as defined previously for the symbols W, Y and Z and the substituent R1, and are not independently selected, each of the symbols Wa, Ya and Za and the substituent R1a representing identical symbols and substituents,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090018161 - Method for promoting gastrointestinal function and method for screening for promoter of gastrointestinal function: The present invention provides a more effective gastrointestinal function promoter. The present invention also provides a method for the prophylaxis or improvement of functional gastrointestinal disorders, a method for appetite regulation and the like. The present invention also provides a method for screening for a substance capable of promoting a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090018162 - Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection: The present invention provides a use of a therapeutically effective amount of 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (herein referred to as Compound I) or a pharmaceutically acceptable salt thereof, for the production of an agent for the treatment in a patient. The invention further provides a use of Compound I or a salt... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090018164 - Farnesyl protein transferase inhibitors for treating breast cancer: The present invention relates to the use of farnesyl protein transferase inhibitors for preparing pharmaceutical compositions for treating advanced breast cancer.... Agent: Philip S. Johnson Johnson & Johnson

20090018163 - Substituted heterocyclic ethers and their use in cns disorders: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090018165 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such... Agent: Theravance, Inc.

20090018166 - New pyridine analogues x 161: e

20090018167 - Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to... Agent: Henry D. Coleman

20090018169 - Sulfonamide derivatives for the treatment of bacterial infections: This present invention is related to sulfonamide derivatives of Formula (I), pharmaceutical composition thereof, methods of preparation thereof and to their use for the treatment and/or prophylaxis of bacterial infections such as tuberculosis.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090018168 - Therapeutic substituted chlorocyclopentanols: i

20090018170 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20090018171 - Imidazole derivatives: wherein R1, R2, R3, R4, X, Y and R are described hereinabove, or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the imidazole derivatives of formula I, a process for preparing a compound of formula I, and a method of treating or preventing acute... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090018172 - Diphenylurea derivatives and their use as chloride channel blockers or bkca channel modulators: e

20090018173 - Method for controlling the yeast-to-filamentous growth transition in fungi: A method for controlling yeast-to-filamentous growth transition in fungi comprising contacting a fungal cell with an anti-fungal small molecule in an amount effective to reduce or inhibit the yeast-to-filamentous growth transition, wherein the anti-fungal small molecule is 5-(p-Bromobenzylidine)-α-isopropyl-4-oxo-2-thioxo-3-thiozolidineacetic acid or an analog thereof. A method for treating fungal infections comprising... Agent: Antoinette M. Tease

20090018174 - Macrolides as anti-inflammatory agents: Provided herein are macrolide derivatives that can be useful in treating or preventing inflammatory diseases. Also provided are pharmaceutical compositions comprising one or more macrolide derivatives optionally together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixtures thereof, as well as methods for treating or preventing inflammatory diseases.... Agent: Ranbaxy Inc.

20090018175 - Pharmaceutical excipient complex: The present invention encompasses pharmaceutical excipient complexes comprising combining at least one carrier with an oily substance, and processes for preparing the same, stable pharmaceutical compositions comprising such complexes and active pharmaceutical ingredients and processes for preparing the same.... Agent: Kenyon & Kenyon LLP

20090018176 - Fungicide composition comprising an arylamidine derivative and two known fungicide compounds: The present invention relates to a fungicide composition comprising a N2-phenylamidine derivative and two other fungicide compounds, at least, as well as and the corresponding methods of protection by application of the said composition. This composition is intended for protecting crops against fungal diseases.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090018177 - Propane-1,3-dione derivative or salt thereof: Compounds useful as GnRH receptor antagonists are provided. The present inventors have further examined propane-1,3-dione derivatives and confirmed as a result that a propane-1,3-dione having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene), or a compound which has benzene or thiophene ring substituted with a group derived from 1-hydroxymethyl, shows excellent availability, in addition to its excellent... Agent: Sughrue-265550

20090018178 - Use of haloarylpyrazole compounds in the control of parasite infestation on animals: The present invention relates to the use of haloarylpyrazoles as tick-repellent compositions, and to an administration regimen of specific haloarylpyrazoles for controlling ticks on animals.... Agent: Intervet/schering-plough Animal Health Patent Department

20090018179 - Novel crystals and process of making 5-(-methyl)-2-methoxy-benzoic acid: The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.... Agent: Philip S. Johnson Johnson & Johnson

20090018180 - 2-imidazolines: and to their pharmaceutically active salts. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090018181 - Drug composition for prevention or inhibition of advance of diabetic complication: The present invention provides pharmaceutical compositions which can achieve good state of glycemic control and correct postprandial hyperglycemia and early morning fasting hyperglycemia. The present pharmaceutical composition is for administration before meal to prevent or inhibit the progression of diabetic complication, which comprises 5 to 45 mg, as a single... Agent: Sughrue Mion, PLLC

20090018182 - Crystalline forms of atorvastatin: Novel forms of atorvastatin hemi-calcium have been prepared and characterized. These novel forms are particularly useful in pharmaceutical compositions.... Agent: Kenyon & Kenyon LLP

20090018183 - N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands: v

20090018184 - Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases:

20090018185 - Compositions and products containing s-equol, and methods for their making: A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090018186 - Stable beverage products comprising polyunsaturated fatty acid emulsions: A beverage product comprising at least one beverage base and at least one polyunsaturated fatty acid emulsion, said emulsion comprising a continuous liquid phase; an emulsifier; and a discontinuous liquid phase comprising a blend including a polyunsaturated fatty acid source and a dispersing agent, the polyunsaturated fatty acid source comprising... Agent: Sutherland Asbill & Brennan LLP

20090018187 - Strontium (m) ascorbate, compositions containing same, method for making same and method of using same: A compound of formula (ascorbate)2Sr:(M+a)x(ascorbate)y, or ascorbate)2Sr:Ca(ascorbate)2, a composition containing the same, a method of making the same and a method of administering the same as a supplement.... Agent: Ajay Pathak

20090018188 - Bactericidal silver surfactant delivery into coating and polymer compositions: Disclosed are surfactant compounds and compositions that are antimicrobial. Also provided are polymeric compositions incorporating the surfactant compounds. The polymeric compositions may be used to form antibacterial coatings on surfaces.... Agent: Michael Best & Friedrich LLP

20090018189 - Hormone sensitive lipase modulators and methods of use: Disclosed herein are compound useful for inhibition of hormone sensitive lipase, pharmaceutical compositions of these compounds, and methods of treatment using these compounds.... Agent: Marshall, Gerstein & Borun LLP

20090018190 - Compositions and methods for transdermal oxybutynin therapy: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at... Agent: Hedman & Costigan P.C.

20090018191 - Deuterated catecholamine derivatives and medicaments comprising said compounds: The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of... Agent: Kriegsman & Kriegsman

20090018192 - Methods for repelling arthropods using isolongifolenone analogs: A method for for repelling arthropods involving treating an object or area with an arthropod repelling effective amount of at least one isolongifolenone analog (and optionally a carrier or carrier material).... Agent: Usda, Ars, Ott

20090018193 - Essential fatty acids in the prevention of cardiovascular events: The invention concerns the use of essential fatty acids with a high content in eicosapentaenoic acid ethyl ester (EPA) or docosahexaenoic acid ethyl ester (DHA) or a high concentration mixture thereof in the preparation of a medicament useful for preventing mortality, in particular due to sudden death, in patients who... Agent: Arent Fox LLP

20090018194 - Use of antimicrobial agents derived from alliaceous plants for the prevention and control of crop diseases, post-harvest rot and as environmental disinifectant products: The present invention is directed to utilization of antimicrobial agents derived from plants of the alliaceae family for the prevention and control of crop diseases, post-harvest rotting and as environmental disinfection products. The agents include propyl propylthiosulfinate and propyl propylthiosulfonate compounds for pre- and post-harvest treatments, control of rotting in... Agent: Davidson, Davidson & Kappel, LLC

20090018195 - Microfluidic chemostat: A chemostat is described that includes a growth chamber having a plurality of compartments. Each of the compartments may be fluidly isolated from the rest of the growth chamber by one or more actuatable valves. The chemostat may also include a nutrient supply-line to supply growth medium to the growth... Agent: Townsend And Townsend And Crew, LLP

20090018196 - Food composition comprising amino acids: The invention relates to a food composition comprising an amino acid part having at least the amino acids leucine, isoleucine, valine, threonine and lysine in an amount of from about 35 to 90 g/100 g of the total amount of the amino acid part as a method how to produce... Agent: Gauthier & Connors, LLP

20090018198 - Method for treating a motoneuron disorder: The present invention is directed to the use of a class of peptide compounds for treating amyotrophic lateral sclerosis (ALS) and other forms of motoneuron diseases and peripheral neuropathies.... Agent: Harness, Dickey, & Pierce, P.l.c

20090018197 - Methods for treating status epilepticus and related conditions: The present invention is directed to the novel use of a class of peptide compounds for treating status epilepticus or related conditions, e.g. acute repetitive seizures, seizure clusters, etc.... Agent: Harness, Dickey, & Pierce, P.l.c

20090018199 - Methods of administering 3, 3, 14, 14 tetramethyl hexadecane 1, 16 dioic acid: The present invention provides methods for lowering LDL, VLDL, total cholesterol, triglycerides, Insulin resistance and hypertension, and methods for elevating HDL in subjects in need thereof. Additionally, the present invention provides methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid for the above indications.... Agent: Cooper & Dunham, LLP

20090018200 - Composition containing a phenanthrenol: Novel uses of phenanthrenol compounds for improving the appearance and/or texture of the skin.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090018201 - Method of combating bugs: A method of combating bugs comprising contacting the bugs or their food supply, habitat, breeding grounds or their locus with a pesticidally effective amount of a compound of the formula (I) wherein W is Cl or CF3; X and Y are each independently Cl or Br; R1 is alkyl, alkenyl,... Agent: Brinks, Hofer, Gilson & Lione

20090018202 - Modafinil compositions: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.... Agent: Cephalon, Inc.

20090018203 - Modified release compositions of milnacipran: A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a Tmax of 4-10 hours.... Agent: Hunton & Williams LLP Intellectual Property Department

20090018204 - Composition and method for enhancing hair growth: wherein y is 0 or 1, x is 0 or 1 and x and y are not both 1, Y is a radical selected from the group consisting of alkyl, halo, e.g. fluoro, chloro, etc., nitro, amino, thiol, hydroxy, alkyloxy, alkylcarboxy, halo substituted alkyl wherein the alkyl radical comprises from... Agent: Blakely Sokoloff Taylor & Zafman LLP

20090018205 - Methods for treatment of migraine and symptoms thereof: Compositions, methods and kits are provided for the treatment of migraines. The compositions, methods and kits include an effective dose of trimethobenzamide and an ethanolamine antihistamine that, when administered to an individual suffering from migraine headaches, will alleviate symptoms associated with the migraine headaches. Compositions, methods, and kits for the... Agent: Morrison & Foerster LLP

20090018206 - Prevention of hypotension and stabilization of blood pressure in hemodialysis patients: The present invention relates to the use of S-alkylisothiouronium derivatives, including S-ethylisothiouronium diethylphosphate, for stabilizing blood pressure in hemodialysis patients. The compositions of the invention are effective in preventing hypotension in hemodialysis patients.... Agent: Winston & Strawn LLP Patent Department

20090018207 - Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic... Agent: Global Patent Group - Apx Ms. Lavern Hall

20090018208 - Novel succinate salt of o-desmethyl-venlafaxine: A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.... Agent: Choate, Hall & Stewart LLP/wyeth

20090018209 - Curcumin and curcuminoid inhibition of angiogenesis: Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It has further been... Agent: Patrea L. Pabst Pabst Patent Group LLP

20090018210 - A method for promoting fat degradation: A novel, new, and highly effective agent for promoting fat degradation that contains astaxanthin and/or an ester thereof as active ingredient is provided. The agent for promoting fat degradation of the present invention has an effect of reducing fat by lipolysis of fat in either a subject who is in... Agent: Mcleland Patent Law Office, P.l.l.c.

20090018211 - Method for inhibiting of cox2 and inflammation with phenolic aldehydes: A method for inhibiting of COX2 and inflammation by administering a hydroxybenzaldehyde.... Agent: Ian C. Mcleod Ian C. Mcleod, P.C.

20090018212 - Methods of relieving stress: Methods, combinations and compositions for relieving or preventing the effects of stress are provided. In particular, combinations and compositions comprising cis-3-hexen-1-ol, trans-2-hexenal and α-pinene, articles of manufacture impregnated with the combination or composition and methods of relieving stress by exposure to the combination or composition are described.... Agent: Knobbe Martens Olson & Bear LLP

20090018213 - Antiviral method: This invention provides a method of inactivating human noroviruses and other acid stable viruses. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from cationic oligomers and polymers, chaotropic agents, and mixtures thereof.... Agent: Renner Kenner Greive Bobak Taylor & Weber

20090018214 - Composition for promoting vascular smooth muscle relaxation: A composition for topical application to a part of the body comprises a local anaesthetic and optionally a vasodilator as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the active ingredient. The vasodilator may comprise glyceryl trinitrate and the local anaesthetic may... Agent: Miles & Stockbridge PC

20090018215 - Fumigant for wood parasitic nematodes and wood fumigation method: The present invention provides a fumigant for wood parasitic nematodes comprising methyl iodide dissolved in liquefied carbon dioxide, in place of methyl bromide the use of which is globally regulated as ozone depleting substance or a fumigant using methyl iodide dissolved in liquefied carbon dioxide in combination with one or... Agent: Sughrue Mion, PLLC

20090018216 - Polymer micelle complex including nucleic acid: e

20090018217 - Volatile sulfide production inhibitor and method for inhibiting the production of volatile sulfide using the inhibitor: The object of the present invention is to establish a volatile sulfide production inhibitor that can inhibit the production of volatile sulfides from a composition and to provide a method for inhibiting the production of volatile sulfides from a composition by using the inhibitor. The object are solved by providing... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090018218 - Methods of modifying amyloid beta oligomers using non-peptidic compounds: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers from amyloid β1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers.... Agent: Foley & Lardner LLP

  
01/08/2009 > patent applications in patent subcategories. recently filed with US Patent Office

20090011974 - Scavenger receptor b1 (cla-1) targeting for the treatment of infection, sepsis and inflammation: This invention relates to methods and compositions for the treatment of sepsis, inflammation or infection. In particular, the invention concerns the use of molecule(s) that target SR-BI, which is also referred to as CLA-1 (SR-BI/CLA-1), to treat sepsis, bacterial and viral infections, and inflammatory diseases. SRB I/CLA-1 ligands contributing to... Agent: Catherine Joyce Liniak, Berenato & White

20090011975 - Targeted bone marrow protection agents: The invention provides a method of inhibiting cell death in a mammal. The method comprises administering to a mammal an effective amount of a composition comprising a cell protection factor covalently linked to a bone targeting agent via a linkage that is cleaved under physiological conditions, whereby the cell protection... Agent: Leydig Voit & Mayer, Ltd

20090011976 - Stable formulations of peptides: Stable pharmaceutical composition comprising insulinotropic peptide and basal insulin.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090011977 - Novel lipopeptides as antibacterial agents: The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.... Agent: Intellectual Property Department Cubist Pharmaceuticals, Inc.

20090011983 - 186 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090012000 - Anti-viral peptide and use thereof: Disclosed is an anti-viral peptide which non-naturally occurs and is artificially synthesized. The peptide has at least one unit of the following amino acid sequence (a) and at least one unit of the following amino acid sequence (b) or (c): (a) an amino acid sequence constituted by at least five... Agent: Amin, Turocy & Calvin, LLP

20090011997 - Bifunctional hormone and uses thereof: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for... Agent: Darby & Darby P.C.

20090011984 - Biotin-binding receptor molecules: The subject invention pertains to a transmembrane protein capable of binding to biotinylated molecules, the protein comprising a cytoplasmic domain, a membrane-spanning domain and an extracellular domain, wherein the extracellular domain comprises biotin-binding activity, and methods of use. The protein can be expressed in a cell, thereby targeting a biotinylated... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090011998 - Calcium-influx inhibitory factor and method of isolation thereof: A purified factor isolated from human milk is provided. The factor is capable of inhibiting calcium-influx activity in polymorphonuclear leukocytes. A method for purification of the factor is also provided.... Agent: Wilmerhale/dc

20090011990 - Carbohydrate fraction and use thereof for a flat postprandial glucose response: The invention relates to a combination of heat-treated nutritional composition having a carbohydrate fraction comprising a) 5-30 wt % of one or more monosaccharides selected from galactose, ribose and mannose; b) carbohydrates capable of providing b1) sustained release glucose and b2) rapidly available glucose; c) optionally fructose; d) glucose-containing disaccharides... Agent: Foley And Lardner LLP Suite 500

20090011996 - Diagnosing and protecting horses against papillomavirus: Compositions for conferring protection against Equus caballus papillomavirus (EcPV) and Bovine papillomavirus (BPV) infection in a subject are provided and include a virus-like particle assembled from an EcPV L1 protein and virus like particle assembled from a BPV L1 protein. Methods for protecting a subject against EcPV and BPV infection... Agent: Stites & Harbison, PLLC

20090011982 - Flagellin related polypeptides and uses thereof: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20090011985 - Gh secretagogues and uses thereof: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime... Agent: Darby & Darby P.C.

20090011992 - Human coagulation factor vii polypeptides: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090011979 - Immunomodulatory protein and useful embodiments thereof: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.... Agent: Clark & Elbing LLP

20090012001 - Lipid metabolism-improving agent: The present invention relates to an agent for improving lipid metabolism, a food/drink, and a feed, containing αs-casein as an active ingredient thereof. In addition, the present invention relates to an agent for suppressing body weight gain, an agent for reducing body fat, and an agent for reducing blood lipid,... Agent: Wood, Herron & Evans, LLP

20090011988 - Method for treating cartilage disorders: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of... Agent: Heller Ehrman LLP

20090011980 - Method of treating parkinson's disease in humans by direct infusion of glial cell-line derived neurotrophic factor into the zona incerta: A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to the SNc and at least one subthalamic region or, alternatively, to the SNc, at least one sub thalamic region, and at least one putaminal region of the brain... Agent: Kohn & Associates, PLLC

20090011994 - Non-basic melanin concentrating hormone receptor-1 antagonists and methods: Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or... Agent: Louis J. Wille Bristol-myers Squibb Company

20090011991 - Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis: The fluorinated curcuminoid (3,5-bis-(2-fluorobenzylidene)-piperidin-4-one-acetate is about ten times more effective at arresting the growth of tumor cells than cisplatin. Conjugates for delivering a cytotoxic compound, such as a curcuminoid, specifically to cancer cells and to the vascular endothelial cells that nourish solid tumors, and methods of making and using thereof... Agent: Patrea L. Pabst Pabst Patent Group LLP

20090011981 - Novel inhibitors of angiogenesis: The present invention provides novel inhibitors of angiogenesis. The invention relates to PF4var1 and fragments and modifications thereof with anti-angiogenic activity. Therefore, the present invention relates to the use of said proteins and peptides as a medicine, more in particular for the treatment or prevention of angiogenesis or for the... Agent: Clark & Elbing LLP

20090011993 - Novel strategies for delivery of active agents using micelles and particles: The present invention provides biodegradable particles (e.g., three-dimensional particles) and micelles which can be used to encapsulate active agents for delivering to a subject. The present invention further provides methods for producing and delivering such particles and micelles. Additionally, the invention provides vaccination strategies that encompass the use of the... Agent: Mandel & Adriano

20090011999 - Orally active androctonus amoreuxi pesticidal biopeptides: The present invention provides compositions and methods for orally active Androctonus amoreuxi pesticidal polypeptides. Compositions include novel Androctonus amoreuxi pesticidal polypeptides and biologically active variants thereof. Further provided are methods for modulating the pesticide resistance of plants by expressing the sequences disclosed herein. One method comprises stably transforming into the... Agent: Alston & Bird LLP Pioneer Hi-bred International, Inc.

20090011995 - Production of a soluble native form of recombinant protein by the signal sequence and secretional enhancer: The present invention is drawn to a method for enhancing secretional efficiency of a heterologous protein using a secretional enhancer consisting of a modified signal sequence which comprises the N-region of a signal sequence and/or a hydrophobic fragment of the said signal sequence comprising the said N-region and/or the hydrophilic... Agent: Klarquist Sparkman, LLP

20090011986 - Thiosuccinic acid derivatives and the use thereof: The present invention relates to compounds of the Formula (I), wherein X1 and X2 independently represent O, NH or S; R1 and R2 are independently selected from the group consisting of a C1-C30 hydrocarbyl group, an amino acid bonded via an amide bond or a peptide bonded via an amide... Agent: Biogen Idec / Finnegan Henderson, LLP

20090011989 - Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease: The present invention provides a method for treating structural heart disease in a subject, comprising administering an effective amount of an inhibitor of CaMKII to the subject, whereby the administration of the inhibitor treats the structural heart disease in the subject. Also provided are transgenic animal models for treating structural... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090011987 - Use of glp-2 for the treatment of ischemia-reperfusion injury: The present invention relates, inter alia, to the use of GLP-2 compounds in the treatment of ischemia-reperfusion injury in a subject.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090011978 - Use of surfactant preparations for the treatment of surgical adhesions: The invention describes the use of surfactant comprising phospholipids and pulmonary surfactant proteins for the treatment of surgical adhesions.... Agent: Nath & Associates PLLC

20090012002 - Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes: e

20090012003 - Polypeptides homologous to vegf and bmp1: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be... Agent: Genentech, Inc.

20090012004 - Hla binding peptides and their uses: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090012005 - Use of an angiotensin iv antagonist to treat insulin resistance or cardiovascular risk related to metabolic syndrome: The present invention relates to the use of an angiotensin IV antagonist that decreases the effects on angiotensinogen expression of angiotensin IV in vascular smooth muscle cells for preparing a drug to treat or prevent type II diabetes, insulin resistance or cardiovascular risk related to metabolic syndrome, as well as... Agent: Clark & Brody

20090012006 - Par-2 antagonists: Compounds represented by the general formula (1) or salts thereof or solvates of both; PAR-2 antagonists containing the compounds; and preventive or therapeutic agents for PAR-2 related diseases containing the antagonists as the active ingredient: (1) wherein R1 is hydrogen, halogeno, or a group represented by the general formula (2):... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090012010 - Amino acid derivatives as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds containing both an amino acid functionality and multiple aromatic rings are disclosed of the general formula (1) where X is benzhydryl, or... Agent: Morrison & Foerster LLP

20090012009 - Composition and method for treating inflammatory disease: A method of treating inflammatory diseases, and compositions and compounds therefor are described. More particularly, a method of treating inflammatory disease states with vitamin-hapten conjugates is described.... Agent: Barnes & Thornburg LLP

20090012007 - Mimetic peptides and the use thereof in the form of 20s, 26s and immunoproteasome inhitibors: The present invention relates to peptide-mimetic compounds, the synthesis and use thereof fort he inhibition of proteasomes and the induction of apoptosis in tumour cells. The present invention furthermore relates to pharmaceutical compositions comprising the compounds and the use of the compounds for a treatment of diseases, in particular cancer... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090012011 - Novel compounds: e

20090012008 - Pharmaceutical composition for photodynamic therapy and a method for treating oncological diseases by using said composition: The present invention relates to the field of medicine, particularly to oncology and provides a pharmaceutical composition intended for the photodynamic therapy of malignant tumors, comprising a therapeutically effective amount of at least one of derivatives of fullerene C60 selected from the group consisting of a compound in which a... Agent: Ladas & Parry LLP

20090012012 - Intratracheal administration of endothelin-suppressing agents for the treatment of respiratory disorders: The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of an agent that suppresses the activity of endothelin. Such agents may take the form of: 1) an endothelin-converting enzyme (ECE) inhibitor such as phosphoramidon, or 2) an endothelin receptor antagonist such... Agent: Jerome Cantor, Md

20090012014 - Compound, composition and a process thereof: The present invention provides a novel steroidal glycoside for management of rheumatic and inflammatory disease conditions. In addition, the present invention also provides a process for preparation of steroidal glycoside from plant fenugreek. Further, the invention also provides a pharmaceutical composition of the steroidal glycoside for management of rheumatic disease... Agent: Buchanan, Ingersoll & Rooney PC

20090012015 - Large dose ribavrin formulatons: The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin.... Agent: Arent Fox LLP

20090012026 - Association between the tdoa gene and osteoarthritis: The present invention arises from the identification of an association between the TDOA gene and osteoarthritis (OA). It therefore relates to diagnostic techniques for determining a patient's susceptibility to develop OA by detecting all or part of the TDOA gene, its precursors or products (mRNA, cDNA, genomic DNA, or protein).... Agent: Fish & Richardson P.C.

20090012027 - Biodegradable polyphosphoramidates for controlled release of bioactive substances: The present invention is directed to a series of new polycationic biodegradable polyphosphoramidates. Process for making the polymers, compositions containing these polymers and bioactive ligands to enhance the cellular uptake ad intracellular trafficking, articles and methods for delivery of drugs and genes using these polymers are described. A gene delivery... Agent: Greenberg Traurig LLP (la)

20090012029 - Cyst nematode resistant transgenic plants: Compositions and methods for providing cyst nematode resistance are provided. One aspect provides transgenic plants or cells comprising an inhibitory nucleic acid specific for one or more cyst nematode esophageal gland cell polypeptides. Other aspects provide transgenic plants or cells resistant to at least two different cyst nematode species.... Agent: Patrea L. Pabst Pabst Patent Group LLP

20090012023 - Decoy-olignucleotide inhibition of cd40-expression: The present invention relates to decoy oligonucleotides with the nucleic acid sequence according to SEQ ID NO: 1 to 36 and their use as pharmaceutical agents.... Agent: Fulbright & Jaworski L.L.P.

20090012033 - Delivery of biologically active materials using core-shell tecto(dendritic polymers): The present invention concerns core-shell tecto (dendritic polymers) that are associated with biologically active materials (such as nucleic acids for use for RNAi and in transfection). Also included are formulations for their use. The constructs are useful for the delivery of drugs to an animal or plant and may be... Agent: Technology Law, PLLC

20090012021 - Delivery of sirna by neutral lipid compositions: The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides methods for the delivery of a siNA (e.g., a siRNA) to a cell via a neutral (non-charged) liposome. These methods may be used to treat a disease, such as cancer.... Agent: Fulbright & Jaworski L.L.P.

20090012031 - Ezh2 cancer markers: The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in prostate cancer.... Agent: Casimir Jones, S.c.

20090012032 - Genes and polypeptides relating to human colon cancers: The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the... Agent: Townsend And Townsend And Crew, LLP

20090012022 - Hybrid interfering rna: The invention relates to a hybrid interfering RNA molecule comprising a duplex RNA and a single stranded DNA molecule and its use in the ablation of mRNA and in polymerase chain reactions.... Agent: Bozicevic, Field & Francis LLP

20090012020 - Inhibiting formation of atherosclerotic lesions: The invention features a method of inhibiting formation of atherosclerotic lesions by administering to a mammal, e.g., a human patient who has been identified as suffering from or at risk of developing atherosclerosis, a compound that reduces expression or activity of AFABP.... Agent: Ingrid A. Beattie, Ph.d., J.d. Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090012018 - Inhibition of pancretic cancer cell growth: The present invention relates to compositions and methods for inhibition of signal transduction pathways in cancer cells. In particular, the present invention provides methods and compositions comprising Wnt and Hedgehog pathway inhibitors for reducing proliferation of adenocarcinoma cells.... Agent: Medlen& Carroll LLP

20090012025 - Methods and compositions for treatment of sepsis: Methods of treatment of sepsis are disclosed. These methods comprise administering to a subject a composition comprising at least one siRNA directed against at least one gene encoding a pro-apoptotic polypeptide. The pro-apoptotic polypeptide, in some aspects, can be other than Fas or caspase-8. In some embodiments, an siRNA can... Agent: Washington University-snr C/o Sonnenschein Nath & Rosenthal L.l.p

20090012019 - Methods and compositions related to tr4: Disclosed are compositions and methods related to TR4 and aging.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090012028 - Polyglutamic acids functionalized by cationic groups and hydrophobic groups and applications thereof, in particular therapeutic applications thereof: These polyglutamates modified by cationic groups are easily and economically converted into particles for the vectorization of active principles, these particles being themselves capable of forming stable aqueous colloidal suspensions. These modified polyglutamates exhibit the advantage of being less viscous than other analogous polymers while retaining an ability to associate... Agent: Patton Boggs LLP

20090012017 - Polypeptide complex that regulates cell cycle and anergy: An active ubiquitin E3 ligase, GRAIL, is crucial in the induction of anergy in cells of the immune system, and in the regulation of cellular proliferation. GRAIL is shown to associate with, and be regulated by Otubain isoforms, including OTUBAIN-1 (DOG, the Destabilizer of GRAIL) and an alternative reading frame... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20090012030 - Rnai-mediated inhibitin of htra1 for treatment of macular degeneration: RNA interference is provided for inhibition of HTRA1 mRNA expression for treating patients with an HTRA1-mediated ocular disorder. In particular, methods are provided for treating age-related macular degeneration (AMD) and using interfering RNA molecules that attenuate expression of HTRA1 in patients having AMD or at risk of developing AMD.... Agent: Alcon

20090012016 - Short interfering rna and micro-rna compounds and methods of designing, making, and using the same: Methods of identifying, designing and synthesizing uniquely targeting siRNA nucleotide sequences for a target mRNA sequence of a target species are disclosed. Methods of identifying, designing and synthesizing miRNA nucleotide sequences that does not function as a siRNA nucleotide sequence for mRNA of a target species are disclosed. Method of... Agent: Pepper Hamilton LLP

20090012024 - Stem cell markers: We disclose gene markers of stem cells, typically prostate stem cells, and in particular cancer stem cells, for example prostate cancer stem cells; therapeutic agents and diagnostic assays based on said stem cell genes; and including screening assays to identify therapeutic agents.... Agent: Crowell & Moring LLP Intellectual Property Group

20090012034 - Non-nucleoside reverse transcriptase inhibitors: Compounds of formula I, wherein R1, R2, R3, X and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090012035 - Dendrimer conjugates of agonists and antagonists of the gpcr superfamily: Disclosed are conjugates comprising a dendrimer and a ligand, which is a functionalized congener of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily, for example, wherein the functionalized congener is an A1 adenosine receptor agonist having a purine nucleoside moiety and a functional group... Agent: Leydig, Voit & Mayer, Ltd.

20090012036 - Stable s-adenosyl-l-methionine: Stable compositions of defined non-racemic diastereomeric ratios of S-adenosyl-L-methionine, methods for their synthesis and methods for their uses are described. The compositions according to the invention are very stable and are valuable for use as active constituents in pharmaceutical compositions.... Agent: Rolland Hebert

20090012037 - Antiviral compounds: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20090012038 - Methods for microbial biofilm destruction and interference with microbial cellular physiology: The formation and maintenance of microbial biofilms is shown to be dependent on signaling pathways mediated by cyclic di-GMP. In the absence of such signaling, microbes detach from a biofilm, and thereby become more readily treatable with conventional antibiotics. Chemical or biological means that interfere with cyclic-di-GMP signaling induce biofilm... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20090012039 - Use of methylcobalamin nasal spray to treat disorders: A method of treating a disorder by nasally administering methylcobalamin, with or without folinic acid. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dislexia, depth perception problems, color viewing problems, visual... Agent: Fulbright And Jaworski LLP

20090012040 - Biocompatible polymers, process for their preparation and compositions containing them: A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AaXxYy wherein: A represents a monomer selected from the group consisting of a sugar or —(O—CH2—CH2—CO)—, X represents a carboxyl group bonded... Agent: Ip Group Of Dla Piper US LLP

20090012042 - Hydroxypropyl-sulfobutyl-beta-cyclodextrin, the preparation method, the analytical method, and the pharmacutical application thereof: Hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin, the preparation method, analytical method, and the pharmaceutical application thereof. The hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin is a derivate of cyclodextrin which is substituted by hydroxypropyl group and sulfobutyl group: n-(2,3,6-O-2-hydroxypropyl)-m-(2,3,6-O-sulfobutyl)-&bgr;-cyclodextrin. The number of substituent groups per mole cyclodextrin is n hydroxypropyl groups and m sulfobutyl groups. “n” represents the average substituent degree... Agent: Schmeiser, Olsen & Watts

20090012041 - Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma.... Agent: Jacobson Holman PLLC

20090012043 - Inhibitors of polysialic acid de-n-acetylase and methods for using the same: The invention relates to inhibitors of polysialic (PSA) de-N-acetylase, methods of their production and use. The methods involve use of a PSA de-N-acetylase inhibitor for modifying the growth of cells, such as inhibiting the growth of cancer cells. The compositions include an inhibitor of a PSA de-N-acetylase, such as N-substituted... Agent: Bozicevic, Field & Francis LLP

20090012044 - Novel hiv protease inhibitors: The present invention provides novel HIV protease inhibitors containing substituted borane, carborane or metallacarborane clusters with 6 to 12 boron atoms in each cluster. The charge of each borane, carborane or metallacarborane cluster is 0, −1 or −2. The number of borane, carborane or metallacarborane clusters in the inhibitor molecule... Agent: Egbert Law Offices

20090012045 - Methods of treating cell proliferative disorders: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a RET kinase inhibitor. Cell proliferative disorders treatable by the methods include, thyroid tumors.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090012046 - Methods of treating mutated hiv: Analysis of the genotype of >1700 of these viruses showed that the combination of active site mutations M184V+Y115F correlated most with resistance to NcRTI-1 (FC=75). Analysis also indicated that the K65R mutation is associated with hypersusceptibility to NcRTI-1 and that it reverses the reduced susceptibility caused by M184V. These findings... Agent: Philip S. Johnson Johnson & Johnson

20090012013 - Steroid modified solatrioses: The invention pertains to steroid modified solatrioses and the synthesis thereof as well as to intermediate compounds useful for the synthesis of the steroid modified solatrioses.... Agent: Kagan Binder, PLLC

20090012047 - Crystalline forms of ibandronate sodium: Provided are crystalline forms of ibandronate sodium, as well as processes for the preparation thereof.... Agent: Kenyon & Kenyon LLP

20090012048 - Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection: The present invention relates to Mycobacterium avium subspecies paratuberculosis (MAP) as the etiological agent of IBD, including ulcerative colitis and Crohn's disease, as well as Multiple Sclerosis and Alzheimer's Disease. As such, the present invention provides a method for diagnosing Multiple Sclerosis and Alzheimer's Disease by detecting the presence of... Agent: Licata & Tyrrell P.C.

20090012049 - Use of an unsaponifiable extract of plant pulp in the treatment of skin ageing.: The field of the present invention relates to the use of an unsaponifiable extract of plant pulp in the preparation of a cosmetic, pharmaceutical or nutraceutical product intended for treating and/or preventing skin disorders associated with ageing.... Agent: The Firm Of Hueschen And Sage

20090012051 - External preparation: The present invention provides an external preparation which comprises 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1′-cyclopentane] represented by Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, comprising 0.5 to 15% by mass of a solvent component in which the solubility of the active ingredient is 4 mg/mL or more, and the like.... Agent: Fitzpatrick Cella Harper & Scinto

20090012050 - Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of muscular dystrophies: Use of idebenone for the preparation of a medicament for the treating of a muscular dystrophy in particular for treating and/or preventing weakness and/or loss of skeletal muscle tissue and/or cardiomyopathy associated with a muscular dystrophy.... Agent: Kilyk & Bowersox, P.l.l.c.

20090012052 - Method for treating er+ breast cancer: A method for selecting a female breast cancer patient for AT1 receptor antagonist therapy comprises (a) determining whether the cancer comprises a tumor that is ER+ and/or PR+; and (b) selecting the patient for AT1 receptor antagonist therapy only if the cancer is determined to comprise an ER+ and/or PR+... Agent: Harness, Dickey, & Pierce, P.l.c

20090012053 - Use of lxr agonists for the treatment of osteoarthritis: Disclosed herein are methods of preventing and treating osteoarthritis through the use of LXR agonists.... Agent: Potter Anderson & Corroon LLP/wyeth

20090012054 - Cephem compounds and use as antimicrobial agents: The present invention provides a compound of the formula [I]: wherein R1 is lower alkyl, etc. and R2 is hydrogen, etc., or R1 and R2 are bonded together to form lower alkylene; R3 is a group represented by wherein R6 and R7 are independently optionally protected amino, etc.; m and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090012055 - Organic compounds: e

20090012056 - Quinoline compounds capable of binding the cb2 and/or the 5-ht6 receptor:

20090012057 - Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use: The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases;... Agent: Wilmerhale/dc

20090012058 - Prophylactic or therapeutic agents for allergic ophthalmic diseases or allergic nasal diseases, comprising tricyclic triazolobenzazepine derivative: The present invention provides a pharmaceutical composition for use in the prophylaxis or treatment of allergic ophthalmic diseases or allergic nasal diseases, which comprises 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzazepine, 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to the present invention has few side effects, exerts strong prophylactic and therapeutic effects... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090012059 - Dipeptidyl peptidase inhibitors: e

20090012061 - A method of treating cancer: The present invention relates to a method of treating cellular proliferative diseases, in particular cancer, which comprises administering a modulator of the activity of the mitotic kinesin KSP, wherein the activity of the KSP modulator is dependent on the presence of microtubules. It is believed that the KSP modulators utilized... Agent: Merck And Co., Inc

20090012060 - Antitumor agent: [wherein —X—Y-Z- represents —O—CR3═N— (wherein R3 represents a hydrogen atom, a substituted or unsubstituted aromatic heterocyclic group and the like) and the like, R1 represents —NR10R11 (wherein R10 and R11 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like)... Agent: Fitzpatrick Cella Harper & Scinto

20090012063 - Novel imidazole derivatives: h

20090012062 - Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases: a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according... Agent: Philip S. Johnson Johnson & Johnson

20090012064 - Compositions controlling ph range of release and/or release rate: p

20090012066 - Method of use of deacetylase inhibitors: The present invention provides methods of treating and/or preventing pathologic cardiac hypertrophy and heart failure comprising administering hydroxamate compounds which are deacetylase inhibitors.... Agent: Novartis Corporate Intellectual Property

20090012065 - Therapeutic applications of pro-apoptotic benzodiazepines: wherein R1, R2, R3 and R4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune... Agent: Casimir Jones, S.c.

20090012067 - Modulation of hypothalamic atp-sensitive potassium channels: Provided are methods of increasing KATP activity in the hypothalamus of a mammal, methods of reducing glucose production and peripheral blood glucose levels in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, and methods of increasing glucose production and peripheral blood glucose levels in a mammal.... Agent: Amster, Rothstein & Ebenstein LLP

20090012068 - Condensed imidazole derivatives as aldosterone synthase inhibitors: The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R1, R2, R3, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090012069 - Novel antidiabetic compounds: Disclosed are novel compounds of general formula (I) where the symbols are as defined in the specification, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The compounds are... Agent: Nixon & Vanderhye, PC

20090012070 - Pesticidal heterocycles: It has now been found that certain novel heterocyclic derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): R Preferred are those compounds of formula (I) where R2 and R3 taken together is ═NCH(R6)CH(R7)N(R8)—, ═NC(R6)=C(R7)N(R8)-, or ═CHN═C(R7)N(R8)—, and tautomers thereof, and where R4 and R5 taken... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090012071 - 4-substituted-1h-isothiazolo[5,4-b][1,4]oxazino[2,3,4-ij]quinoline-7,8(2h,9h)-diones and related compounds as anti-infective agents: The present invention provides compounds of the formula that possess antimicrobial activity. Certain compounds provided herein possess potent antibacterial, antiprotozoal, or antifungal activity. Particular compounds provided herein are also potent and/or selective inhibitors of microbial DNA synthesis and reproduction. The invention provides anti-microbial compositions, including pharmaceutical compositions, containing a compound... Agent: Cantor Colburn, LLP

20090012072 - Fluoroquinolone compositions: The invention relates to pharmaceutical compositions comprising (i) a fluoroquinolone, (ii) a salt formed between a carboxylate anion and a divalent metal cation, (iii) a liquid comprising an organic solvent selected from the group consisting of glycerol, propylene glycol, glycerol formal, and (iv) optionally water. The invention further relates to... Agent: Townsend And Townsend And Crew, LLP

20090012073 - N-aroyl cyclic amines: e

20090012074 - Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor:

20090012075 - Fluorinated arylamide derivatives: The present invention relates to a novel class of fluorinated arylamide derivatives. The instant compounds can be used to treat cancer. The fluorinated arylamide derivatives can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby... Agent: Merck And Co., Inc

20090012077 - Novel compound - 827: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.... Agent: Fish & Richardson P.C.

20090012076 - Tyrosine kinase inhibitors: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20090012078 - Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases: e

20090012080 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Ropes & Gray LLP

20090012079 - Triazolopyridine compounds: A compound of formula (Ia): or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof, or a compound of formula (Ib): or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof, and the use of a compound of formula (Ia) or (Ib) in the treatment of a TNF-mediated disease, disorder,... Agent: Pfizer Inc.

20090012081 - Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells: c

20090012084 - 3-cinnolinecarboxamide derivatives and their use for treating cancer: or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and... Agent: Astrazeneca R&d Boston

20090012082 - Mediators of hedgehog signaling pathways, compositions and uses related thereto: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway... Agent: Millen, White, Zelano & Branigan, P.C.

20090012083 - N-aroyl cyclic amine derivatives as orexin receptor antagonists: e

20090012085 - Dosage forms and methods of treatment using a tyrosine kinase inhibitor: This invention provides dosage forms of a compound of formula 1, 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, or pharmaceutically acceptable salts or solvates thereof. The invention further provides methods of treating abnormal cell growth in a patient, such as cancers, by administering the dosage forms to the patient. The invention further provides methods of treating... Agent: Pfizer Inc

20090012087 - New aza-bicyclohexane compounds useful as inhibitors of thrombin: This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.... Agent: Pepper Hamilton LLP

20090012086 - Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumor cells: The invention relates to the use of substance P antagonists and, in particular, the use of non-peptidic NK1 receptor antagonists for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human Hodgkin's lymphoma KM-H2, lymphoblastic leukaemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human... Agent: Ostrolenk Faber Gerb & Soffen

20090012088 - Compounds for the treatment of neurodegeneration and stroke: Compounds and related methods for synthesis, and the use of compounds for the treatment of neurodegenerative diseases are disclosed. Compounds are disclosed in connection with PARG and/or PARP inhibition. Therapeutic applications are relevant for preventing or inhibiting neurological cell death for a variety of neurodegenerative conditions including Parkinson's disease, ischemia,... Agent: Greenlee Winner And Sullivan P C

20090012089 - Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators: m

20090012090 - Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy: This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be... Agent: Millen, White, Zelano & Branigan, P.C.

20090012091 - Oximide derivatives and their therapeutical application: i

20090012092 - Hiv inhibiting 1,2,4-triazin-6-one derivatives: a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein ring A and ring B represent phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; n and m are 1 to 4; R1 represents hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxyC1-6alkylcarbonyl substituted with C1-6alkyloxycarbonyl;... Agent: Philip S. Johnson Johnson & Johnson

20090012093 - Receptor function regulator: The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.... Agent: Edwards Angell Palmer & Dodge LLP

20090012095 - Human n-type calcium channel blockers: This invention features a method for modulating human N-type calcium channel α1B+SFVG subunit activity. The method includes administering to a subject in need thereof an effective amount of a compound of formula (I), (II), or (III):... Agent: Wyeth Patent Law Group

20090012096 - Pharmaceutical composition for reducing the area of myocardial infarction and its use: This invention relates to a pharmaceutical composition for preventing and curing myocardium ischemia and reducing area of myocardial infarction, its pharmaceutical preparation and applications. The composition includes (a) levocarnitine or its derivatives, and (b) trimetazidine or its medicative salts. The quantity of levocarnitine or its derivatives, and trimetazidine or its... Agent: Squire, Sanders & Dempsey LLP

20090012097 - Polycyclic 1,2,3,4-tetrahydro-isoquinoline derivatives and compositions comprising them as ppar modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.... Agent: Genomics Institute Of The Novartis Research Foundation

20090012094 - Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions... Agent: Wilson Sonsini Goodrich & Rosati

20090012098 - 5-ht1a receptor subtype agonist: s

20090012099 - Novel compounds: Disclosed is a method for use of phenyl sulfone compounds of formula (I) in the treatment of Alzheimer's disease and age related cognitive decline.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090012101 - Mucarinic agonists and methods of use thereof: A method of forming analogs of CDD-0304, i.e., tetra(ethyleneglycol) (4-methoxy-1,2,5-thiadiazol-3-yl)[3-(1-methyl-1,2,4,5-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl]ether hydrochloride includes one or more of the following steps: a) replacing the tetrahydropyridine moiety with one of the following heterocyclic rings, including quinuclidine, [2.2.1]-exo-azabicy-cloheptane, [2.2.1]-endo-azabicycloheptane and terahydropyrimidine; b) varying the length of the linking group by replacing the tetra(ethylene) glycol... Agent: Macmillan Sobanski & Todd, LLC

20090012100 - Selective insecticides based on substituted cyclic ketoenols and safeners: m

20090012102 - Imidazo[1,2-c]pyrimidinylacetic acid derivatives: The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and... Agent: Jones Day

20090012103 - Substituted heterocyclic compounds: e

20090012105 - Combination of mtor inhibitor and antipolate compound: Use of a combination of an mTOR inhibitor and an antifolate compound.... Agent: Novartis Corporate Intellectual Property

20090012104 - Inhibitors of 5'-methylthioadenosine phosphorylase and 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidase: Described are compounds of the general formula (I), VI and (VII). Also described are pharmaceutical compositions comprising the compounds identified. The compounds and pharmaceutical compositions described are inhibitors of 5′-methylthioadenosine/S-adenosylhomocystein nucleosidase (MTAN) and/or 5′-methylthioadenosine phosphorylase (MTAP). Methods of treatment using the compounds and pharmaceutical compositions described are also provided for... Agent: Bradley Arant Rose & White

20090012106 - Methods, compositions, and kits for organ protection during systemic anticancer therapy: Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents.... Agent: Morgan Lewis & Bockius LLP

20090012107 - Antiviral compounds and methods of using thereof: Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral... Agent: Office Of The Staff Judge Advocate (sks) U.s. Army Med. Research & Materiel Command

20090012108 - Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile: The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.... Agent: Philip S. Johnson Johnson & Johnson

20090012109 - Cyclopamine analogs: The invention provides novel derivatives of cyclopamine having the following formula:... Agent: Morrison & Foerster LLP

20090012110 - Morphine compounds for pharmaceutical compositions: e

20090012111 - Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin: A crystalline polymorph of 7-ethyl-10-hydroxycamptothecin exhibiting an X-ray diffraction pattern having peaks at 10.9±0.2, 13.2±0.2, 23.9±0.2, and 26.1±0.2 2-theta degree.... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090012112 - Alpha 1a-adrenoceptor antagonists: This invention relates to novel compounds that are dihydroindoles derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel dihydroindoles derivatives that are derivatives of silodosin. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090012113 - Methods of treating a subject suffering from irritable bowel syndrome: Disclosed are methods of treating a subject suffering from irritable bowel syndrome which involves administering rifaximin to the subject and reducing the symptoms of irritable bowel syndrome. Also disclosed are methods of improving the symptoms in a subject caused by irritable bowel syndrome.... Agent: Knobbe Martens Olson & Bear LLP

20090012114 - Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing same: s

20090012115 - Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations: The present invention provides methods and compositions useful in the treatment or prevention of cardiovascular disorders in individuals for whom therapy with a COX-1 enzyme inhibitor is not feasible due to sensitivity, intolerance, or resistance to the inhibitor. Additionally, the invention provides methods of treating cardiovascular disorders in an individual... Agent: Seed Intellectual Property Law Group PLLC

20090012116 - Muscarinic receptor antagonists: Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary or gastrointestinal system mediated through muscarinic receptors. Also provided are processes for preparing compounds described herein, pharmaceutical compositions comprising compounds described herein, and methods for treating diseases mediated through muscarinic receptors.... Agent: Ranbaxy Inc.

20090012117 - Bicyclic derivatives as modulators of ion channels: Bicyclic derivatives having formula (I) and a composition thereof are useful as ion channel antagonists:... Agent: Vertex Pharmaceuticals Inc.

20090012119 - Fluoroalkylpyrrolidine derivative: This compound exhibits broad and strong antibacterial activity to both Gram positive and Gram negative bacteria as well as high safety, and therefore, this compound is useful as a quinolone antibacterial drug, and a prophylactic and/or therapeutic drug for an infectious disease.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090012118 - Kynurenic acid amide derivatives as nr2b receptor antagoni: The new kynurenic acid amide derivatives of formula (I): and optical antipodes, racemates and the salts thereof are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.... Agent: K.f. Ross P.C.

20090012120 - Synthesis of n-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines: An ylide-based aza-Payne rearrangement of 2,3-aziridin-1-ols leads to an efficient process for the preparation of pyrrolidines. The aza-Payne rearrangement under the basic reaction conditions favors the formation of epoxy amines. Subsequent nucleophilic attack of the epoxide by the ylide yields a bis-anion, which upon a 5-exo-tet ring closure yields the... Agent: Ian C. Mcleod Ian C. Mcleod, P.C.

20090012121 - Polymorphs of fexofenadine hydrochloride: The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII through XV and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of ethyl acetate, while Form IX is a solvate of... Agent: Kenyon & Kenyon LLP

20090012122 - N-aroyl cyclic amine derivatives as orexin receptor antagonists: e

20090012123 - Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient: As a result of intensive studies for the purpose of finding a new medicinal use of an indazole derivative, it was found that an indazole derivative inhibits glutamate-induced retinal neuronal cell death in rat fetal retinal neuronal cells, in other words, the indazole derivative acts directly on the retinal neuronal... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090012124 - 4-(2,6-dichloro-benzoylamino)-1h-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors: The invention provides an acid addition salt of 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide and crystals thereof, the salt being formed with an acid selected from methanesulphonic acid and acetic acid and mixtures thereof. Also provided are the novel uses of salts of 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide, processes for the preparation of 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid... Agent: Heslin Rothenberg Farley & Mesiti PC

20090012125 - Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them: The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as... Agent: Fish & Richardson P.C.

20090012126 - Certain chemical entities, compositions, and methods: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090012127 - Thiophene-2-carboxamide derivatives as alpha 7 nicotinic receptor modulators: Compounds of Formula (I) wherein E, A and R1 are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090012128 - Microbicidal agent and microbicidal composition: A microbicidal agent comprising as an effective ingredient at least one selected from the group consisting of p-hydroxybenzaldehyde, 5,7,4′-trihydroxy-3′,5′-dimethoxyflavone, 3-hydroxypyridine and vanillin, and a microbicidal composition comprising the microbicidal agent.... Agent: Sughrue Mion, PLLC

20090012129 - Novel biaromatic compounds that modulate ppar-receptors: m

20090012130 - Strategies for designing drugs that target the sir2 family of enzymes: The instant invention describes methods of identifying compounds that modulate the activity of Sir2 enzymes. Sir2 enzymes form a unique class Of NAD+ dependent deacetylases required for diverse biological processes including transcriptional silencing, regulation of apoptosis, fat mobilization, and lifespan regulation. Sir2 activity is regulated by nicotinamide, a non-competitive inhibitor... Agent: Edwards Angell Palmer & Dodge LLP

20090012131 - 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for their therapeutic use: wherein the various unnamed substituents are defined herein. The compounds are suitable for the treatment of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090012132 - Pharmaceutical package: The present invention relates to a pharmaceutical package including a pharmaceutical preparation containing 2-ethoxy-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or 2-cyclopropyl-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or a salt thereof, and a desiccant. According to the present invention, a pharmaceutical package having a decreased uncomfortable odor is provided.... Agent: Foley And Lardner LLP Suite 500

20090012133 - Polymorphic form of -acetic acid: The present invention relates to a novel polymorphic form of the compound {2-methyl-4-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylthio]phenoxy}-acetic acid, methods of preparing it, pharmaceutical compositions and medicaments containing the same, and use of such polymorphs, compositions and medicaments in the treatment of PPAR mediated diseases or conditions.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090012134 - Arylsulfonyl benzofused heterocycles as 5-ht2a antagonists: Compounds of formula (I): are potent and selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of various CNS disorders.... Agent: Merck And Co., Inc

20090012135 - Isothiazolone-containing preservative with improved effectiveness: The invention relates to a preservative which 5 comprises a) one or more isothiazolones and b) one or more glycerol monoalkyl ethers, to the use of the preservatives for microbicidal finishing of cosmetic and pharmaceutical products, and to corresponding microbicidally finished products.... Agent: Young & Thompson

20090012136 - Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists: The present invention provides new methods of treating thrombosis and cardiovascular diseases using of antithrombotic agents, as well as methods of determining therapeutically effective amounts of antithrombotic agents and unit dose formulations thereof.... Agent: Seed Intellectual Property Law Group PLLC

20090012137 - Antmicrobial and radioprotective compounds: The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (I), in which X and Y are either the same or different and selected from a heteroatom; is a double or single... Agent: Haynes And Boone, LLPIPSection

20090012138 - 4-imidazolines: and to their pharmaceutically active salts, with the exclusion of the racemic compound 4-benzyl-4,5-dihydro-1H-imidazole or its tautomer (CAS 131548-83-9). Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090012139 - Amino-5-[4-(difluoromethoxy) phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase: d

20090012140 - Preparation of telmisartan salts with improved solubility: New alkali and earth-alkali salts of telmisartan in amorphous form and a new crystalline sodium salt of telmisartan have been prepared by preparing a solution despite low solubility of telmisartan and rapidly vacuum evaporating to dryness.... Agent: Arent Fox LLP

20090012141 - Composition and method for making oligo-benzamide compounds: The present invention includes compound compositions and methods of making compounds that include an oligo-benzamide compound having at least two optionally substituted benzamides.... Agent: Chalker Flores, LLP

20090012142 - Compositions and methods for increasing lean muscle mass and/or reducing fat gain: Compositions and methods for increasing lean muscle mass and/or reducing fat gain in growing animals by feeding the animals a composition having a total lysine to metabolizable energy ratio of from about 2.5 to about 6 g/Mcal and comprising (a) arginine in a total arginine to total lysine ratio of... Agent: Colgate-palmolive Company

20090012143 - Chemical compounds, process for their preparation and use thereof: Disclosed are compounds of formula (I) or pesticidally acceptable salts thereof wherein, for example, W is ═CR8— or ═C(NR9R10)—, R8 is halogen, R9 and R10 are independently of one another hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, aralkyl or heterocyclylalkyl, R1 is cyano, methyl, trifluoromethyl or —CS—NH2, R2 is C1-C6-alkyl,... Agent: Frommer Lawrence & Haug

20090012144 - Optically active 2,5-bisaryl-delta&sup1; -pyrrolines and their use as pest control agents: s

20090012145 - Therapeutic esters:

20090012146 - Solubility-enhanced pharmaceutical compositions comprising zafirlukast: Stable pharmaceutical compositions comprising zafirlukast and pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof, together with one or more pharmaceutically acceptable polymers, and processes for their preparation.... Agent: Dr. Reddy''s Laboratories, Inc.

20090012147 - Indolone derivatives, processes for preparing them and their uses: The present invention relates to indolone derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090012149 - Prodrug of an ice inhibitor: Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders,... Agent: Vertex Pharmaceuticals Inc.

20090012148 - Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis: Compounds disclosed herein may be used in disclosed methods for reducing the amount of cholesterol in a cell, for treating a patient suffering from a disorder characterized by cellular accumulation of cholesterol (such as Niemann-Pick Disease Type C or atherosclerosis), and/or for treating or preventing phospholipidosis. In some embodiments, the... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090012151 - Novel compounds 951: The present invention relates to amide compounds useful as pharmaceuticals for treating respiratory disorders such as asthma, rhinitis and COPD.... Agent: Fish & Richardson P.C.

20090012150 - Stablized pharmaceutical composition comprising an amorphous active substance: The invention relates to the pharmaceutical composition comprising the amorphous active substance which is atorvastatin calcium. The process of stabilization of the pharmaceutical composition comprising the pharmaceutical formulation with amorphous atorvastatin calcium, the process of stabilization of the pharmaceutical formulation comprising amorphous atorvastatin calcium and the process of stabilization of... Agent: Darby & Darby P.C.

20090012152 - Use of tetramic acid derivatives for controlling insects from the genus of the plane lice (sternorrhyncha): e

20090012153 - Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase n inhibitors: The invention relates to novel compounds of formula (I): H2N—CH(R1)—CH2—S—S—CH2—CH(R2)—CONH—R5, wherein R1 is a hydrocarbon chain, phenyl or benzyl radical, methylene radical substituted by a 5 or 6 atom heterocycle; R2 is a phenyl or benzyl radical, a 5 or 6 atom aromatic heterocycle, methylene group substituted by a 5... Agent: Harness, Dickey & Pierce, P.L.C

20090012154 - Antagonists of the transient receptor potential vanilloid 1 and uses thereof: One of the major disabling symptoms of gastroparesis is nausea and vomiting which can be difficult to control with currently available treatments. It is postulated that signaling of gastrointestinal causes of nausea starts with activation of vagal afferent nerves that trigger the central emetic pathway. Most vagal afferent nerves are... Agent: Benjamin Aaron Adler Adler & Associates

20090012156 - Composition comprising polyphenol: A fat based spread or a dairy based drink comprising from to 1 wt % of isorhamnetin can advantageously be used to control blood pressure. It has been found that these products have an effect on vasorelaxation.... Agent: Unilever Patent Group

20090012155 - Composition of skin external application for anti-aging: The present invention relates to an anti-aging composition for external use on skin, and more particularly, to an anti-aging composition for external use on skin comprising at least one of catechins and flavonols as an active ingredient to inhibit decomposition and promote generation or protection at the dermis-epidermis junction.... Agent: Nixon & Vanderhye, PC

20090012157 - Sesamol derivatives as novel inhibitors of arachidonic acid formation: The invention relates to a novel class of inhibitor of arachidonic acid useful for treating inflammatory conditions. Specifically, the invention relates to hydrophobic and hydrophilic derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.... Agent: K&l Gates LLP

20090012158 - Pesticide compositions and methods: New pesticide compositions comprising an alkyl formate and an isothiocyanic ester are described, as are methods of delivering fumigants and methods of pest control using a combination of fumigants.... Agent: Merchant & Gould PC

20090012159 - High purity bases of 3,3-diphenylpropylamino monoesters: The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked... Agent: Kenyon & Kenyon LLP

20090012160 - Carnitine conjugates as dual prodrugs, methods of production and uses thereof: The present invention discloses novel dual prodrug compounds of formula (1), methods for their preparation and intermediates in their syntheses, formula (1): wherein A is a single bond, —O—, or —CH2—; m and n vary independently and are an integer from 1 to 15; p and q vary from 0... Agent: Technology Law, PLLC

20090012161 - Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor: This invention describes a new combination for the treatment of bladder function disorders which comprises a serotonin- and/or norepinephrine-reuptake inhibitor and a beta-3-adrenoceptor agonist.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090012162 - Composition for treating or preventing cell degeneration using at least one molecule capable of maintaining adhesion molecule expression reversibility and vascular endothelium actin fibre polymerisation: The invention relates to the use of a molecule selected from the group which consists of geranyl acetate, geraniol, isomenthone, limonene or a mixture of at least two of the above, for preparing a drug for treating or preventing vascular endothelial cell senescence and subjacent tissue degeneration induced by repeated... Agent: Birch Stewart Kolasch & Birch

20090012163 - Compositions containing mg/zn/f-cap plus inhibitors of pro-inflammatory cytokines (alpha ketoalkanoic acid compound) for osteoporosis prevention, therapy and treatment of bone diseases: A method is described for the treatment of bone disease by oral dosing of a patient with an inhibitor(s) or pro-inflammatory Cytokines which are comprised of a combination of alpha ketoalkanoic acid admixed in a pharmaceutically acceptable carrier with calcium/phosphate/magnesium/zinc or strontium salt compound ion—a hydroxyapatite matrix.... Agent: Allen R. Kipnes Watov & Kipnes, P.C.

20090012164 - Pinolenic acid compositions, products made thereof, and methods of making pinolenic acid compositions and products: Compositions of pinolenic acid or derivatives thereof. Method of using TOFA for obtaining pinolenic acid or derivatives thereof. Products, including foods, beverages, personal care, beauty, pharaceutical or other products comprising TOFA derived pinolenic acid or derivatives thereof.... Agent: Arizona Chemical Company C/o Bo Segers

20090012165 - Pharmaceutical combination of nsaid and prostaglandin compound: m

20090012166 - Oligomers of straight-chain and unbranched fatty acids and drugs containing these: The present invention relates to new substances which are derived from naturally occurring straight-chain and unbranched fatty acids and also from semi-synthetic and synthetic compounds with principally the same structure in that they represent dimers, trimers, tetramers or higher oligomers of the starting substances.... Agent: Millen, White, Zelano & Branigan, P.C.

20090012167 - Omega-3 fatty acids and dyslipidemic agent for lipid therapy: A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with... Agent: Arent Fox LLP

20090012168 - Adiponection inducers or secretagogues: The present invention discloses an adiponectin inducer or secretagogue which comprises an amino acid(s) selected from the group consisting of leucine, isoleucine, valine, methionine, cystein, alanine and a mixture(s) thereof, and a therapeutic agent of hypoadiponectinemia, hyperlipemia, hypertension or vascular disorders or an anti-inflammatory agent, which comprises the adiponectin inducer... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090012169 - Combined use of l-carnitine, acetyle l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia: L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts, or their pharmaceutically acceptable salts, are used in combination to treat oligoasthenoteratosperia including oligospermia, asthenospermia, and teratospermia.... Agent: Nixon & Vanderhye, PC

20090012170 - Treatment of symptoms of motor dysfunction: The present invention relates to the use of a COMT inhibitor in combination with a dopamine precursor and a peripheral decarboxylase inhibitor in the treatment of motor dysfunctions.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090012172 - Cosmetic/pharmaceutical compositions comprising retinoids and anti-irritants and treatment of keratinization disorders therewith: Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among the salts of 18β-glycyrrhetinic acid and derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to a disorder of keratinization relating to cell differentiation... Agent: Buchanan, Ingersoll & Rooney PC

20090012171 - Novel compounds, their preparation and use: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090012173 - Method for treatment of nocturia: A method for treatment of nocturia by administering to a mammal, such as a human, in need of such treatment, a therapeutically effective amount of loxoprofen or a pharmacologically acceptable salt thereof.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090012174 - Compositions having a high antiviral and antibacterial efficacy: Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain (a) a disinfecting alcohol, (b) an organic acid, (c) a buffering agent, and (d) water, wherein the composition has a pH of about 5 or less.... Agent: Marshall, Gerstein & Borun LLP (dial)

20090012175 - Methods of treating cancer with hdac inhibitors: The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo Attn: Patent Intake Customer No. 35437

20090012176 - Process for manufacturing entacapone: Processes for manufacturing entacapone are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090012177 - Treatment of psychiatric disorders using entacapone, tolcapone and other comt inhibitor or mb-comt inhibitor drugs: The invention provides a method for the treatment of certain psychiatric disorders using entacapone, tolcapone and other COMT inhibitor drugs or MB-COMT inhibitor compounds. The method is effective in particular for improving positive and negative symptoms of Schizophrenia (SCZ), major depression, the depressive phase of Bipolar Disorder (BD) and substance... Agent: Rahim Shafa

20090012178 - Benzoxazocines and their therapeutic use: A compound selected from (1S)-8-cyano-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine; (1R)-8-cyano-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine; (1S)-8-cyclopropyl-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine; (1S)-8-cyclopropyl-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine; (1S)-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine-8-carboxamide; (1R)-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5H-benz[f]-2,5-oxazocine-8-carboxamide; and the salts thereof. These compounds have therapeutic utility.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090012179 - Use of tyrphostins to stimulate neurite outgrowth: Disclosed herein are several methods for promoting nerve regeneration. The methods include administering at least one tyrphostin, or a pharmaceutically acceptable salt thereof. In one non-limiting example, the tyrphostin is tyrphostin A9. These methods can be used to promote nerve growth in the central or peripheral nervous system. The methods... Agent: Klarquist Sparkman, LLP

20090012180 - Titration of tapentadol: The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a<dose b, for the treatment of pain.... Agent: Crowell & Moring LLP Intellectual Property Group

20090012181 - Patch: A Bisoprolol patch, wherein the skin penetration rate of Bisoprolol after 24 hours is 15 to 60% of the maximum skin penetration rate thereof, shows a little difference between the maximum level of the concentration in blood and the minimum level thereof in repeated administration and, therefore, scarcely exhibits side... Agent: Licata & Tyrrell P.C.

20090012182 - Crystal forms of o-desmethylvenlafaxine succinate: Provided are crystalline forms of O-desmethylvenlafaxine succinate, methods for their preparation, and pharmaceutical composition thereof.... Agent: Kenyon & Kenyon LLP

20090012183 - Composition comprising polyphenol: A food product comprising from 0.05 to 1 wt % of trans-resveratrol can advantageously be used to control blood pressure. Preferred food products are spreads or drinks.... Agent: Unilever Patent Group

20090012184 - Production of dosage forms comprising a solid dispersion of a microcrystalline agent: A method is described for the production of dosage forms, which comprise a solid dispersion of a microcrystalline active substance, in which a thermoplastic polymer with a glass transition temperature Tg of at least 40° C. is melted and an active substance is dissolved homogeneously in the melt; crystallization of... Agent: Edwards Angell Palmer & Dodge LLP

20090012185 - Surfactant composition: A surfactant composition contains at least one sorbitan ester and at least one sorbitol ester wherein the mean number of carbon atoms of the hydrophobe of the sorbitan ester is greater than that of the sorbitol ester. The surfactant composition is particularly suitable for use in stabilising emulsions, especially personal... Agent: Jones Day

20090012186 - Mite composition, use thereof, method for rearing the phytoseiid predatory mite amblyseius sirskii, rearing system for rearing said phytoseiid mite and methods for biological pest control on a crop: The present invention relates to a novel mite composition comprising a population of the phytoseiid predatory mite species Amblyseius swirskii. and a factitious host population, which may be employed for rearing said phytoseiid predatory mite species or for releasing the phytoseiid predatory mite species in a crop. According to further... Agent: Bozicevic, Field & Francis LLP

  
01/01/2009 > patent applications in patent subcategories. recently filed with US Patent Office

20090005292 - Novel peptides that bind to the erythropoietin receptor: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also... Agent: Darby & Darby P.C.

20090005293 - Methods and compositions for increasing the anaerobic working capacity in tissues: Provided are compositions comprising beta-alanylhistidine peptides and beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.... Agent: Bell, Boyd & Lloyd LLP

20090005294 - Peptides for the treatment of cancer associated with the human papilloma virus (hpv) and other epithelial tumors: This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII)... Agent: Hoffmann & Baron, LLP

20090005310 - (en) pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms: i

20090005301 - 207 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090005313 - Activatable clostridial toxins: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.... Agent: Dean G. Stathakis Allergan, Inc. -t2-7h

20090005296 - Ammonium/ammonia transporter: The present invention relates to methods and means for ammonia and/or ammonium transport in a variety of organisms, including mammals, yeast and plants. In particular, the present invention is related to the use of isolated polypeptide molecules, which are particular members of the aquaporin superfamily, and isolated nucleic acid molecule... Agent: Michael Best & Friedrich LLP

20090005300 - Antimicrobial peptides and methods of use: Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also... Agent: Greenlee Winner And Sullivan P C

20090005297 - Aprotinin variants: The present invention relates to the field of proteins that inhibit serine protease activity. The invention also relates to the field of nucleic acid constructs, vectors and host cells for producing serine protease inhibiting proteins, pharmaceutical compositions containing such proteins, and methods for their use.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090005298 - Bone sialoprotein collagen-binding peptides: The present invention provides Novel collagen-binding peptides of bone sialoprotein (BSP). Peptides comprising a portion of the N-terminal collagen binding domain of BSP (residues 1-100) are used to stimulate mineralization, nucleate hydroxyapatite, and promote bone formation in collagen expressing tissues. Medicaments for use in the same are also contemplated. Chimeric... Agent: The Nath Law Group

20090005307 - Compositions and methods for detection of colorectal cancer: We have identified a new variant of ileal bile acid binding protein (IBABP), designated IBABP-L, which is a biomarker for colorectal cancer. The transcript for IBABP-L arises from an alternative start site and includes three exons that are absent in IBABP. IBABP-L also shares part of a fourth exon with... Agent: Biotechnology Law Group C/o Portfolioip

20090005304 - Human kcnq5 potassium channel, methods and compositions thereof: An isolated polynucleotide encoding a novel potassium channel polypeptide, KCNQ5, that is expressed primarily in brain and skeletal muscle is described. The new polypeptide has been cloned and isolated from a human brain cDNA library and is a member the KCNQ family of potassium channels. The provided human KCNQ5 nucleic... Agent: Louis J. Wille Bristol-myers Squibb Company

20090005311 - Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof: Fructooligosaccharide (FOS)-related protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, FOS-related fusion proteins, antigenic peptides, and anti-FOS-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and host cells into... Agent: Alston & Bird LLP

20090005299 - Method for producing carboxy-terminal-amidified peptides: The invention relates to the production of carboxy-terminal (C-terminal) amidified peptides with C-terminal amidified lysin, in particular with the biological activity of GLP-1, the chemical and/or biotechnological precursors and intermediate products thereof. The invention also relates to a method for the production and use thereof for producing pharmaceutical products.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090005302 - Method, apparatus, and compound for effecting localized, non-systemic, immunogenic treatment of cancer: Anthracyclin-treated turn or cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclins induce the rapid, pre-apoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knock down of CRT suppressed the... Agent: Samuel A. Kassatly

20090005306 - Novel bacillus thuringiensis gene with lepidopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20090005312 - Novel glp-1 analogues linked to albumin-like agents: Novel GLP-1 agonists which are protracted by coupling to a protraction protein.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090005303 - Proteases from carica having mitogenic activity and their methods of use: Proteases having mitogenic activity isolated from the genus Carica are provided. In particular the proteases are cysteine proteases isolated from Carica candamarcensis. In addition, the recombinant forms of the protease, including fragments and mutants with substantial homology are provided. Also provided are pharmaceutical compositions useful for treating wounds that include... Agent: Rosenbaum & Associates, P.C.

20090005305 - Service for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt translocation: Anthracyclines-treated tumor cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclines induce the rapid, pre-apoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knock down of CRT suppressed the phagocytosis... Agent: Samuel A. Kassatly

20090005309 - Substituted piperidines: Disclosed herein are substituted piperidine-based muscarinic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20090005295 - Syndecans and angiogenesis: The invention provides methods and materials related to modulating syndecan levels and angiogenesis in an animal. The invention provides syndecan polypeptides and nucleic acids encoding syndecan polypeptides, including dominant negative syndecan polypeptides. The invention also provides polynucleotides and polynucleotide analogues for modulating angiogenesis, as well as cells and embryos containing... Agent: Fish & Richardson P.C.

20090005308 - Variants derived from actriib and uses therefor: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions... Agent: Ropes & Gray LLP

20090005316 - Alpha-conotoxin mii analogs: The invention relates to novel conopeptides and/or novel uses of conopeptides. The conopeptides of the invention are analogs of α-Conotoxin MII that are selective for α6-containing nAChRs as described herein.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090005314 - Compositions and methods for modulating pgc-1alpha to treat neurological diseases and disorders: The present invention provides methods for modulating mitochondrial function, modulating lesion formation in the brain, modulating neurite growth, modulating neuronal degeneration, and treating and preventing neurological diseases or disorders comprising modulating the expression or activity of PGC-1α. The present invention also provides an animal, e.g., transgenic mouse, in which the... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090005315 - Vip fragments and methods of use: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorders.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20090005317 - Methods for treating a corneal disorder and promoting skin wound healing: A method for treating a corneal disorder or for promoting skin wound healing comprising administering to a patient in need thereof a composition containing pharmaceutically effective amounts of (i) a first peptide comprising an amino acid sequence containing the following consecutive amino acids: Ser-Ser-Ser-Arg (SEQ ID NO: 1), or an... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090005318 - Controlled release composition and method of producing the same: A controlled release composition comprising (1) a physiologically active substance or salt thereof in an amount of about 14% (w/w) to about 24% (w/w) based on the total composition weight, (2) hydroxynaphthoic acid selected from the group consisting of 3-hydroxy-2-naphthoic acid and 1-hydroxy-2-naphthoic acid or salt thereof, and (3) a... Agent: Foley And Lardner LLP Suite 500

20090005319 - Topical compositions for delaying ejaculation and methods of using the same: A method, composition, and kit for topical application of a composition to a male penis to delay premature ejaculation during intercourse without adversely affecting response in a female partner are disclosed. The method includes applying to the penis a topical composition immediately prior to intercourse. The composition includes an effective... Agent: Greenberg Traurig, LLP

20090005320 - Compositions comprising amino acid bicarbonate and methods of use thereof: The invention relates to compositions comprising one or more ionic salts, each of said ionic salts consisting of a bicarbonate anion and a cation selected from the group consisting of an amino acid, an amino acid derivative, a di-peptide and a tri-peptide, and to methods of making and using said... Agent: Morse, Barnes-brown & Pendleton, P.C. Attn: Patent Manager

20090005321 - Phenylazetidinone derivatives: Various azetidinone derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.... Agent: Heslin Rothenberg Farley & Mesiti PC

20090005322 - Physiologically- active composition based on collagen: The present invention concerns a physiologically active composition which contains an enzymatically hydrolysed collagen as the active component I and at least one component of the non-vitamin type having anti-oxidative and/or anti-inflammatory properties as the active component II. Collagen of animal origin that is soluble in cold water comes into... Agent: Fulbright & Jaworski, LLP

20090005323 - Cathepsin k inhibitors and obesity: This invention relates to the treatment of obesity, the treatment of obesity related disorders, prevention of weight gam, prevention of weight regain or for weight maintenance by the use of a cathepsin K inhibitor as active ingredient, alone or in conjunction with other anti-obesity agents The invention also relates to... Agent: Merck And Co., Inc

20090005324 - Biologically active extract from dendrobium plant, use thereof and process for preparing the same: i

20090005325 - Ketolide derivatives as antibacterial agents: Provided herein are ketolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm,... Agent: Ranbaxy Inc.

20090005326 - Single dose roxithromycin: The invention relates to a method of treating a bacterial infection in an animal by administering a single dose of roxithromycin.... Agent: Townsend And Townsend And Crew, LLP

20090005327 - Essential n-3 fatty acids in cardiac in sufficiency and heart failure therapy: The present invention concerns a method of therapeutic prevention and treatment of a heart disease chosen from cardiac insufficiency and heart failure including the administration of an essential fatty acid containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), either alone or in combination... Agent: Arent Fox LLP

20090005328 - Methods of modulating tubulin deacetylast activity: The present invention provides methods for identifying agents that modulate a level or an activity of tubulin deacetylase polypeptide, as well as agents identified by the methods. The invention further provides methods of modulating tubulin deacetylase activity in a cell. The invention further provides methods of modulating cellular proliferation by... Agent: Bozicevic, Field & Francis LLP

20090005331 - Ache antisense oligonucleotide as an anti-inflammatory agent: Disclosed is a novel use for AChE antisense oligonucleotides as anti-inflammatory agents, wherein said oligonucleotides are preferably as denoted by SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:7. Methods of treatment of inflammatory conditions, as well as fever, and particularly inflammation-associated neuropathies such as Guillain-Barré Syndrome, are described.... Agent: Cooper & Dunham, LLP

20090005332 - Compositions and methods for modulating gene expression using self-protected oligonucleotides: The present invention is directed to novel nucleic acid molecules which include a region complementary to a target gene and one or more self-complementary regions, and the use of such nucleic acid molecules and compositions comprising the same to modulate gene expression and treat a variety of diseases and infections.... Agent: Seed Intellectual Property Law Group PLLC

20090005335 - Compounds for the modulation of beta-catenin expression: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating... Agent: Dechert LLP

20090005330 - Methods and compositions to inhibit p2x7 receptor expression: Methods and compositions for the downregulation of P2X7 receptor expression or activity are disclosed. Preferred compositions comprise siNA. The methods and compositions are useful in the treatment of diseases characterised by increased 112X7 receptor activity, such as neuronal degeneration, Alzheimer's disease, inflammatory diseases, and some cancers.... Agent: Fish & Richardson PC

20090005329 - Nucleic acid based ladder copolymers: The present invention relates to a copolymer termed a ladder copolymer because it has two backbones that serve as legs/sides of a ladder structure. These two backbones, one of which is a nucleic acid or nucleic acid-like polymer, are linked together as the legs/sides of a ladder are linked together... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090005334 - Nucleic acid derivatives: A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090005337 - Pde11a mutations in adrenal disease: The invention provides previously uncharacterized variants of PDE11A that are correlated with a newly discovered form of Cushing Syndrome that presents at a young age. The invention also provides methods useful to research, screen for, treat, or prevent diagnose the disease using the PDE11A variants, as well as other methods... Agent: Leydig, Voit & Mayer, Ltd.

20090005333 - Reducing culling in herd animals growth hormone releasing hormone (ghrh): One aspect of the current invention is a method of decreasing an involuntary cull rate in farm animals, wherein the involuntary cull results from infection, disease, morbidity, or mortality. Additionally, milk production, animal welfare, and body condition scores are improved by utilizing methodology that administers the isolated nucleic acid expression... Agent: Pepper Hamilton LLP

20090005336 - Use of the microrna mir-1 for the treatment, prevention, and diagnosis of cardiac conditions: Among >300 miRNAs known to date, miR-1 is considered muscle-specific. Here we show that that miR-1 overexpressed in individuals with coronary artery disease, and when overexpressed, it exacerbated arrhythmogenesis in both infarcted and normal hearts of rats whereas elimination of miR-1 by its antisense inhibitor relieved it. MiR-1 rendered slowed... Agent: Louis Tessier

20090005338 - Carbonyl-substituted titanocenes: o

20090005339 - Methods of treating ear infections: Methods of treating and/or preventing otitis media in a subject are provided. Methods of treating and/or preventing otitis externa are also provided.... Agent: 3m Innovative Properties Company

20090005340 - Bioactive agents produced by submerged cultivation of a basidiomycete cell: The invention in one aspect is directed to a method for cultivating a Basidiomycete cell in liquid culture medium, said method comprising the steps of providing a Basidiomycete cell capable of being cultivated in a liquid growth medium, and cultivating the Basidiomycete cell under conditions resulting in the production intracellularly... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090005342 - Composition having blood pressure reducing and/or elevation suppressing effect and food and drink containing the same: The present invention regards the composition having a blood pressure reducing and/or elevation suppressing effect comprising a mannose-based oligosaccharide mass comprising 1 to 10 molecules of monosaccharides linked together, said molecules mainly comprising mannose. It is the object of the present invention to provide an economical and simple food and... Agent: Fitch Even Tabin & Flannery

20090005341 - Process for the preparation of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained: A new method is described for the oversulfation of (epi)K5-N-sulfates to obtain (epi)K5-amine-O-oversulfates at extremely high degree of sulfation and for the transformation of these intermediates into new N-acyl-(epi)K5-amine-O-oversulfates basically free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field. Also described are pharmaceutical compositions... Agent: Nixon & Vanderhye, PC

20090005343 - B-cyclodextrin derivatives and their use against anthrax lethal toxin: The invention provides low molecular weight compounds that block the pore formed by protective antigen and inhibit anthrax toxin action. Structures of the compounds are derivatives of β-cyclodextrin. Per-substituted alkylamino derivatives displayed inhibitory activity, and they were protective against anthrax lethal toxin action at low micromolar concentrations. Also, the addition... Agent: Keown & Zucchero, LLP

20090005344 - Compounds and methods of use thereof: Imidazole and benzimidazole boronic acid compounds, analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.... Agent: Alston & Bird LLP

20090005345 - Detoxification of shellfish: The present invention relates to the detoxification of bivalves and other shellfish. More particularly, the invention relates to a feed composition and a method for detoxifying shellfish, and the use of a surface-active agent for the detoxification of bivalves and other shellfish.... Agent: Volpe And Koenig, P.C.

20090005346 - Azacytosine derivatives useful as antiviral agents: The present invention provides 5-azacytosine derivatives with antiviral activity, specifically having viral replication inhibiting properties, more particularly in DNA viruses such as pox-, papilloma- and herpes viruses in humans. The invention also provides pharmaceutical compositions comprising such 5-azacytosine derivatives as active ingredients in combination with pharmaceutically acceptable carriers, which are... Agent: Clark & Elbing LLP

20090005347 - Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis: A bisphosphonate for the treatment of osteonecrosis and/or osteonecrosis dissecans. The drug may further be used to prevent the onset of osteonecrosis and/or osteonecrosis dissecans and any complications associated with both diseases.... Agent: Bozicevic, Field & Francis LLP

20090005348 - Compounds having cytokine modulating properties: A method of modulating one or more immuno-regulatory cytokines, such as pro-inflammatory and/or anti-inflammatory cytokines, comprising administering to a subject a therapeutically effective amount of one or more phosphate derivatives of one or more hydroxy chromans, or complexes thereof.... Agent: Michael Best & Friedrich LLP

20090005349 - Therapeutic uses of glutathione mimics: A prodrug having antioxidant activity, including a phosphorylated compound having a thiol group. A method of treating oxidative stress by administering a prodrug of a phosphorylated compound including a thiol group, removing a phosphate group of the prodrug, and treating oxidative stress. A method of increasing bioavailability of a thiol... Agent: Kohn & Associates, PLLC

20090005350 - Cyclooxygenase-2 selective inhibitors, compositions and methods of use: The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a... Agent: Wilmerhale/nitromed

20090005351 - Hormone replacement therapy: This invention relates to methods and pharmaceutical compositions for providing hormone replacement therapy in perimenopausal, menopausal, and postmenopausal women through the continuous administration of combinations of conjugated estrogens and medroxyprogesterone acetate.... Agent: Wyeth/finnegan Henderson, LLP

20090005352 - Prodrugs of propofol, compositions and uses thereof: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090005355 - Piperidine compound and process for preparing the same: e

20090005356 - Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators: Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway... Agent: Wilson Sonsini Goodrich & Rosati

20090005354 - New amino derivatives and their use as pharmaceuticals: which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD;... Agent: Pharmacia Corporation Global Patent Department

20090005353 - Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators: to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with... Agent: Pepper Hamilton LLP

20090005358 - Compositions and methods for treating medical conditions: The invention features methods, compositions, and kits for the treatment of pain or pruritus in a patient. In one embodiment, the methods, compositions, and kits of the invention provide for a combination therapy including a tricyclic compound and a tetra-substituted pyrimidopyrimidine.... Agent: Clark & Elbing LLP

20090005357 - Pharmacological treatment for sleep apnea: The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.... Agent: Marshall, Gerstein & Borun LLP

20090005359 - Heterocyclic compounds useful as raf kinase inhibitors: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.... Agent: Choate, Hall & Stewart LLP

20090005360 - Modified release preparations containing oxcarbazepine and derivatives thereof: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.... Agent: Foley And Lardner LLP Suite 500

20090005361 - Combination of organic compounds: The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising a therapeutic agent acting on the renin-angiotensin system (RAS) or a pharmaceutically acceptable salt thereof and comprising at least one CB1 antagonist, or a pharmaceutically acceptable salt thereof. The present invention furthermore relates... Agent: Novartis Corporate Intellectual Property

20090005362 - Compositions comprising antihistamines or mast cell stabilizers, and methods of making and using same: Compositions comprise: (a) a material selected from the group consisting of antihistamines, stabilizers, salts thereof, and combinations thereof; and (b) a vasoconstrictor, decongestant, or a salt thereof, provided when the material consists of an antihistamine or a salt thereof, at least one antihistamine other than ketotifen and salts thereof is... Agent: Bausch & Lomb Incorporated

20090005363 - Organic compounds: m

20090005364 - Azole derivatives with antimuscarinic activity: The present invention relates to compounds of formula (I) wherein R1, R2, x, X, Y and B are as defined in the description for the treatment of muscarinic acetylcholine receptor mediated diseases, in particular M3 muscarinic receptor mediated diseases.... Agent: Ladas & Parry LLP

20090005365 - Therapeutic pyrazolonaphthyridine derivatives: e

20090005367 - Composition and method for treating alcoholism and other substance addictions: Disclosed are pharmaceutical compositions comprising a benzodiazepine, an alcohol aversive agent, and an abuse aversive agent, and methods of use in preventing alcohol or cocaine abuse.... Agent: Michael Best & Friedrich LLP

20090005366 - Deuterium-enriched olanzapine: The present application describes deuterium-enriched olanzapine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090005368 - Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives: The invention relates to antibiotic ethanol or 1,2-ethanediol cyclohexyl derivatives of formula (I) wherein R1 represents (C1-C4)alkoxy; one or two of U, V, W and X represents) N and the remaining represent each independently CH or, in the case of V or X, may also represent CRa; Ra represents halogen;... Agent: Hunton & Williams LLP Intellectual Property Department

20090005370 - Isoxazole-imidazole derivatives: e

20090005369 - Oxazolidinone compounds and compositions and methods related thereto: The invention provides new oxazolidinones of formula (I), where R1, R2, R3 and R4 are independently selected from H, F and Cl; A is certain heterocycles optionally substituted; X is selected from O, S, NR8 and CR8R9; R8 and R9 having different meanings; Y is selected from O, S, SO,... Agent: Birch Stewart Kolasch & Birch

20090005371 - Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods: Fused [1,2]imidazo[4,5-c] ring compounds, e.g., fused [1,2]imidazo[4,5-c]quinolines and [1,2]imidazo[4,5-c]naphthyridines, with a substituent, e.g., a substituted alkoxy substituent, at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in... Agent: Wolf Greenfield & Sacks, P.C.

20090005374 - Imidazopyridinyl thiazolyl histone deacetylase inhibitors: A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.... Agent: Harness, Dickey & Pierce, P.L.C

20090005373 - Substituted sulfonamido-macrocycles as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same: and salts, N-oxides, or solvates thereof, to pharmaceutical compositions comprising said substituted sulfonamido-macrocycles, to methods of preparing said substituted sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth,... Agent: Millen, White, Zelano & Branigan, P.C.

20090005372 - Triazolophthalazines: d

20090005375 - Acetyl coenzyme a carboxylase inhibitors:

20090005376 - 1-alkoxy 1h-imidazo ring systems and methods: Imidazo-containing compounds (e.g., imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines) with an alkoxy substituent at the 1-position, pharmaceutical compositions containing the compounds and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: 3m Innovative Properties Company

20090005377 - Pyrazolopyridine derivates: New compounds of formula (I) and the salts thereof, wherein the meanings for the various substituents are as disclosed in the description, are useful as p38 kinase inhibitors.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090005379 - Azaindole-2-carboxamide derivatives: The present invention relates to compounds of formula (I) wherein R1 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090005378 - Pyrrolo-pyridine kinase modulators: The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.... Agent: Wilson Sonsini Goodrich & Rosati

20090005380 - Cyclohexyl derivatives: e

20090005381 - Methods of treating serotonin-mediated diseases and disorders: Methods are disclosed for treating serotonin-mediated diseases and disorders, which comprise inhibiting tryptophan hydroxylase (TPH) in patients in need thereof.... Agent: Lexicon Pharmaceuticals, Inc.

20090005382 - Methods of using and compositions comprising tryptophan hydroxylase inhibitors: Methods and compositions comprising tryptophan hydroxylase inhibitors are disclosed. Particular methods are directed at reducing or avoiding serotonin-mediated adverse effects associated with some drugs.... Agent: Lexicon Pharmaceuticals, Inc.

20090005383 - Thyroid hormone analogs: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090005384 - Method for producing adsorptive porous body: The present invention relates to a method for producing a 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one adsorptive porous material characterized by treating a porous material with a halogen-containing organic solvent in which 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one is dissolved. The production method of the present invention is simple and easy, and the obtained adsorptive porous material is excellent in... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090005389 - 2,5 diaza-bicyclo [2.2.1] heptane derivatives as calcium channel blockers: 2,5-diaza-bicyclo[2.2.1]heptane derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel... Agent: Merck And Co., Inc

20090005388 - 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists: This invention relates to novel 3,9-diazabicyclo[3.3.1]nonane derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as... Agent: Birch Stewart Kolasch & Birch

20090005386 - Methods for modulating ion channels: In one embodiment, the invention provides an ion having the formula: (I) In another embodiment, the invention provides a method for modulating potassium, sodium, and cyclic nucleotide-modulated ion channels in a mammal in need thereof. In a further embodiment, the invention provides a method for modulating ligand-gated ion channels or... Agent: Irving N. Feit Hoffmann & Baron

20090005390 - Novel quinuclidine derivatives and their use: This invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous... Agent: Birch Stewart Kolasch & Birch

20090005387 - Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090005385 - Treatment or prevention of cancer or cardiovascular disease with methenyltetrahydrofolate synthetases: The present invention relates to a method of screening test substances for chemotherapeutic activity or for efficacy in treating cardiovascular disease by providing one or more cells transformed with a nucleic acid molecule encoding methenyltetrahydrofolate synthetase, contacting the cells with test substance(s), and identifying those test substances which modulate methenyltetrahydrofolate... Agent: Nixon Peabody LLP - Patent Group

20090005391 - Tricyclo substituted amides: Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.... Agent: Eli Lilly & Company

20090005392 - Crystal of 6-[4-(4-pyridylamino) phenyl]-4,5-dihydro-3(2h-pyridazinone hydrochloride trihydrate: m

20090005393 - Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase:

20090005394 - Endothelin receptor antagonists: This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090005395 - Sildenafil n-oxide as prodrug: or a pharmacologically acceptable salt, hydrate, or solvate thereof. Other embodiments of the present invention relate to a pharmaceutical composition containing this compound, to methods for preparing this compound, and to methods for preparing compositions containing this compound. Yet other embodiments of the invention relate to uses of this compound,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090005396 - Use of pyrazolyl-pyrimidine derivatives in the treatment of pain: This invention relates to the use of a pyrazolyl-pyrimidine of the formula (I). n=0, 1, 2 or 3 (I) in the manufacture of a medicament for use in the treatment or prophylaxis of pain. and to their pharmaceutical formulations and to their methods of use.... Agent: Fish & Richardson P.C.

20090005397 - Substituted oxindol derivatives and medicaments containing the same: The invention relates to novel oxindol derivatives of general formula (1) wherein the substituents A, B, R1, R2 and R3 have the designations cited in patent claim 1, and to medicaments containing said derivatives for the prophylaxis and/or treatment of vasopressin-dependent or oxytocin-dependent diseases.... Agent: Dykema Gossett PLLC

20090005398 - Methods for the treatment of central nervous system tumors: Methods for the treatment of primary and secondary central nervous system tumors in a mammal which comprise administration of a benzimidazole thiophene compound are provided.... Agent: Glaxosmithkline Corporate Intellectual Property

20090005399 - Substituted imidazo[2,1-b]thiazole compounds and uses thereof: t

20090005400 - Biologically active aphrocallistin compounds: The subject invention provides novel compositions of biologically active compounds which can advantageously be used in blocking cellular proliferation and/or treatment of cancer.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090005401 - Novel compounds: This invention relates to a novel group of 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N″-substituted-N′-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090005402 - Medicine containing pyrimidine derivative: [R1 represents a hydrogen atom or C1-C6 alkyl group, R2 represents a C1-C6 alkyl group or the like, A represents a carbon atom or the like, D represents a C1-C6 alkylene group or the like, E represents a carbon atom or the like and Arom represents an aryl group or... Agent: Nixon & Vanderhye, PC

20090005403 - Alkinyl-oxypyrimidines used in the form of pesticides: 1

20090005404 - Pyridylsulfonamido pyrimidines for treating diabetic nephropathy: The present invention relates to the use of a compound of formula (I) wherein R1 is pyridyl or thiazolyl, any of which may optionally be substituted with C1-8alkyl or C2-8alkenyl; and a) R2 is methoxy and n is zero or one; or b) R2 is chlorine and n is zero... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090005405 - Compositions and methods for treating and preventing dermatoses: The invention encompasses protectant agents including uracil or a metabolite thereof that effectively prevent and/or treat the cutaneous toxicities and dermatological side-effects associated with chemotherapeutic agents. Additionally, and surprisingly compositions including uracil or a metabolite thereof are effective for treating or preventing various dermatoses.... Agent: Morgan Lewis & Bockius LLP

20090005406 - Cancer treatment method: The present invention relates to a method of treating cancer in a mammal by administration of pyrimidine derivatives. In particular, the method relates to a method of treating cancer by administration of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or a salt or solvate thereof.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090005407 - Particulate (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of its use: Particulate (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone is disclosed. Also disclosed are pharmaceutical formulations and dosage forms comprising particulate (3′-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl) and methods of their use.... Agent: Lexicon Pharmaceuticals, Inc.

20090005408 - Process for the production of an abuse-proofed dosage form: The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.... Agent: Norris, Mclaughlin & Marcus, P.A.

20090005411 - Combinations of organic compounds: e

20090005410 - N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl) hetaryl arylsulfonamides: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as... Agent: Brinks Hofer Gilson & Lione

20090005409 - Pyrrolo[3,2-c] pyrdine derivatives and processes for the preparation thereof: The present invention provides novel pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump... Agent: Sughrue Mion, PLLC

20090005412 - Novel quinuclidine derivatives and medicinal compositions containing the same: Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090005413 - Novel salt of montelukast: The invention relates to a novel salt of montelukast with tert-butylamine and its use in the process for the preparation of highly pure free montelukast acid and/or pharmaceutically acceptable salts thereof, in particular montelukast sodium.... Agent: Matthias Scholl

20090005414 - Polymorph of n,n-diethyl-4-(3-fluorophenyl-piperidin-4-ylidene-methyl)-benzamide hydrochloride salt: Polymorphs of N,N-diethyl-4-(3-fluorophenyl-piperidin-4-ylidene-methyl)-benzamide hydrochloride salt, methods of making these polymorphs and uses thereof are described.... Agent: Pepper Hamilton LLP

20090005415 - 1,2-diarylimidazoles for use as cb1 modulators: Salts of 1,2-diarylimidazole-4-carboxamides and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20090005416 - Benzimidazole derivatives: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds... Agent: Pfizer Inc

20090005417 - Substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their preparation and use in medicaments: The present invention relates to substituted indazolyl sulfonamide and 2,3-dihydroindolyl sulfonamide compounds of general formula I, a process for their preparation, medicaments comprising said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds as well as the use of said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds for the preparation of medicaments,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090005418 - Mitotic kinesin inhibitors: The present invention relates to dihydroisoxazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20090005419 - Organic compounds: e

20090005420 - Inhibitors of matrix metallaproteinases: The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are... Agent: Schwegman, Lundberg & Woessner, P.A.

20090005421 - Novel pyridine derivatives: The invention relates to novel pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.... Agent: Dickstein Shapiro LLP

20090005422 - Bacterial thioredoxin reductase inhibitors and methods for use thereof: The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR... Agent: Milde & Hoffberg, LLP

20090005423 - Systems and methods for effecting cessation of tobacco use: The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation.... Agent: Bozicevic, Field & Francis LLP

20090005424 - Composition and method for treating fibrotic diseases: The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones have enhanced anti-fibrotic activities than 5-methyl-1-(non-substituted phenyl)-2(1H)-pyridones. An representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone. Accordingly, there are provided compositions comprising one or more compounds selected from the group consisting of 5-methyl-1-(substituted phenyl)-2(1H)-pyridones and methods of using the same to treat or prevent fibrosis... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090005425 - Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof: The present invention relates to a complex formulation for oral administration including amlodipine camsylate and simvastatin, and a preparation method thereof. The complex formulation of the present invention comprising amlodipine camsylate, simvastatin and a stabilizing agent can be used advantageously for preventing and treating diseases such as hyperlipidemia, atherosclerosis, hypertension,... Agent: Sughrue Mion, PLLC

20090005426 - Pharmaceutically active sulfonyl hydrazide derivatives: e

20090005427 - Substituted oxadiazole compounds and their use as opioid receptor ligands: in which X denotes CH, CH2, CH═CH, CH2CH2, CH2CH═CH or CH2CH2CH2; R1 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; or a C1-3 alkyl group-linked aryl or heteroaryl group, in each case unsubstituted or mono- or polysubstituted; R2 denotes aryl or heteroaryl, in each case unsubstituted... Agent: Crowell & Moring LLP Intellectual Property Group

20090005428 - Imidazole derivatives for the treatment of gastrointestinal disorders: The present invention relates to novel compounds having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease,... Agent: White & Case LLP Patent Department

20090005429 - Process for the preparation of carvedilol and its enantiomers: The present invention relates to a process for the preparation of carvedilol as well as of the optically active R and S enantiomers thereof and of mixtures of these enantiomers and, more particularly, relates to an improved process for the preparation of carvedilol and its enantiomers characterized by the use... Agent: Lucas & Mercanti, LLP

20090005430 - Receptor blocker and vasodilator comprising indole derivative as active ingredient: (wherein R1 represents a hydrogen, alkyl group, alkenyl group, alkynyl group, aromatic group, aralkyl group, acyl group, arylsulfonyl group, alkylsulfonyl group, or hydroxyl group; R2 represents a hydrocarbon group; R3, R4, R5, R6, and R7 are the same or different and represent a hydrogen, halogen, alkyl group, or alkoxy group;... Agent: Birch Stewart Kolasch & Birch

20090005431 - Substituted pyrrolidines: Disclosed herein are substituted pyrrolidine-based muscarinic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20090005432 - Pharmaceutical compositions including low dosages of desmopressin: The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin... Agent: Goodwin Procter LLP Patent Administrator

20090005433 - Fluorinated compounds: e

20090005434 - Novel salicylic anilides: Novel salicylic anilides are chemical uncouplers useful e.g. for the treatment of obesity.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090005435 - Novel compounds, pharmaceutical compositions containing same, and methods of use for same: A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula (II), wherein R1 and R2, the same or different from each other, are H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CH2CORS, —CH2C(O)NRS, —C(O)R5, or —CH2OR5, and can optionally contain halogen atoms, where R5 is a C1-C12... Agent: Jacobson Holman PLLC

20090005436 - Substituted aminoalkyl- and amidoalkyl-benzopyran derivatives: p

20090005437 - Alpha-ketoglutarates and their use as therapeutic agents: The present invention relates generally to the field of pharmaceuticals and medicine. More particularly, the present invention relates to certain compounds (e.g., α-ketoglutarate compounds; compounds that activate HIFα hydroxylase; compounds that increases the level of α-ketoglutarate, etc.) and their use in medicine, for example, in the treatment of cancer (e.g.,... Agent: Nixon & Vanderhye, PC

20090005439 - Stable organic peroxide compositions: Methods of treating acne include the use of formulations including a benzoyl peroxide solution and an antioxidant.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20090005438 - Use of isothiocyanates compounds in treating prostatic diseases and skin cancer: A method for preventing and treating prostatic diseases and skin cancer using naturally or artificially synthesized isothiocyanates compounds or the derivatives or metabolites thereof.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090005440 - Pharmaceutical composition and health food comprising extract of phellinus sp.pl 3 or phellinsin a isolated from the same as an effective component for prevention and treatment of cardiovascular disease: The present invention relates to a pharmaceutical composition and health food comprising Phellinus sp. PL3 extract or phellinsin A isolated from the same as an effective component. More particularly, the present invention relates to a pharmaceutical composition and health food comprising Phellinus sp. PL3 extract or phellinsin A isolated from... Agent: Frommer Lawrence & Haug

20090005441 - Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism: Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.... Agent: Kelley Drye & Warren LLP

20090005442 - Carbamate compounds for use in preventing or treating neurodegenerative disorders: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent: Philip S. Johnson Johnson & Johnson

20090005443 - Treatment of depression: There is described a compound selected from the group consisting of tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof, for the treatment or alleviation of depression. There is also described a method of treating a... Agent: K&l Gates LLP

20090005444 - Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus: Methods of treating alcohol withdrawal, central pain, anxiety, or pruritus in a patient comprising orally administering a therapeutically effective amount of a propofol prodrug having high oral bioavailability are disclosed.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090005445 - Article comprising calcium for reducing the production of tsst-1: Articles comprising one or more calcium salts are provided. The articles can contain one or more calcium salts in an amount effective to reduce the production of TSST-1 by at least about 50% when measured by the Shake Flask Method. In certain embodiments, the one or more calcium salts can... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090005446 - Prophylactic antistress agent: The present invention relates to a prophylactic antistress agent and a central fatigue improver, which contain chlorogenic acids or pharmaceutically acceptable salts thereof as active ingredients. The present invention makes it possible to prevent and improve mental task fatigue, physical fatigue, central fatigue, central fatigue syndrome, overwork and the like.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090005447 - Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism: Methods, pharmaceutical compositions, and compounds for reducing body weight, modulating body lipid metabolism, and reducing food intake in mammals are provided. The compounds of the invention include fatty acid ethanolamide compounds, homologues and analogs of which the prototype is the endogenous fatty acid ethanolamide, oleoylethanolamide.... Agent: Townsend And Townsend And Crew, LLP

20090005448 - Injection for mastitis: Disclosed is infusion for mastitis which contains a main ingredient, medium-chain fatty acid monoglyceride and an oily base wherein diffusivity and dispersivity of the main ingredient are improved by the monoglyceride to enhance dissolubility and thus absorbency of the main ingredient. In comparison with conventional infusions for mastitis, the infusion... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090005449 - Structured compositions comprising betaine: Provided are structured compositions comprising an anionic surfactant, a betaine, and a branched fatty alcohol, the composition having a Yield Stress from about 1 Pascal (Pa) to about 1500 Pa, as well as methods of making and using such compositions.... Agent: Philip S. Johnson Johnson & Johnson

20090005450 - Use of creatine compounds for the treatment of eye disorders: The present invention provides methods of treating an eye disorder (i.e., glaucoma, macular degeneration, diabetic retinopathy, macular edema, ocular rosacea, amblyopia, cataracts, dry eye, iritis, retinitis pigmentosa, uveitis etc.) by administering a creatine compound to a subject.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090005451 - Compounds for the treatment of metabolic disorders: e

20090005452 - Diphenyl urea derivatives: The invention relates to novel specifically trifluoromethyl and halogen substituted 1,3-diphenyl ureas and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects like the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as... Agent: Dickstein Shapiro LLP

20090005453 - Crystalline forms of tigecycline and processes for preparation thereof: The present invention provides crystalline forms of Tigecycline, and methods of for preparation of crystalline forms and amorphous.... Agent: Kenyon & Kenyon LLP

20090005454 - Method of reducing nosocomial infections: Nosocomial infections, particularly nosocomial infections of intubated patients, are reduced by applying a liquid disinfectant directly to the mucosa, before intubation, by a swab applicator or by a spray applicator.... Agent: 3m Innovative Properties Company

20090005455 - N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs: or a tautomer, stereoisomer, hydrate, or solvate thereof, wherein R1 is H or CH3. Other embodiments of the invention relate to a pharmaceutical composition containing these compound, to methods for preparing these compounds, and to methods for preparing compositions containing these compounds. Yet other embodiments of the invention relate to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090005456 - Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the... Agent: Morgan, Lewis & Bockius LLP (sf)

20090005457 - Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof: Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (−)—O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective... Agent: Jones Day

20090005458 - Tapentadol for treating pain due to osteoarthritis: The use of tapentadol for treating pain due to osteoarthritis.... Agent: Crowell & Moring LLP Intellectual Property Group

20090005459 - Nmda receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau: Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemically-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same.... Agent: The Firm Of Hueschen And Sage

20090005460 - Methods of making and using structured compositions comprising betaine: Provided are methods of making structured compositions comprising an anionic surfactant, a betaine, and a branched fatty alcohol, the composition having a Yield Stress from about 1 Pascal (Pa) to about 1500 Pa.... Agent: Philip S. Johnson Johnson & Johnson

20090005461 - Use of cannabidiol in the treatment of hepatitis: Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune systems mediating a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind are also psychoactive thereby limiting their clinical use. Cannabidiol (CBD) is the most abundant nonpsychotropic plant cannabinoid but has not... Agent: Dority & Manning, P.A.

20090005462 - Structured depilatory compositions: Provided are compositions comprising a depilatory active; and a surfactant, wherein the composition has a Yield Stress of from about 1 Pascal (Pa) to about 1500 Pa, and methods of use thereof.... Agent: Philip S. Johnson Johnson & Johnson

20090005463 - Liquid solubilizers comprising ethoxylated fatty alcohols and ethoxylated triglycerides: o

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141113: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.09254 seconds

PATENT INFO